Document:

EX-10.10

 Exhibit 10.10 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

OUT-LICENCE AGREEMENT 
 by and between 
 ASTRAZENECA AB 

and 

FLEXION THERAPEUTICS AG 
 DATE: JUNE, 12 2009 
 Execution Copy 

 TABLE OF CONTENTS 
  

							
	 1
	  	Definitions	  	 	1	  
			
	 2
	  	Construction	  	 	15	  
			
	 3
	  	Grant of Rights	  	 	15	  
			
	 4
	  	Development And Selection Of A Back-Up Compound	  	 	23	  
			
	 5
	  	Improvements	  	 	25	  
			
	 6
	  	Development	  	 	25	  
			
	 7
	  	Consideration	  	 	28	  
			
	 8
	  	Delivery of Study Drug	  	 	37	  
			
	 9
	  	Ownership of Intellectual Property	  	 	38	  
			
	 10
	  	Adverse Event Reporting	  	 	38	  
			
	 11
	  	Confidentiality & Non-Disclosure	  	 	38	  
			
	 12
	  	Trademarks	  	 	42	  
			
	 13
	  	Representations and Warranties	  	 	43	  
			
	 14
	  	Indemnity	  	 	46	  
			
	 15
	  	Maintenance and Prosecution of Patents	  	 	48	  
			
	 16
	  	Enforcement of Patents	  	 	49	  
			
	 17
	  	Potential Third Party Rights	  	 	51	  
			
	 18
	  	Term and Termination	  	 	54	  
			
	 19
	  	Force Majeure	  	 	65	  
			
	 20
	  	Assignment	  	 	66	  
			
	 21
	  	Sub-Contracting	  	 	67	  

  
 (i)

							
	 22
	  	Severability	  	 	67	  
			
	 23
	  	Governing Law	  	 	67	  
			
	 24
	  	Dispute Resolution and Arbitration	  	 	68	  
			
	 25
	  	Notices	  	 	69	  
			
	 26
	  	Relationship of the Parties	  	 	70	  
			
	 27
	  	Entire Agreement	  	 	70	  
			
	 28
	  	English Language	  	 	71	  
			
	 29
	  	Amendment	  	 	71	  
			
	 30
	  	Waiver and Non-Exclusion of Remedies	  	 	71	  
			
	 31
	  	Confirmatory Patent Licences	  	 	71	  
			
	 32
	  	Further Assurance	  	 	71	  
			
	 33
	  	Expenses	  	 	72	  
			
	 34
	  	Announcements	  	 	72	  
			
	 35
	  	Counterparts	  	 	72	  

 Schedule 1—Primary Compound and Licensed Patents 
 Schedule 2—Back-Up Nomination Criteria: 
 Schedule 3—Ethics Standards 

Schedule 4—Designated Persons 
 Exhibit 1

 Exhibit 2 

  
 (ii)

 Exhibit 3 

  
 (iii)

 LICENCE AGREEMENT 

This Licence Agreement (the “Agreement”) is made as of the 12th of June, 2009 (the “Effective Date”) by and
between: 
  

	(1)	ASTRAZENECA AB, a Swedish corporation with offices at S-151 85 Södertälje, Sweden (“AstraZeneca”); and 

 

	(2)	Flexion Therapeutics AG, a Swiss corporation with offices at Aeschenvorstadt 36, CH-4051 Basel, Switzerland (“Flexion”). 

Recitals 
  

	(A)	WHEREAS, AstraZeneca is or has been engaged in the research of anti-inflammatory inhibitors against p38 mitogen-activated (MAP) kinase (the “P38 Programme”)
and in relation to which AZ has identified certain Compounds (as defined below) including the compound known as [...***...]. 

  

	(B)	WHEREAS, Flexion has specialised experience in, among other things, the development and commercialisation of pharmaceutical compounds; and 

 

	(C)	WHEREAS, AstraZeneca desires to grant a licence to Flexion, and Flexion desires to take a licence, to develop and commercialise the above-mentioned pharmaceutical
compound in accordance with the terms and conditions set forth below. 

 NOW, THEREFORE, in consideration of the mutual covenants
contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

 

	1	Definitions 

Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, shall have the
following meanings: 
  

	1.1	“Acceptance Criteria” shall have the meaning set out in Section 4.3.1. 

 

	1.2	“Affected Countries” shall have the meaning set out in Section 18.5. 

 

	1.3	 “Affiliate” means, with respect to a Person, any Person that controls, is controlled by or is under common control with such first
Person. For purposes of this definition 

  

***Confidential Treatment Requested 

  
 1 

	 	
only, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance or otherwise, or (b) to own, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or other ownership interest of such Person.

  

	1.4	“Applicable Law” means the applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Health
Authorities, that may be in effect from time to time in the Territory. 

  

	1.5	“Back-Up Compound” means a Nominated Compound which Flexion has notified AstraZeneca has been selected by Flexion in accordance with
Section 4.3.3. 

  

	1.6	“Back-Up Nomination Criteria” means the criteria established for the nomination of a Nominated Compound by AstraZeneca as set out in Schedule 2.

  

	1.7	“Breaching Party” has the meaning set forth in Section 18.2. 

 

	1.8	“Business Day” means a day other than a Saturday, Sunday, bank or other public holiday in the United Kingdom. 

 

	1.9	“Calendar Quarter” means each successive period of three (3) calendar months commencing on 1st January, 1st April, 1st July and
1st October and “Quarterly” shall be construed accordingly. 

  

	1.10	“Calendar Year” means each successive period of twelve (12) calendar months commencing on 1st January. 

 

	1.11	“Change of Control,” with respect to Flexion, means an event in which: 

 

	 	1.11.1	any other Person or group of Persons acquires beneficial ownership of securities of Flexion representing more than fifty percent (50%) of the voting power of the
then outstanding securities of Flexion with respect to the election of directors of Flexion (“Controlling Ownership”); or 

  

	 	1.11.2	 Flexion enters into a merger, consolidation or similar transaction with another Person in which (i) Flexion is not the surviving entity in such
transaction and (ii) Persons having Controlling Ownership in Flexion immediately prior to 

  
 2 

	 	
such transaction do not have Controlling Ownership in the surviving entity immediately after the transaction; or 

 

	 	1.11.3	a sale of a material portion of the assets of Flexion representing not less than fifty percent (50%) of the fair market value of Flexion; 

provided always that any of the above listed events shall not be considered a Change of Control, if the sole or predominant purpose of
the event or the related transaction is the financing of Flexion’s business activities from private (e.g. venture capital or private equity companies or private investors) or public (e.g. capital markets) sources. For the purposes of this
Agreement a Change of Control shall be deemed to occur upon closing of the respective event or transaction and upon satisfaction of all regulatory or other requirements or conditions in relation to such event or transaction. 

 

	1.12	“Collaborator” shall mean (i) in respect of Flexion, a Third Party that Flexion is collaborating with for the purpose of research and development
of the Compounds (or any analogs or derivatives thereof) and (ii) in respect of AstraZeneca, a Third Party that AstraZeneca or any of its Affiliates is collaborating with in respect of its or their business. 

 

	1.13	“Combination Products” means products in forms suitable for human applications that contain a Compound as an active ingredient together with one or
more other active ingredients. 

  

	1.14	“Commence” or “Commencement” when used to describe a Phase I Clinical Trial, Phase II Clinical Trial, or Phase III Clinical Trial,
means the first administration of Compound or Licensed Product or the comparator or the placebo to the first human in such trial related to Compound or Licensed Product. 

 

	1.15	 “Commercially Reasonable Efforts” means, with respect to the research, Development, Manufacture or commercialisation of a Compound or
Licensed Product, as the case may be, efforts and resources commonly used in the research- based pharmaceutical industry for compounds or products with similar commercial and scientific potential at a similar stage in their lifecycle. Commercially
Reasonable Efforts after First Regulatory Approval Filing shall be determined on a market-by-

  
 3 

	 	
market basis for each Compound and each Licensed Product, as applicable, provided that it is understood that Commercially Reasonable Efforts with respect to commercialisation require the Party
responsible for commercialisation of a Compound or Licensed Product under this Agreement to apply for Health Registration Approval and Exploit Compound or Licensed Product at least in the Major Markets, unless commercialisation in a specific Major
Market is (in itself) commercially not viable and/or reduces the overall economic value of a Compound or Licensed Product. Commercially Reasonable Efforts requires that a Party, at a minimum, assign responsibility for such obligations to qualified
employees, set annual goals and objectives for carrying out such obligations, and allocate resources designed to meet such goals and objectives. 

  

	1.16	“Complaining Party” has the meaning set forth in Section 18.2. 

 

	1.17	“Completion” when used to describe a Phase I Clinical Trial, a Phase II Clinical Trial or a Phase III Clinical Trial, means the date of database lock
related to such clinical trial or in the absence of a database lock the read out of the trial results and “Complete” shall be construed accordingly. 

 

	1.18	“Compound” or “Compounds” means one or both of the following: (a) the Primary Compound; and (b) a Back-Up Compound.

  

	1.19	“Confidential Information” has the meaning set forth in Section 11.1. 

 

	1.20	“Control” means, with respect to any item of Information, Patent or Intellectual Property Right, possession of the right, whether directly or
indirectly, and whether by ownership, licence or otherwise, to assign, or grant a licence, sublicense or other right to or under, such Information, Patent or Intellectual Property Right as provided for herein without violating the terms of any
agreement or other arrangement with any Third Party. 

  

	1.21	“Data Exclusivity” means any data or market exclusivity periods established by Applicable Law, including any such periods listed in the FDA’s
Orange Book or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 (as amended), and all international equivalents. 

  
 4 

	1.22	“Data Room” a due diligence data room containing the data and information to the extent required and necessary for an informed decision related to the
Compound(s) and Licensed Product(s) that Flexion has generated since the Effective Date, including the final report of clinical trial results, minutes of interactions with regulatory bodies and summary CMC and manufacturing data and batch reports.

  

	1.23	“Develop” or “Development” means, with respect to the Compound(s) and/or Licensed Product(s), the performance of all research, pre-clinical,
clinical and regulatory activities required to obtain Health Registration Approval of a Product in the Territory. 

  

	1.24	“Disclosing Party” has the meaning set forth in Section 11.1. 

 

	1.25	“Effective Date” has the meaning set forth in the preamble to this Agreement. 

 

	1.26	“Ethics Standards” means the standards set out in Schedule 3. 

 

	1.27	“Europe” means the European Economic Area as it may be constituted from time to time and Switzerland. 

 

	1.28	“Exclusive Licensed Know-How” shall mean the Know-How described as such in Schedule 1. 

 

	1.29	“Exploit” means to make, have made, import, use, sell, or offer for sale, including to research, Develop, register, modify, enhance, improve,
Manufacture, have Manufactured, hold/keep (whether for disposal or otherwise), formulate, have used, export, transport, distribute, promote, market or have sold or otherwise dispose or offer to dispose of, a product or process.

  

	1.30	“Exploitation” means the act of Exploiting a product or process. 

 

	1.31	“Field” means the prevention, diagnosis and treatment of medical conditions in humans. 

 

	1.32	 “First Commercial Sale” means the first sale for monetary value for use or consumption by the general public of a Licensed Product in
a country in the Territory after all Regulatory Approvals for such Licensed Product have been obtained in such country. For the avoidance of doubt, sales prior to receipt of all Regulatory Approvals necessary to commence regular commercial sales,
such as so-called 

  
 5 

	 	
“treatment IND sales”, “named patient sales” and “compassionate use sales”, shall not be construed as a First Commercial Sale. 

 

	1.33	“First Regulatory Approval Filing” means the date on which the first Regulatory Approval for Compound or Licensed Product in any country in the
Territory has been submitted to a Health Authority. 

  

	1.34	“Flexion Product Data” has the meaning set forth in Section 18.6.2. 

 

	1.35	“Flexion Trademarks” means all Trademarks used by or on behalf of Flexion, its Affiliates or Sublicensees prior to the termination of this Agreement in
connection with the Compounds or Licensed Products and any registrations thereof, or any pending applications relating thereto. 

  

	1.36	“Force Majeure” has the meaning set forth in Section 19.1. 

 

	1.37	“Force Majeure Party” means a Party prevented or delayed in its performance under this Agreement by an event of Force Majeure.

  

	1.38	“Good Clinical Practices” or “GCP” means current Good Clinical Practices as specified in the United States Code of Federal Regulations, at
the time of testing, and all FDA and ICH guidelines, including the ICH Consolidated Guidelines on Good Clinical Practices. 

  

	1.39	“Good Laboratory Practices” or “GLP” means current Good Laboratory Practices as specified in the United States Code of Federal Regulations at
Title 21 (21 CFR § 58) at the time of testing and all applicable ICH guidelines. 

  

	1.40	 “Good Manufacturing Practices” or “GMP” means current Good Manufacturing Practices and standards as provided for (and as
amended from time to time) in European Community Directive 91/356/EEC (Principles and Guidelines of Good Manufacturing Practice for Medicinal Products) and in the Current Good Manufacturing Practice Regulations of the United States Code of Federal
Regulations Title 21 (21 CFR §§ 210-211) in relation to the production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by ICH Harmonized Tripartite Guideline, Good Manufacturing Practice Guide for
Active 

  
 6 

	 	
Pharmaceutical Ingredients, and subject to any arrangements, additions or clarifications agreed from time to time between the Parties. 

 

	1.41	“Grant-Back Patents” means any Patents that, at the termination of this Agreement, Flexion or its Affiliates own or otherwise Control and are necessary
or reasonably useful for the Exploitation of the Licensed Products or Compounds or that claim or cover Flexion’s Improvements to the Licensed Products or Compounds and any freedom to operate and immunity from suit rights granted to Flexion
and/or its Affiliates in respect of the Licensed Products or Compounds. 

  

	1.42	“Health Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments,
bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Compounds or Licensed Products in the Territory. 

 

	1.43	“Health Registration Approval” means, with respect to a country in the Territory, any and all approvals, licences, registrations or authorisations of
any Health Authority necessary to commercially distribute, sell or market a Licensed Product in such country, including, where applicable, (a) Regulatory Approval, (b) pricing or reimbursement approval in such country, (c) pre- and
post-approval marketing authorisations (including any prerequisite Manufacturing approval or authorisation related thereto), (d) labelling approval and (e) technical, medical and scientific licences. 

 

	1.44	“Improvements” means any invention, discovery, development or modification with respect to a Compound or Licensed Product or relating to the
Exploitation thereof, whether or not patented or patentable, that is conceived, reduced to practice, discovered, developed or otherwise made at any time during the term of this Agreement, including any enhancement in the efficiency, operation,
Manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of such Compound or Licensed Product, any discovery or development of any new or expanded indications for such Compound or Licensed Product or any
discovery or development that improves the stability, safety or efficacy of such Compound or Licensed Product. 

  
 7 

	1.45	“IND Filing” means an Investigational New Drug Application (as more fully defined in Title 21 CFR 312.22 and 312.23) and all amendments and supplements
thereto filed with the FDA. 

  

	1.46	“Indemnified Party” means a Party seeking to recover a Loss under Section 14.1 or 14.2. 

 

	1.47	“Indemnifying Party” means a Party from whom recovery of a Loss is sought under Section 14.1 or 14.2. 

 

	1.48	“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes. 

 

	1.49	“Intellectual Property Rights” means trademarks, service marks, trade names, registered designs, design rights, copyrights (including rights in
computer software), database rights and any rights or property similar to any of the foregoing (other than Patents) in any part of the world whether registered or not registered together with the right to apply for the registration of any such
rights. 

  

	1.50	“Knowledge” means the good faith understanding of the [...***...] team and the [...***...] of the facts and information then in their
possession without any duty to conduct any investigation with respect to such facts and information. 

  

	1.51	 “Know-How” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods,
processes, techniques, practices, formulae, instructions, skills, techniques, procedures, formulations, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, databases, inventions,
specifications, data, results and other material, including: high-throughput screening, gene expression, genomics, proteomics and other drug discovery and development technology; biological, chemical, biochemical, pharmacological, toxicological,
pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing, stability and quality control data and information, including study designs and protocols; assays and biological methodology; Manufacturing and quality control
procedures and data, including test 

  

***Confidential Treatment Requested 

  
 8 

	 	
procedures; and synthesis, purification and isolation techniques; in each case, whether or not confidential, proprietary, patented or patentable in written, electronic or any other form now known
or hereafter developed. 

  

	1.52	“Licensed Know-How” means (a) the Exclusive Licensed Know-How and (b) the Non-Exclusive Licensed Know-How. 

 

	1.53	“Licensed Patents” means (a) all patent applications and patents identified as such and set forth in Schedule 1 hereto, and (b) any Patents
deriving from such patent applications or patents that AstraZeneca or its Affiliates Control at any time during the term of this Agreement that cover or claim any Compounds or Licensed Product in the Territory. 

 

	1.54	“Licensed Products” means the Products and the Combination Products. 

 

	1.55	“Losses” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties, reasonable
lawyers’ fees and disbursements and “Loss” shall be construed accordingly. 

  

	1.56	“Major Market” means [...***...]. 

  

	1.57	“Manufacture” and “Manufacturing” and “Manufactured” means, with respect to a product or compound, the synthesis,
manufacturing, processing, formulating, packaging, labelling, holding and quality control testing of such product or compound. 

  

	1.58	“Net Sales” means the gross amount invoiced for Licensed Products by Flexion and its Affiliates and Sublicensees to Third Parties after deduction of:

  

	 	1.58.1	normal and customary trade or quantity discounts (including chargebacks and allowances) actually allowed; 

 

	 	1.58.2	amounts repaid or credited by reason of rejection, returns (including allowance for specific return reserves based on notified returns) or recalls of goods, rebates or
bona fide price reductions determined by Flexion or its Affiliates or Sublicensees in good faith; 

  

***Confidential Treatment Requested 

  
 9 

	 	1.58.3	rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of
the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program in the United States or equivalent governmental program in any other country; 

 

	 	1.58.4	transportation costs, distribution expenses, special packaging and related insurance charges to the extent that such items are included in the gross amount invoiced;

  

	 	1.58.5	excise taxes, Indirect Taxes and customs duty imposed on the sale, importation, use or distribution of the Licensed Products (but not including taxes assessed against
the income derived from such sale). 

 Any of the deductions listed above that involves a payment by Flexion or its
Affiliates or Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is incurred by such entity. For purposes of calculating the Net Sales of bundled products, deductions shall be apportioned across all products in
the bundle on a fair and reasonable basis, provided that the percentage rebate or discount apportioned to the Licensed Product shall not exceed the percentage rebate or discount applied in total to the bundled products. Similarly the total price
payable for a bundled product shall be apportioned between Licensed Product and other product within the bundle on a fair and reasonable basis. For the avoidance of doubt, if in addition to the invoiced amount for a specific shipment of Product,
Flexion, an Affiliate or a Sub-Licensee receives another cash payment as consideration for such Product from a Third Party, then that payment will be deemed to be a Net Sale in that Calendar Quarter for the purpose of calculating payments to
AstraZeneca from Flexion, its Affiliate or Sub-Licensee. 
  

	1.59	“Nominated Compound(s)” has the meaning set out in Section 4.1.3. 

 

	1.60	“Non-Exclusive Licensed Know-How” means the Know-How specified in Schedule 1.2. 

 

	1.61	“Non-OA Indications” means indications in the Field other than Osteoarthritis. 

 

	1.62	“Notice Period” has the meaning set forth in Section 18.2. 

  
 10 

	1.63	“Osteoarthritis” means arthritis typically with onset during middle or old age that is characterized by degenerative and sometimes hypertrophic changes
in the bone and cartilage of one or more joints and a progressive wearing down of apposing joint surfaces with consequent distortion of joint position and is marked symptomatically especially by pain, swelling, and stiffness.

  

	1.64	“P38 Kinase Inhibitor” or “P38 Inhibitor” means a compound whose primary known mechanism of action is the direct inhibition of P38 Kinase.

  

	1.65	“P38 Kinase” or “P38” means the mitogen-activated protein (hereinafter MAP) kinase family of enzymes which are known to be activated by
physiological stress such as that induced by ionising radiation, cytotoxic agents, and toxins, for example endotoxins such as bacterial lipopolysaccharide, and by a variety of agents such as the cytokines, for example TNFa and IL-1 (also known as cytokine suppressive binding protein and reactivating kinase). P38 Kinase is known to exist in isoforms identified as p38a and p38ß.

  

	1.66	“Party” means either AstraZeneca or Flexion and “Parties” means both AstraZeneca and Flexion. 

 

	1.67	“Patents” means (a) all national, regional and international patents and patent applications, including provisional patent applications,
(b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part,
provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and
design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary
protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction
patent or registration patent or patent of additions to any such foregoing patent applications and patents. 

  

	1.68	“Payments” has the meaning set forth in Section 7.12.1. 

  
 11 

	1.69	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organisation, including a government or political subdivision, department or agency of a government. 

 

	1.70	“Phase I Clinical Trial” means a clinical trial during which the first dose of the Compound or a Licensed Product is given to a human volunteer or
patient. 

  

	1.71	“Phase II Clinical Trial” means a clinical trial of a Product on human, including possibly pharmacokinetic studies, the principal purpose of which is
to make a preliminary determination that such Product is safe for its intended use and to obtain sufficient information about such Product’s efficacy to permit the design of further clinical trials, and generally consistent with Title 21 (21
CFR § 312.21(b)). A Phase II Clinical Trial may be either a Phase II(a) Clinical Trial or a Phase II(b) Clinical Trial. 

  

	1.72	“Phase II(a) Clinical Trial” means a Phase II Clinical Trial intended for dose exploration, dose response, duration of effect, kinetic/dynamic
relationship and preliminary efficacy and safety study of a candidate drug in the target patient population. 

  

	1.73	“Phase II(b) Clinical Trial” means a controlled dose ranging Phase II Clinical Trial to evaluate further the efficacy and safety of a candidate drug in
the target patient population and to define the optimal dosing regimen. 

  

	1.74	 “Phase III Clinical Trial” means a large scale, pivotal, multi-centre, human clinical trial to be conducted in a number of patients
estimated to be sufficient to primarily establish efficacy of a Licensed Product in the claim(s) of Osteoarthritis and/or Non- OA Indications and at a standard suitable to obtain a Health Registration Approval to market and sell such Licensed
Product in a Major Market. A Phase III Clinical Trial shall also include any well-controlled study intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable Health Registration Approval (such as a
combined Phase II/Phase III study, or any Phase III study in lieu of a Phase II study), whether or not such study is a traditional Phase III 

  
 12 

	 	
study. A Phase III Clinical Trial shall be deemed to have commenced on the date the first patient is enrolled in such Phase III Clinical Trial. 

 

	1.75	“Primary Compound” means the P38 Inhibitor, known as, [...***...] which is more particularly described in Schedule 1. 

 

	1.76	“Products” means products in forms suitable for human application that contain a Compound as the sole active ingredient. 

 

	1.77	“Proof of Concept” means, with regard to a Compound or Licensed Product, clinical trial results which provide meaningful evidence of efficacy and
safety in not less than [...***...]. 

  

	1.78	“Regulatory Approval” means, with respect to a country in the Territory any approval, licence, registration or authorisation approving a Regulatory
Filing issued by any Health Authority with respect to a Licensed Product. 

  

	1.79	“Regulatory Documentation” means all applications, registrations, licences, authorisations and approvals (including all Regulatory Filings, Regulatory
Approvals and Health Registration Approvals), all correspondence submitted to or received from Health Authorities (including minutes and official contact reports relating to any communications with any Health Authority) and all supporting documents
and all clinical studies and tests, relating to any Compounds or Licensed Products, and all data contained in any of the foregoing, including all Health Registration Approvals, regulatory drug lists, advertising and promotion documents, adverse
event files and complaint files. 

  

	1.80	“Regulatory Filing” means a New Drug Application (as more fully defined in Title 21 CFR § 314.5 et. seq) and all amendments and supplements
thereto filed with the FDA or the equivalent application or filing filed with any equivalent Heath Authority outside the United States (including any supra-national agency such as in the European Union) (for example an MAA or JNDA) necessary to
Commence human clinical trials in such jurisdiction, and including all regulations at Title 21 (21 CFR § 312 et. seq.) and equivalent foreign regulations, including all documents, data and other information concerning a pharmaceutical
product which are necessary for gaining Regulatory Approval to market and sell such pharmaceutical product. 

  

***Confidential Treatment Requested 

  
 13 

	1.81	“Retained Patents” means (a) all patent applications and patents identified as such and set forth in Schedule I hereto, and (b) any Patents
deriving from such patent applications or patents that AstraZeneca or its Affiliates Control at any time during the term of this Agreement that cover or claim any Compounds in the Territory, 

 

	1.82	“Study Drug” shall mean the study drug specified in Schedule 1. 

 

	1.83	“Sublicensee” has the meaning set out in Section 3.5. 

 

	1.84	“Territory” means all countries in the world except for those Affected Countries in respect of which this Agreement is terminated.

  

	1.85	“Third Party” means any Person not including the Parties, the Parties’ respective Affiliates or Sublicensees. 

 

	1.86	“Third Party Claim” has the meaning set forth in Section 14.1. 

 

	1.87	“Trademark” means any word, name, symbol, colour, designation or device or any combination thereof, including any trademark, trade dress, brand mark,
trade name, brand name, logo or business symbol used by Flexion or its Affiliates or Sublicensees in connection with the Compounds or Licensed Products. 

  

	1.88	“United States” or “U.S.” means the United States of America, including its territories and possessions, the District of Columbia and
Puerto Rico. 

  

	1.89	“Valid Claim” means, with respect to a particular country, either: 

 

	 	1.89.1	any claim of a granted and unexpired Patent in such country that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or
other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue
or disclaimer or otherwise; or 

  

	 	1.89.2	a claim of a pending Patent application, which claim was filed and is being prosecuted in good faith and has not been cancelled, withdrawn, abandoned or finally
disallowed without the possibility of appeal or re-filing of the application. 

  
 14 

	2	Construction 

Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of
any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to
calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or limit the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term
“including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the
Parties and no rule of strict construction shall be applied against any Party. 
  

	3	Grant of Rights 

  

	3.1	Licence Grants to Flexion. Subject to the terms and conditions of this Agreement, AstraZeneca hereby grants to Flexion (i) an exclusive (including with
regard to AstraZeneca and its Affiliates) royalty-bearing licence in the Territory, with the right to grant sublicences pursuant to Section 3.5, under AstraZeneca’s rights, titles, and interests in and to the Licensed Patents and the
Exclusive Licensed Know-How, and (ii) a non-exclusive royalty-bearing licence in the Territory, with the right to grant sublicences pursuant to Section 3.5 under AstraZeneca’s rights, titles and interests in and to the Non-Exclusive
Licensed Know-How, in each case to Develop and Exploit the Compounds and the Licensed Products for all purposes in the Field. For the avoidance of doubt, the grant of rights in this Section 3.1 does not include the right for Flexion to Develop
and Exploit any compounds covered or claimed in the Licensed Patents other than the Compounds. 

  

	3.2	AstraZeneca Retained Rights. The exclusive rights granted to Flexion under Section 3.1 above are subject to the following retained rights:

  

	 	3.2.1	 The right of AstraZeneca, its Affiliates and any Collaborators of AstraZeneca to use the Licensed Patents to the extent only that the relevant use is
solely for (a) the purposes of research in Non-OA Indications by and on behalf of AstraZeneca, its Affiliates and Collaborators and not for the purposes of the 

  
 15 

	 	
development or commercialisation of any pharmaceutical product falling within the scope of the Licensed Patents; (b) the research does not include [...***...] trials; and
(c) disclosure of the results of the research is in connection with [...***...]. 

  

	 	3.2.2	Notwithstanding the limitations of the rights retained pursuant to sub-section (a) above, the right of AstraZeneca, its Affiliates and any Collaborators of
AstraZeneca to use the Licensed Patents (a) to make or have made intermediates other than for the purpose of selling them as active ingredients for the Licensed Products; and (b) to use processes disclosed under the Licensed Patents for
any purpose other than any use in relation to Compound(s) or Licensed Products. 

 AstraZeneca shall be entitled to
assign its rights under this Section 3.2 without the prior written consent of Flexion. 
  

	3.3	Licensed Know-How. Flexion acknowledges that (a) the Licensed Know-How is secret and substantial and that without the Licensed Know-How Flexion would not be
able to apply to obtain and maintain Health Registration Approvals, (b) such Health Registration Approvals together with the Health Registration Approvals assigned or licensed to Flexion hereunder may give, or may allow Flexion to obtain and
maintain, Data Exclusivity with respect to the Compounds and Licensed Products, (c) access to the Licensed Know-How and such Health Registration Approvals may provide Flexion with a competitive advantage in the marketplace beyond the
exclusivity afforded by the Licensed Patents and the Data Exclusivity, and (d) the milestone payments and royalties set forth in Sections 7.1 and 7.2 are, in part, intended to compensate AstraZeneca for such exclusivity and such competitive
advantage, and shall be payable regardless of whether or not Flexion does in fact achieve a competitive advantage therefrom. 

  

	3.4	 Freedom to Operate. AstraZeneca shall not, and shall procure that its Affiliates, Collaborators, sub-licensees and assigns shall not, enforce
any Retained Patents against Flexion, its Affiliates and Sublicensees in respect of any use by Flexion, its Affiliates, and Sublicensees to the extent only that the relevant use is solely for the

  

***Confidential Treatment Requested 

  
 16 

	 	
purposes of exercising the rights granted at Section 3.1 above. If Flexion abandons (without the consent of AstraZeneca) the prosecution and/or maintenance of a Licensed Patent then
AstraZeneca’s undertaking in this Section 3.4 shall automatically terminate with respect to the country in which the Licensed Patent has been abandoned. 

 

	3.5	Sublicences. Subject to Section 18.6.5, Flexion shall have the right to grant sublicences under the licences granted in Section 3.1, to its Affiliates
and to any other Persons in the Territory or in any country of the Territory without the prior written consent of AstraZeneca; provided, however, that: (a) Flexion shall ensure the performance by each Sublicensee of the terms of
each such sublicence; (b) notwithstanding any such sublicence, Flexion shall remain solely liable for the performance of its obligations hereunder; and (c) Flexion shall promptly after the execution of each such sublicence notify
AstraZeneca in writing of such sublicence stating the name of the Sublicensee and the countries covered by such sub-licence; and (d) Flexion shall not seek to grant or grant any sublicences, in any part of the Territory other than Japan, prior
to [...***...]; and (e) Flexion’s selection of a Sublicensee shall be made in good faith consideration of the Ethics Standards. Where Flexion grants a sublicence to a Person that is not an Affiliate of Flexion, including to market,
promote, sell, distribute or otherwise Exploit Compounds or Licensed Products in any country in the Territory such Person shall be a “Sublicensee” for purposes of this Agreement. Flexion shall ensure that all Persons to which it
grants sublicences will not exceed the scope of the rights granted to Flexion under this Agreement with respect to the Licensed Patents, the Licensed Know-How and the Retained Patents. The Sublicence shall contain obligations on the Sublicensee
which are no less onerous than those set out in Section 6.3 (Diligence Obligations), Section 6.5 (Records and Reporting); Section 7.9 (Records Retention and Audit); Section 9 (Ownership of IP); Section 11 (Confidentiality
and Non-Disclosure); Section 18.2 (Termination for Breach); Section 18.6.5 (Consequences of Termination); Section 18.8 (Termination upon Insolvency); Section 20 (Assignment). Each sublicence shall further contain such covenants
or representations and warranties as reasonably required to ensure that the Sublicensee meets the Ethics Standards during the term of such sublicence. 

  

***Confidential Treatment Requested 

  
 17 

	3.6	AstraZeneca Right of Final Offer. 

  

	 	3.6.1	If Flexion, at any time prior to [...***...] is interested in offering rights relating to a Compound(s) or a Licensed 
Product(s) to a Third Party, Flexion
shall have the obligation to inform AstraZeneca promptly in writing accordingly. Within [...***...] days after receipt of Flexion’s written notice, AstraZeneca shall confirm to Flexion whether AstraZeneca is interested to review further
information related to such Compound(s) or Licensed Product(s). If during the above mentioned [...***...] day period, AstraZeneca does not confirm its further interest or if AstraZeneca does not contact Flexion at all, then Flexion shall be
free to enter into an agreement with a Third Party related to such Compound or Licensed Product without further notice to AstraZeneca. 

  

	 	3.6.2	If AstraZeneca does confirm its interest to Flexion then as soon as reasonably possible after Flexion receives such confirmation, Flexion shall make available to
AstraZeneca a Data Room. Flexion shall allow a reasonable number of AstraZeneca personnel to access the Data Room. 

  

	 	3.6.3	 Within [...***...] days following the opening of the Data Room to AstraZeneca, AstraZeneca shall advise Flexion if it is interested in acquiring
the rights to Compound(s) and/or Licensed Product(s) offered by Flexion. If AstraZeneca is interested in acquiring the rights then it shall make an initial good faith offer as to the commercial terms and conditions on which it would be prepared to
acquire the rights offered by Flexion. Following receipt of such initial offer, Flexion shall either enter into non-exclusive good faith negotiations to agree to a definitive agreement with AstraZeneca with regard to the rights for a maximum period
of [...***...] days (or such other time period as the Parties may mutually agree) or reject such offer outright. If the Parties have not agreed a definitive agreement within the [...***...] day period (or such longer period as they may
mutually agree) or if Flexion at any time in its discretion terminates such negotiations, then Flexion shall be free to enter into a transaction regarding such Compound(s) or Licensed Product with any Third Party, provided that, AstraZeneca shall
have the right to make a 

  

***Confidential Treatment Requested 

  
 18 

	 	
final offer to Flexion within [...***...] days after [...***...], and provided further that Flexion shall not enter into any agreement with a Third Party on financial terms and
conditions which are more favourable for the Third Party when taken in their totality than the terms and conditions last offered by AstraZeneca [...***...]. 

 

	3.7	Exclusivity Term. Flexion’s exclusive position granted by Section 3.1 shall expire with respect to each separate Licensed Product, on a
country-by-country basis, on the date when Flexion’s obligation to pay royalties with respect to such Licensed Product pursuant to Section 7.6 expires. Upon expiry of Flexion’s exclusive position with respect to a Licensed Product in
a country, Flexion’s licence with respect to such Licensed Product in such country shall become non-exclusive, fully paid-up, perpetual and irrevocable and the Net Sales of such Licensed Product in such country shall be excluded from the
royalty calculations in Sections 7.2 and 7.3 (but not the thresholds and ceilings contained in Sections 7.2 and 7.4). Flexion and its Affiliates and Sublicensees shall be allowed to continue Exploiting such Licensed Product and using all
Non-Exclusive Licensed Know-How in connection therewith on a non-exclusive basis and all Exclusive Licensed Know-How on an exclusive basis in such country with no further consideration to AstraZeneca. 

 

	3.8	Assignment of Regulatory Documentation. AstraZeneca hereby assigns to Flexion free of charge all of its rights, title and interest in and to all Regulatory
Documentation (if any), Controlled by AstraZeneca as of the Effective Date. Flexion shall be responsible for the payment of any fee becoming due after the Effective Date payable by Flexion to Third Parties on the transfer of such Regulatory
Documentation. 

  

	3.9	Change of Control. 

  

	 	3.9.1	 If a Change of Control occurs at any time within [...***...] of the Effective Date of this Agreement, then AstraZeneca shall have the right to
terminate this Agreement by giving [...***...] notice in writing to Flexion. Flexion shall give AstraZeneca notice of any Change of Control of 

  

***Confidential Treatment Requested 

  
 19 

	 	
Flexion as soon as practicable (taking into account any restrictions imposed by Applicable Law) and in any event within thirty (30) days after the occurrence of the Change of Control.
AstraZeneca’s right to terminate this Agreement under this Section 3.9.1 shall expire at the later of [...***...] days after the occurrence or after the notification of such Change of Control. 

 

	 	3.9.2	If a Change of Control occurs after [...***...] from the Effective Date but prior to the Commencement of [...***...] with respect to the first Compound to
enter such a trial, then AstraZeneca shall have the right to terminate this Agreement in its entirety, in accordance with and subject to the following provisions: 

 

	 	a)	Flexion shall give AstraZeneca written notice of any Change of Control of Flexion as soon as practicable (taking into account any restrictions imposed by Applicable
Law) and in any event within thirty (30) days after the occurrence of the Change of Control. Flexion shall, at the same time as it notifies AstraZeneca of the Change of Control, also [...***...]. 

 

	 	b)	Upon receipt of the notification as per sub-section (a) above, AstraZeneca may in its sole discretion, elect to terminate this Agreement by serving immediate
written notice to Flexion. 

  

	 	c)	In case AstraZeneca elects to initiate [...***...], AstraZeneca shall, at the latest sixty (60) days after [...***...], notify Flexion in writing
whether AstraZeneca has decided to terminate the Agreement or not. 

  

	 	d)	If AstraZeneca elects to terminate this Agreement in accordance with sub-sections (b) or (c) above, the Applicable Fee (as defined below) shall become due for
payment by AstraZeneca within thirty (30) days after AstraZeneca has sent the termination notice to Flexion. 

  

***Confidential Treatment Requested 

  
 20 

	 	
Flexion may, it its sole discretion, at any time after receipt of a termination notice from AstraZeneca (if any) in accordance with sub-sections (b) or (c) above, but by no later than
fifteen (15) days after the commencement of the payment period in sub-section (d) above, notify AstraZeneca in writing that Flexion is willing to pay AstraZeneca the Applicable Fee. In such case, and provided that AstraZeneca receives the
Applicable Fee within the time period stated below (and subject to a cure period for payment delay under Section 18.2 below), AstraZeneca’s right to terminate for the Change of Control shall be forfeit and this Agreement shall continue in
full force and effect as if AstraZeneca had not served the notice to terminate for a Change of Control. The Applicable Fee shall become payable by Flexion within thirty (30) days following Flexion’s written notification of its intention to
pay to AstraZeneca the Applicable Fee. 

  

	 	3.9.3	For the purposes of this Section 3.9, the Applicable Fee shall be defined as follows: If the Change of Control occurs in the period which is later than
[...***...] after the Effective Date and prior to [...***...] then the Applicable Fee shall be [...***...]. If the Change of Control occurs in the period which is after [...***...] then the Applicable Fee shall be
[...***...]. 

  

	 	3.9.4	If Flexion pays AstraZeneca the Applicable Fee in accordance with Section 3.9.2 above, then it shall be entitled to [...***...]. 

 

	3.10	Japan. 

  

	 	3.10.1	The Parties recognise that Japan is an important market. In consideration for the fact that Japan [...***...] for the purposes of this Agreement and in
consideration for the enhanced sub-licensing rights which AstraZeneca has granted to Flexion with respect to Japan, the Parties have agreed the following provisions with regard to Japan. 

  

***Confidential Treatment Requested 

  
 21 

	 	3.10.2	If upon [...***...], neither Flexion nor its Sublicensee has [...***...] in Japan then Flexion shall at its option either (a) pay to AstraZeneca
[...***...] or (b) terminate this Agreement on no less than thirty (30) days prior written notice to AstraZeneca with respect to Japan only whereupon the provisions of Section 18.6.2 shall apply. 

 

	 	3.10.3	If Flexion has sublicensed the rights to Japan prior to [...***...] and [...***...] then Flexion shall pay to AstraZeneca a one-off sublicensing fee in
consideration for the rights to sublicense in Japan of [...***...] payable if and when the following events occur (and in the case of (b), (c) and (d) below within thirty (30) days of the date of AstraZeneca’s written
notice to Flexion that such event has occurred): 

  

	 	a)	Upon [...***...] an amount of [...***...]; and 

  

	 	b)	Upon [...***...], an amount of [...***...]; and 

  

	 	c)	Upon [...***...], an amount of [...***...]; and 

  

	 	d)	Upon [...***...], an amount of [...***...]. 

  

***Confidential Treatment Requested 

  
 22 

	3.11	Reversion of Rights in Primary Compound. If the Back-Up Compound does not fall within the scope of the Licensed Patents for the Primary Compound and Flexion
decides that it no longer wishes to Develop and/or commericalise the Primary Compound then it shall promptly notify AstraZeneca of such decision whereupon the rights granted to Flexion pursuant to Section 3.1 with respect to the Primary
Compound shall terminate and revert to AstraZeneca and, with respect to the Primary Compound only, the provisions of Section 18.6.2 shall apply. 

  

	3.12	Reversion of Rights in Back-Up Compound. If Flexion decides that it no longer wishes to Develop and/or commericalise the Back-Up Compound then it shall promptly
notify AstraZeneca of such decision whereupon the rights granted to Flexion pursuant to Section 3.1 with respect to the Back-Up Compound shall terminate and revert to AstraZeneca and, with respect to the Back-Up Compound only, the provisions of
Section 18.6.2 shall apply. 

  

	4	Development And Selection Of A Back-Up Compound 

  

	4.1	AstraZeneca responsibilities. 

  

	 	4.1.1	AstraZeneca will carry out further research and Development activities at its own expense and at its sole discretion for the purposes of providing to Flexion one or, if
more are available, up to [...***...] back-up compounds to the Primary Compound. 

  

	 	4.1.2	AstraZeneca will maintain at all times sole decision making authority with respect to its research and development activities for this purpose including without
limitation decisions regarding staffing and resource allocation. 

  

	 	4.1.3	AstraZeneca will nominate by written notice to Flexion up to [...***...] compounds (the actual number shall be at AstraZeneca’s discretion) as potential
back-up compounds but AstraZeneca will nominate at least [...***...] (“Nominated Compound(s)”). 

  

	 	4.1.4	AstraZeneca will be responsible for filing, in its own name, any Intellectual Property Rights and Patents in respect of the Nominated Compounds. Once a compound has
been nominated by AstraZeneca in accordance with Section 4.1.3 there shall be no further requirement for AstraZeneca to carry 

  

***Confidential Treatment Requested 

  
 23 

	 	
out any additional work in respect of such Nominated Compound or any other potential back-up compounds. 

 

	4.2	Timing for nomination of Nominated Compounds by AstraZeneca. AstraZeneca will use Commercially Reasonable Efforts to propose to Flexion [...***...]
Nominated Compound(s) on (or within 90 days of) the Effective Date. 

  

	4.3	Acceptance of a Back-Up Compound. 

  

	 	4.3.1	Flexion may select any or all of the Nominated Compounds proposed by AstraZeneca in order to determine whether those compounds meet Flexion’s acceptance criteria
for a back-up (“Acceptance Criteria”). The Acceptance Criteria shall be determined by Flexion in its sole discretion. At the request of AstraZeneca, Flexion shall disclose the Acceptance Criteria to AstraZeneca, which Acceptance
Criteria shall constitute Flexion Confidential Information. 

  

	 	4.3.2	AstraZeneca hereby grants Flexion an exclusive, worldwide, royalty-free licence, to carry out research and development on the Nominated Compounds for the purpose of
determining whether those compounds meet the Acceptance Criteria. 

  

	 	4.3.3	If one or more of the Nominated Compounds meet the Acceptance Criteria Flexion shall promptly inform AstraZeneca and shall notify AstraZeneca in writing which one of
the Nominated Compounds Flexion has chosen to accept as the Back-Up Compound. Upon such notice, the chosen Back-Up Compound shall automatically be included and covered by the rights granted to Flexion under Section 3.1.

  

	 	4.3.4	Once Flexion has selected the Back-Up Compound AstraZeneca shall notify Flexion which, if any, Patents, which cover or claim the Back-Up Compound shall fall within the
Licensed Patents and, if applicable, the Retained Patents and shall complete and append to this Agreement an amended Schedule 1 listing all Licensed Patents including those covering the Back-Up Compound. 

 

	 	4.3.5	 Once Flexion has notified AstraZeneca of the selection of the Back-Up Compound, AstraZeneca shall complete and append to this Agreement a

  

***Confidential Treatment Requested 

  
 24 

	 	
Schedule in respect of the Back-Up Compound in substantially the same form as that relating to the Primary Compound contained at Schedule 1. 

 

	4.4	Timing for acceptance of Nominated Compounds by Flexion. 

 Flexion may accept a Nominated Compound at any time up to [...***...] after [...***...] for the Primary Compound. If Flexion does not notify AstraZeneca in writing of its acceptance or
rejection of a Nominated Compound by the end of the time period referred to above, Flexion shall be deemed to have rejected the Nominated Compound in question and all rights in and to the Nominated Compound will revert to AstraZeneca and the licence
rights granted to Flexion at Section 4.3.2 shall terminate. AstraZeneca will bear the costs of prosecuting and maintaining any Patents which claim or cover the Nominated Compounds until 1st January 2011 after which time AstraZeneca shall
have no obligation to prosecute or maintain any such Patents in any country of the Territory unless Flexion agrees to reimburse AstraZeneca for its costs of so doing. 
  

	5	Improvements 

  

	5.1	Any and all Improvements which Flexion and or its Affiliates or Sublicensees makes during the term of this Agreement shall be the sole and exclusive property of
Flexion, its Affiliates, and Sublicensees (as the case may be), and save as set out in this Agreement, AstraZeneca shall not acquire any right to or under any such Improvements. 

 

	5.2	Flexion shall have the right, at its sole discretion, to apply for and file in its own name any and all Intellectual Property Rights and Patents arising in any
Improvement created by Flexion, its Affiliates or any Sublicensee of Flexion. 

  

	6	Development 

  

	6.1	Know-How Disclosure. 

AstraZeneca shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to Flexion, Regulatory
Documentation, and Licensed Know-How in each case that is in existence as of the Effective Date as listed in Schedule 1. In the event that after the Effective Date and the initial disclosure of

  

***Confidential Treatment Requested 

  
 25 

 
Regulatory Documentation and Licensed Know-How by AstraZeneca, Flexion has any requests related to transferred Regulatory Documentation and Licensed Know-How in the [...***...] after the
Effective Date then AstraZeneca will use reasonable efforts to answer such requests and provide additional data and reports available at AstraZeneca not yet disclosed to Flexion (if any), provided that AstraZeneca shall not have any obligation to
generate any new data not in existence at the Effective Date. After such [...***...] period, Flexion may make only limited requests as needed by Flexion in the context of any submission to or communication with a Health Authority. 

 

	6.2	Research and Development costs. Except where AstraZeneca is carrying out additional research and development activities to bring forward Nominated Compounds all
other research and Development costs will be the responsibility of Flexion, including any activities which Flexion undertakes pre-acceptance in order to determine whether a Nominated Compound meets the Acceptance Criteria. 

 

	6.3	Diligence Obligations. 

  

	 	6.3.1	Flexion undertakes to use Commercially Reasonable Efforts at its own cost to (a) Develop and commercialise at least one (1) Licensed Product in each Major
Market in the Territory in accordance with the terms and conditions of this Agreement, and (b) obtain Health Registration Approval(s) to market and sell at least one (1) Licensed Product in each Major Market in the Territory and
(c) market and sell at least one (1) Licensed Product in each Major Market in the Territory. 

  

	 	6.3.2	Flexion shall perform, or cause to be performed, any and all of its Development and commercialisation obligations as set forth in this Agreement, including those
obligations identified in Section 6.3.1, in good scientific manner, and in compliance in all material respects with all Applicable Law. 

  

	 	6.3.3	 Flexion’s designated person shall report verbally to AstraZeneca’s designated person (the Parties’ designated persons are further
specified in Schedule 4 to this Agreement) on a Quarterly basis (at a time and via a media to be mutually 

  

***Confidential Treatment Requested 

  
 26 

	 	
agreed between the Parties) on its progress in the Development of the Licensed Products in the Territory in reasonable detail in order to keep AstraZeneca informed of its progress. Such Quarterly
updates shall cease upon the First Commercial Sale of the first Licensed Product, unless the Parties agree otherwise. 

  

	6.4	Breach of Diligence Obligations. 

  

	 	6.4.1	Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Flexion is in breach of its obligations under Section 6.3 with
respect to a Major Market, then AstraZeneca shall so notify Flexion, specifying the basis for its belief, and the Parties shall meet [...***...] after such notice to discuss in good faith AstraZeneca’s concerns and Flexion’s
Development and commercialisation plans with respect to the Licensed Product(s) to attempt to eliminate AstraZeneca’s concerns. 

  

	 	6.4.2	Right of Termination. If after good faith discussions pursuant to Section 6.4.1, AstraZeneca’s concerns have not been eliminated and (a) the
Parties have not agreed [...***...] under Section 6.4.1 above, upon the reasonable steps to be taken to eliminate such concerns [...***...]; or (b) Flexion does not take the agreed upon reasonable steps
 [...***...]
designed to rectify its breach of its obligations under Section 6.3 in such Major Market [...***...] and thereafter diligently pursue such actions, AstraZeneca may exercise its right of termination provided under Section 18.2.

  

	6.5	 Records and Reporting. Flexion shall prepare and maintain complete and accurate records regarding the Development and commercialisation of the
Licensed Products. Flexion shall provide AstraZeneca by 31st January in each Calendar Year a report for the previous Calendar Year describing the progress in the Development of Licensed Products in the Territory in reasonable detail in order to
keep AstraZeneca informed of its progress. Such report shall cover, in relation to Compounds and Licensed Products, general information on Flexion’s Development activities in the previous

  

***Confidential Treatment Requested 

  
 27 

	 	
Calendar Year and a summary of the activities planned in the next Calendar Year. If and when a Health Registration Approval is obtained in any country of the Territory, Flexion shall inform
AstraZeneca of such Health Registration Approval within thirty (30) days. 

  

	7	Consideration 

  

	7.1	Milestone Payments. In partial consideration of the licences and other rights granted by AstraZeneca to Flexion herein and subject to the terms and conditions of
this Agreement, Flexion shall pay AstraZeneca the following sums: 

  

	 	7.1.1	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days of the Effective Date (this amount includes a
payment of USD$[...***...] in consideration for [...***...]; 

  

	 	7.1.2	a non refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.3	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days of
 [...***...]; and

 Osteoarthritis 
 For the first Licensed Product Developed by Flexion (or a Sublicensee) for the treatment of Osteoarthritis: 
  

	 	7.1.4	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.5	 a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]

  

***Confidential Treatment Requested 

  
 28 

	 	
[...***...]; 

  

	 	7.1.6	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.7	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.8	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]; and

  

	 	7.1.9	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...].

 The milestones payable for Japan shall also be payable in the circumstances set out in Section 3.10
(Japan). 
 Non-OA Indications 
 For the first Licensed Product Developed by Flexion (or a Sublicensee) for the treatment of any Non-OA Indication: 
  

	 	7.1.10	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.11	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

***Confidential Treatment Requested 

  
 29 

	 	7.1.12	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	7.1.13	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]; and

  

	 	7.1.14	a non-refundable payment of USD$[...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...].

 Milestone payments in Section 7.1 will be payable [...***...] and will be payable for such
[...***...]. Other than as outlined above [...***...]. Flexion shall notify AstraZeneca within thirty (30) days of any determination, filing or approval that would trigger a payment by Flexion to AstraZeneca under this
Section 7.1, with details of the amount of the payment required and funds to meet the payment required. 
  

	7.2	Royalties. In addition to the foregoing payments, Flexion shall pay AstraZeneca with respect to the Licensed Products the following royalties on the Net Sales of
the Licensed Products in the Territory during each Calendar Year (provided that calculations for the Combination Products are to be made in accordance with the formula set out in Section 7.3 below): 

 

	 	7.2.1	in respect of sales of Licensed Products [...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products
in the Territory during such Calendar Year that are less than USD$[...***...] ([...***...] United States Dollars) (“Tier 1”); 

  

***Confidential Treatment Requested 

  
 30 

	 	7.2.2	in respect of sales of Licensed Products [...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products
in the Territory during such Calendar Year that equal or exceed 
USD$[...***...] ([...***...] United States Dollars) but are less than USD$[...***...] ([...***...] United States Dollars) (“Tier 2”); and

  

	 	7.2.3	in respect of sales of Licensed Products [...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products
in the Territory during such Calendar Year that equal or exceed 
USD$[...***...] ([...***...] United States Dollars) but are less than USD$[...***...] ([...***...] United States Dollars) (“Tier 3”); and

  

	 	7.2.4	in respect of sales of Licensed Products [...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products
in the Territory during such Calendar Year that equal or exceed
 USD$[...***...] ([...***...] United States Dollars) (“Tier 4”). 

 The calculation of royalties under this Section 7.2 shall be conducted separately for each Licensed Product. All sales of a Licensed Product whether sold for the treatment of Osteoarthritis or Non-OA
Indications or as a Combination Product, shall [...***...]. Thus if Flexion [...***...]. 
  

	7.3	Combination Products. With respect to Combination Products, the Net Sales used for the calculation of the royalties under Section 7.2 shall be determined as
follows: 

    A                
X            Net Sales of the Combination Product, where: 

  A+B 
  

	 	A =	standard sales price of the Licensed Product, containing a comparable amount of Compound as the sole active ingredient as the Combination Product in question, in the
given country. 

  

	 	B =	standard sales price of the ready-for-sale form of a product, containing a comparable amount of the other therapeutically active ingredient(s) that is contained in the
Combination Product in question, in the given country. 

  

***Confidential Treatment Requested 

  
 31 

 In the event, however, that if, in a specific country, (a) the other therapeutically
active ingredient(s) in such Combination Product is not sold separately in such country, Net Sales shall be adjusted by multiplying actual Net Sales of such Combination Product by the fraction A/C, where C is the standard sales price in such country
of such Combination Product, and (b) if a Product containing such compound(s) is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-B)/C, where B is the standard
sales price in such country of the other therapeutically active ingredient(s) in the Combination Product and C is the standard sales price in such country of the Combination Product. The standard sales price for the Product containing such
compound(s) and for each other active ingredient shall be for a quantity comparable to that used in such Combination Product and of the same class, purity and potency. 
 If, in a specific country, the foregoing calculations do not fairly represent the value of the various active ingredients included in a Combination Product, the allocation of Net Sales for such
Combination Product shall be negotiated by the Parties in good faith comparable to such Product or such other active ingredients, as applicable. 
 If, after good faith negotiations the Parties cannot agree on the appropriate allocation of Net Sales for such a Combination Product in any given country, then either Party shall have the right to refer
such dispute to an independent third party who has had experience in a Major Market pricing and reimbursement authority and who is acceptable to both Parties, (agreement not to be unreasonably withheld or delayed by either Party). 

 

	7.4	Sales Related Payments. 

Flexion shall pay to AstraZeneca the following sales related payments: 

 

	 	(i)	USD$[...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed
USD$[...***...] ([...***...] United States Dollars) for the first time. 

  

	 	(ii)	 USD$[...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed

  

***Confidential Treatment Requested 

  
 32 

	 	
USD$[...***...] ([...***...] United States Dollars) for the first time. 

  

	 	(iii)	USD$[...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed
USD$[...***...] ([...***...] United States Dollars) for the first time. 

 The sales related payments
shall be paid at the end of the Calendar Quarter in which the relevant Net Sales threshold was achieved at the same time as Flexion pays the royalties due for that Calendar Quarter. 

The sales related payments set out above are subject to increase in accordance with the terms of Section 17 below (Potential Third
Party Rights). 
  

	7.5	Reduction of Royalty. 

 In
the event that, or from and after the date on which, (a) [...***...] exists in a country, and (b) [...***...] exists in such country, the royalty rate payable to AstraZeneca by Flexion under Section 7.2 with respect to Net
Sales of such Licensed Product in such country, shall be [...***...]. Any royalties owed to AstraZeneca after such a reduction in the royalty rate shall be compensation for Flexion’s use of the Licensed Know-How in accordance with
Section 3.3. 
  

	7.6	Royalty Term. Flexion’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Licensed Product, on the
date of First Commercial Sale of such Licensed Product in such country. The obligation shall expire, on a country-by-country basis, with respect to each separate Licensed Product on the later to occur of: (a) the twelfth (12th) anniversary
of the First Commercial Sale of such Licensed Product in such country, and (b) such time as there is no longer (i) any Valid Claim of a Licensed Patent that claims or covers the Exploitation of such Licensed Product in such country, and
(ii) any Data Exclusivity with respect to such Licensed Product in such country. 

  

	7.7	Sales Subject to Royalties. Sales between Flexion, its Affiliates and Sublicensees shall not be subject to royalties hereunder. Royalties shall be calculated on
Flexion’s, 

  

***Confidential Treatment Requested 

  
 33 

 its Affiliates’ and its Sublicensees’ sale of the Licensed Products to a Third
Party. Royalties shall be payable only once for any given batch of the Licensed Products. For purposes of determining Net Sales, the Licensed Product shall be deemed to be sold when shipped and a “sale” shall not include, and no royalties
shall be payable on, transfers of Licensed Products that are used as samples or in clinical trials or other transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory or governmental purposes. 

 

	7.8	Royalty Payments. The royalties shall be calculated quarterly as of the last day of March, June, September and December respectively, for the Calendar Quarter
ending on that date. Flexion shall pay the royalties in conjunction with the delivery of a written report to AstraZeneca within sixty (60) days after the end of each Calendar Quarter that shows, with respect to each country and each Licensed
Product, the sales volume, gross sales amount and Net Sales of the Licensed Products during such Calendar Quarter. 

  

	7.9	Records Retention; Audit. 

  

	 	7.9.1	Flexion shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate records or books of account in accordance with generally accepted
accounting principles showing the information that is necessary for the accurate determination of the royalties due hereunder with respect to the sale of such Licensed Product. Such books and records shall be retained by Flexion and its Affiliates
and Sublicensees until the later of (a) five (5) years after the end of the period to which such books and records pertain, and (b) the expiration of the applicable tax statute of limitations (or any extensions thereof), or for such
longer period as may be required by Applicable Law. 

  

	 	7.9.2	 Upon the written request of AstraZeneca, Flexion shall, and shall cause its Affiliates and Sublicensees to, permit a certified public accountant or a
person possessing similar professional status and associated with an independent accounting firm acceptable to the Parties to inspect during regular business hours and no more than [...***...] a year and going back no more than
[...***...] preceding the current year, all or any part of Flexion’s records and books necessary to check the accuracy of the royalties paid. Any period may be 

  

***Confidential Treatment Requested 

  
 34 

	 	
included in such audit only once. The accounting firm shall enter into appropriate obligations with Flexion to treat all information it receives during its inspection in confidence. The
accounting firm shall disclose to AstraZeneca and Flexion only whether the royalty reports are correct and details concerning any discrepancies, but no other information shall be disclosed to AstraZeneca. The cost of such review, including the
charges of any accounting firm, shall be paid by [...***...], except that if the royalties have been [...***...] by more than [...***...], the costs shall be paid by [...***...]. If any such audit concludes that Flexion has
overpaid royalties it may offset the amount of any such overpayment against future royalty payments. 

  

	 	7.9.3	In the event of a dispute regarding the amount of royalties owed to AstraZeneca under Section 7.2 or 7.3, AstraZeneca and Flexion shall work in good faith to
resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, the dispute shall be submitted for arbitration to a certified public accounting firm selected jointly by
each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Arbitrator”). The decision of the Arbitrator shall be final and the costs of such arbitration as well as the initial
review shall be borne by the losing Party. Not later than ten (10) days after such decision, Flexion shall pay to AstraZeneca any additional royalties owed to AstraZeneca in accordance with such decision. 

 

	 	7.9.4	The receiving Party shall treat all information subject to review under this Section 7.9 in accordance with the confidentiality provisions of Article 11 and the
Parties shall cause the Arbitrator to enter into a reasonably acceptable confidentiality agreement with Flexion obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement.

  

	7.10	Mode of Payment. All payments set forth in this Article 7 shall be remitted by wire transfer to the following bank account of AstraZeneca or such other account
as AstraZeneca may designate in writing to Flexion: 

  

***Confidential Treatment Requested 

  
 35 

 BANK ACCOUNT 
 Bank Name: [...***...] 
 Bank Address: [...***...] 

Account Name: [...***...] 
 Account No: [...***...] 
 SWIFT Address: [...***...] 

 

	7.11	Currency. All payments required under this Article 7 shall be made in U.S. Dollars. If any currency conversion shall be required in connection with any payment
hereunder, such conversion shall be made by using the arithmetic mean of the exchange rates for the purchase of U.S. dollars as published in The Wall Street Journal, Eastern Edition, on the first Business Day of each Calendar Quarter and the
last Business Day of each month in the Calendar Quarter to which such payments relate. 

  

	7.12	Taxes. 

  

	 	7.12.1	General. The royalties, milestones and other amounts payable by Flexion to AstraZeneca pursuant to this Agreement (“Payments”) shall not be
reduced on account of any taxes unless required by Applicable Law. AstraZeneca alone shall be responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be paid by Flexion) levied on account of, or measured
in whole or in part by reference to, any Payments it receives. Flexion shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if AstraZeneca is entitled under
any applicable tax treaty to a reduction of the rate of or the elimination of, applicable withholding tax, it may deliver to Flexion or the appropriate governmental authority (with the assistance of Flexion to the extent that this is reasonably
required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Flexion of its obligation to withhold tax, and Flexion shall apply the reduced rate of withholding, or dispense
with withholding, as the case may be, provided that Flexion has received evidence, in a form reasonably satisfactory to Flexion, of AstraZeneca’s delivery of all applicable forms (and, if necessary, its receipt of

  

***Confidential Treatment Requested 

  
 36 

	 	appropriate governmental authorization) at least fifteen (15) days prior to the time that the Payments are due. If, in accordance with the foregoing, Flexion
withholds any amount, it shall pay to AstraZeneca the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to AstraZeneca proof of such payment within sixty (60) days following that payment.

  

	 	7.12.2	Indirect Taxes. Notwithstanding anything contained in Section 7.12.1, this Section 7.12.2 shall apply with respect to Indirect Taxes. All Payments are
exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, Flexion shall pay Indirect Taxes at the applicable rate in respect of any such Payments following the receipt of an Indirect Taxes invoice in the
appropriate form issued by AstraZeneca in respect of those Payments, such Indirect Taxes to be payable on the later of the due date of the payment of the Payments to which such Indirect Taxes relates and sixty (60) days after the receipt by
Flexion of the applicable invoice relating to that Indirect Taxes payment. 

  

	7.13	Interest on Late Payment. If any payment due to AstraZeneca under this Agreement is overdue then Flexion shall pay interest thereon (before and after any
judgment) at an annual rate (but with interest accruing on a daily basis) of [...***...] published in respect of the period starting on the due date of payment and ending on the actual date of payment, such interest to run from the date upon
which payment of such sum became due until payment thereof in full together with such interest. 

  

	8	Delivery of Study Drug 

 AstraZeneca shall deliver the Study Drug to Flexion (free of charge except for that amount already included in the payment at Section 7.1.1) on the Effective Date by keeping it ready for
Flexion’s collection at AstraZeneca’s [...***...] facility in
 [...***...]. Flexion shall at its own cost and risk, take possession of such Study Drug by collecting it at said location and AstraZeneca shall co-operate fully
with Flexion to enable shipping of Study Drug to a destination of Flexion’s choosing. 

  

***Confidential Treatment Requested 

  
 37 

	9	Ownership of Intellectual Property 

  

	9.1	Ownership of Technology. Subject to Section 9.2 and the licence grants to Flexion under Section 3.1, as between the Parties, each Party shall own and
retain all right, title and interest in and to any and all: (a) Know-How and other inventions that are conceived, discovered, developed or otherwise made, as necessary to establish authorship, inventorship or ownership under Applicable Law, by
or on behalf of such Party under or in connection with this Agreement (or its Affiliates or its licensors or sublicensees), whether or not patented or patentable, and any and all Patent and Intellectual Property Rights with respect thereto, and
(b) other Know-How or other inventions, and Patent and Intellectual Property Rights that are owned or otherwise Controlled (other than pursuant to the licence grants set forth in Section 3.1) by such Party, its Affiliates or its Licensors
or sublicensees. 

  

	9.2	Ownership of Licensed Patents and Licensed Know-How. Subject to the licence grants to Flexion under Section 3.1 as between the Parties, AstraZeneca shall
own and retain all right, title and interest in and to all Licensed Patents and Licensed Know-How. 

  

	9.3	Ownership of Retained Patents. As between the Parties, AstraZeneca shall own and retain all right, title and interest in and to all Retained Patents and without
prejudice to Section 3.4 grants no right, title and interest in or to the Retained Patents to Flexion. 

  

	10	Adverse Event Reporting 

 Flexion shall undertake all responsibility for all pharmacovigilence activities relating to the safety of each Licensed Product. 

 

	11	Confidentiality & Non-Disclosure 

  

	11.1	Defined; General Obligations. 

  

	 	11.1.1	 In this Agreement, “Confidential Information” shall, subject to Section 11.3, mean any and all data, results, know-how (including
the Licensed Know-How), plans, business information and other Know-How, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party, including the terms of this

  
 38 

	 	
Agreement. At all times during the term of this Agreement and for a period of five (5) years following termination or expiration hereof, each Party (the “Receiving Party”)
shall, and shall cause its officers, directors, employees, agents, Affiliates and Sublicensees to, keep confidential and not publish or otherwise disclose and not use, directly or indirectly, for any purpose, any Confidential Information provided to
it by the other Party (the “Disclosing Party”), except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary for the performance of this Agreement.

  

	11.2	Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: 

 

	 	11.2.1	made in response to a valid order of a court of competent jurisdiction or other competent authority; provided, however, that the Receiving Party shall,
where practical and permitted, first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash any such order or obtain a protective order requiring that the Confidential Information and documents
that are the subject of such order be held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order was issued and where permitted have the commercial terms redacted; and provided
further that if such order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be
disclosed in response to such court or governmental order; 

  

	 	11.2.2	made by the Receiving Party to a Health Authority as may be necessary in connection with any filing, application or request for or to achieve a Health Registration
Approval; provided, however, that reasonable measures shall be taken to ensure confidential treatment of such information, to the extent such protection is available; 

 

	 	11.2.3	 made by the Receiving Party to a patent authority as may be necessary or reasonably useful for purposes of obtaining or enforcing a Patent (consistent
with the terms and conditions of Article 16); provided, however, that 

  
 39 

	 	
reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

 

	 	11.2.4	otherwise required by law; provided, however, that the Receiving Party shall (a) provide the Disclosing Party, where practicable and permitted, with
reasonable advance notice of and an opportunity to comment on any such required disclosure, (b) if requested by the Disclosing Party, seek confidential treatment with respect to any such disclosure to the extent available, and (c) use good
faith efforts to incorporate the comments of the Disclosing Party in any such disclosure or request for confidential treatment; or 

  

	 	11.2.5	made by Flexion or its Affiliates or Sublicensees to Third Parties as may be necessary in connection with the Development, Exploitation or Manufacture of the Compounds
or the Licensed Products as contemplated by this Agreement, including permitted subcontracting or sublicensing transactions in connection therewith provided all such disclosures are subject to obligations of confidentiality substantially similar to
the terms set out in this Article 11; or 

  

	 	11.2.6	made by Flexion to Third Parties in connection with fund raising or financings or a due diligence or similar investigations by such Third Parties, and disclosure to
potential Third Party investors or financial institutions or advisors in financing documents, provided in each case that any such Third Party agrees to be bound by obligations of confidentiality and non-use on substantially similar terms as those
set out in this Article 11 for a minimum period of three years. 

 Notwithstanding the foregoing, in the event that
either Party is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body to disclose this Agreement, in whole or in part, the Parties shall reasonably agree on a redacted version of this
Agreement as necessary to protect the Confidential Information of the other Party prior to making such disclosure. 

  
 40 

	11.3	Exclusions. Notwithstanding the foregoing, Confidential Information shall not include any information that: 

 

	 	11.3.1	is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of
the Receiving Party; 

  

	 	11.3.2	can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s or its Affiliates’ possession prior to disclosure by the
Disclosing Party; 

  

	 	11.3.3	is subsequently received by the Receiving Party or its Affiliates from a Third Party who is not bound by any obligation of confidentiality with respect to said
information; 

  

	 	11.3.4	is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or 

 

	 	11.3.5	is independently developed by or for the Receiving Party or its Affiliates without reference to the Disclosing Party’s Confidential Information.

 Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in
the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential Information shall
not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and
its principles are in the public domain or in the possession of the Receiving Party. 
  

	11.4	Publications. 

 Flexion
shall have the sole right to publish any papers regarding results and other information related to Compounds and Licensed Products or the development thereof, including oral presentations and abstracts. Upon submission for peer review, Flexion shall
provide AstraZeneca with a copy of each such proposed publication. 

  
 41 

	11.5	Use of Name. Neither Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in
any publication, press release, promotional material or other form of publicity without the prior written consent of the other Party (which shall not be unreasonably withheld or delayed), except for those disclosures for which consent has previously
been obtained. The restrictions imposed by this Section 11.5 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law or the requirements of a national securities exchange or
another similar regulatory body, provided that any such disclosure shall be governed by this Article 11. Further, the restrictions imposed on each Party under this Section 11.5 are not intended, and shall not be construed, to prohibit a Party
from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this Article 11. 

 

	11.6	Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in this Article 11 are reasonable and necessary to protect the legitimate
interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of this Article 11 will result in irreparable injury to
the other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of this Article 11 by one Party, the other Party shall be authorised and entitled to obtain from any court of competent
jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other
rights or remedies to which such other Party may be entitled in law or equity. Nothing in this Section 11.6 is intended, or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any
other provision of this Agreement. 

  

	12	Trademarks 

Flexion shall have the sole right to select the Trademarks for the marketing and sale of the Licensed Products in the Territory. Flexion
shall own such Trademarks and all rights and goodwill with respect thereto. 

  
 42 

	13	Representations and Warranties 

  

	13.1	Representations, Warranties and Covenants. Each Party hereby represents, warrants and covenants to the other Party as of the Effective Date as follows:

  

	 	13.1.1	Corporate Authority. Such Party (a) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder,
and (b) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party
and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of
creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. 

 

	 	13.1.2	Litigation. Such Party is not aware of any pending or threatened litigation (and has not received any communication) that alleges that such Party’s
activities related to this Agreement have violated, or that by conducting the activities as contemplated herein such Party would violate, any of the Intellectual Property Rights of any other party. 

 

	 	13.1.3	Consents, Approvals, etc. All necessary consents, approvals and authorizations of all Health Authorities and other Persons required to be obtained by such Party
in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

  

	 	13.1.4	Conflicts. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate
any provision of the articles of incorporation, bylaws or any similar instrument of such Party in any material way, and (b) do not conflict with, violate, or breach or constitute a default or require any consent under, any contractual
obligation or court or administrative order by which such Party is bound. 

  
 43 

	 	13.1.5	Debarment. No such Party nor any of its Affiliates has been debarred or is subject to debarment and neither such Party nor any of its Affiliates will use in any
capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the Federal Food, Drug, and Cosmetic Act, as amended, or who is the subject of a conviction described in
such section. Each Party will inform the other Party in writing immediately if it or any Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to such Party’s knowledge, is threatened, relating to the debarment or conviction of such Party or any Person performing services hereunder. 

 

	 	13.1.6	Compliance with Applicable Laws. 

 Each Party shall use all reasonable efforts to comply with all Applicable Laws in exercising its rights and complying with its obligations pursuant to this Agreement. 

 

	13.2	Additional Representations and Warranties of AstraZeneca. As of the Effective Date, AstraZeneca represents and warrants to Flexion that:

  

	 	13.2.1	AstraZeneca Controls the Patents listed on Schedule 1 and the Licensed Know-How, and is entitled to grant the licences specified herein and except as set forth in
Section 3.1, neither AstraZeneca nor any of its Affiliates has granted any licence or other right to any Third Party with respect to Compounds, Licensed Products, Licensed Patents or Exclusive Licensed Know-How; 

 

	 	13.2.2	To AstraZeneca’s Knowledge, the Licensed Patents are being procured from the respective Patent Offices in accordance with Applicable Law; 

 

	 	13.2.3	AstraZeneca has not received notice from any Third Party claiming that the manufacture, use or sale of Compounds or Licensed Products infringes the Patents of any Third
Party; 

  

	 	13.2.4	AstraZeneca is not a party to any legal action, suit or proceeding relating to Compounds, Licensed Products, Licensed Patents or Licensed Know-How;

  
 44 

	 	13.2.5	To AstraZeneca’s Knowledge, it has not withheld any material information relating to (a) pre-clinical and clinical data, regulatory filings and regulatory
communications, relating exclusively to the Compounds and the Licensed Products and (b) the filing and prosecution of the Licensed Patents, and (c) ownership of the Licensed Patents and the Licensed Know-How. 

For the avoidance of doubt Flexion acknowledges and agrees that AstraZeneca shall not be in breach of this warranty for failure to
disclose, and shall be under no obligation to disclose, to Flexion any opinions created or obtained by or on behalf of AstraZeneca with regard to the potential infringement or non-infringement of any intellectual property rights of Third Parties.

  

	 	13.2.6	 The Study Drug meets the specifications as determined by AstraZeneca’s analytical methodology as at 1st June 2009 (such specifications as are set out in Schedule 1)
and to AstraZeneca’s Knowledge shall, upon delivery to Flexion in accordance with Section 8 (provided that such delivery occurs by 1st September 2009), meet the specifications set out in Schedule 1. 

 

	 	13.2.7	To AstraZeneca’s Knowledge, it does not own or Control any Intellectual Property Rights or Patents that are necessary to Exploit the Compounds or the Licensed
Patents or Licensed Know-How. In the event that the Parties discover at a later date that AstraZeneca does own or Control, any such Intellectual Property Rights or Patents and did so as at the Effective Date, then AstraZeneca shall grant to Flexion
a freedom to operate right in the terms of Section 3.4, in respect of the same. 

  

	13.3	 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 13.1 AND 13.2, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR IN THE CASE OF ASTRAZENECA ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-

  
 45 

	 	
INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  

	14	Indemnity 

  

	14.1	Indemnification of AstraZeneca. In addition to any other remedy available to AstraZeneca, Flexion shall indemnify, defend and hold harmless AstraZeneca, its
Affiliates and its and their directors, officers and employees (“AstraZeneca Indemnitees”) in full and on demand, from and against any and all Losses incurred by them to the extent resulting from arising out of or in connection with
any claims made or suits brought by a Sublicensee or Third Party (collectively, “Third Party Claims”) against any AstraZeneca Indemnitee, that arise or result from (a) any intentional misconduct or negligence on the part of
Flexion or its Affiliates in performing any activity contemplated by this Agreement, or the breach of any provision of this Agreement by Flexion or (b) the Exploitation by Flexion, its Affiliates or Sublicensees of the Licensed Products
(including any claims for death, personal injury or infringement of a Third Party’s rights) except where and to the extent that any Third Party Claims or Losses have been caused or increased by the negligence or wilful misconduct of any
AstraZeneca Indemnitee after the Effective Date of this Agreement. 

  

	14.2	Indemnification of Flexion. In addition to any other remedy available to Flexion, AstraZeneca shall indemnify, defend and hold harmless Flexion, its Affiliates
and its and their directors, officers and employees (“Flexion Indemnitees”) in full and on demand, from and against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with any Third
Party Claims against any Flexion Indemnitee, that arise or result from any intentional misconduct or negligence on the part of AstraZeneca or its Affiliates in performing any activity contemplated by this Agreement, or the breach of any provision of
this Agreement by AstraZeneca or any breach of the representations or warranties made by AstraZeneca under this Agreement, except where and to the extent that any such Third Party Claims or Losses have been caused or increased by the negligence or
wilful misconduct of any Flexion Indemnitee after the Effective Date of this Agreement. 

  
 46 

	14.3	Indemnification Procedure. Should the Indemnified Party intend to claim indemnification hereunder from the Indemnifying Party, the Indemnified Party shall
promptly notify the Indemnifying Party in writing of any Losses in respect of which the Indemnified Party intends to claim such indemnification and the Indemnifying Party shall be entitled, but not obligated, to assume the defence of any Third Party
Claim thereof with counsel selected by it. The Indemnified Party, including its Affiliates, directors, officers and employees, shall co-operate fully, at the Indemnifying Party’s expense, with the Indemnifying Party and its legal
representatives in the investigation and defence of any Third Party Claim covered by this indemnification. The indemnification shall not apply to amounts paid in settlement of any Third Party Claim if such settlement is effected without the consent
of the Indemnifying Party, not to be unreasonably withheld or delayed. 

  

	14.4	LIMITATION ON DAMAGES. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS
UNDER SECTION 14.1 OR 14.2, NO PARTY OR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (a) THE
DEVELOPMENT, MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT OR COMPOUND DEVELOPED, MANUFACTURED OR MARKETED HEREUNDER, (b) THE USE OR REFERENCE OF THE LICENSED PATENTS, LICENSED KNOW-HOW, REGULATORY DOCUMENTATION, OR (c) ANY BREACH OF OR
FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT. 

  

	14.5	Insurance. Flexion shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply, use and sale of the Compounds and the
Licensed Products as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, and shall upon request provide AstraZeneca with confirmation of such insurance in that regard, and any amendments and revisions
thereto. 

  
 47 

	15	Maintenance and Prosecution of Patents 

  

	15.1	Licensed Patents. Flexion shall at its sole cost and expense, using reputable patent and legal counsel of its own choosing, file, prosecute (including any
interferences, reissue proceedings and re-examinations) and maintain the Licensed Patents in at least the List Two Countries. The List Two Countries are set out in Exhibit 2 to this Agreement. In the prosecution, maintenance, and defence of the
Licensed Patents, Flexion shall always act in good faith and in the best interests of obtaining and maintaining a scope of claims providing sufficient exclusionary protection to commercialise Licensed Products or
 Compound(s).

  

	15.2	Co-operation. AstraZeneca shall, and shall cause its Affiliates, as applicable, to, cooperate fully with Flexion in the preparation, filing, prosecution, and
maintenance of the Licensed Patents. Such cooperation includes (a) executing all papers and instruments and requiring employees to execute such papers and instruments as reasonable and appropriate so as to enable Flexion to file, prosecute and
maintain the Licensed Patents in any country, and (b) informing Flexion of matters that may affect the preparation, filing, prosecution or maintenance of any such Licensed Patents. Flexion shall provide AstraZeneca with an opportunity to review
and comment on the nature and text of new or pending applications for Licensed Patents and shall advise AstraZeneca, if practicable and possible, at least one (1) month before each patent prosecution deadline as to the response that Flexion
proposes to make. If AstraZeneca provides to Flexion comments with respect to any such application or submission, to the extent such comments relate to any Licensed Patents, Flexion shall reasonably consider such comments, it being understood that
Flexion retains the right to determine whether to comply with or incorporate such comments, if at all. Flexion shall advise AstraZeneca on an annual basis of progress in the prosecution of all patent applications and in the maintenance or extension
of patents falling within the Licensed Patents and shall, on request, furnish AstraZeneca with a copy of the patent application, patent or other document pertinent to the prosecution, maintenance or extension of such applications and patents.

  

	15.3	 Additional Patent Protection. Flexion may seek additional patent protection for the Compounds or Licensed Products in any part of the Territory,
for example, by way of patent registration, patent of importation or revalidation or the like in the name of 

  
 48 

	 	
Flexion, at [...***...]. Any such additional patents shall be [...***...] for the purposes of this Agreement. 

 

	16	Enforcement of Patents 

  

	16.1	Rights and Procedures. In the event that either Party reasonably believes that a Third Party may be infringing any of the Licensed Patents such Party shall
promptly notify the other Party in writing, identifying the alleged infringer and the alleged infringement complained of and furnishing the information upon which such determination is based. [...***...] shall have the [...***...],
through counsel of its choosing and at [...***...], to take any measures it deems appropriate to stop such infringing activities by such Third Party in any part of the Territory. Upon reasonable request by [...***...], [...***...]
shall give [...***...] all reasonable information and assistance, including allowing [...***...] access to [...***...] files and documents and to [...***...] personnel who may have possession of relevant information at
[...***...]. If necessary for
 [...***...] to prosecute any legal action, [...***...] may request [...***...] to join in the legal action provided that [...***...] shall hold [...***...] harmless from and
against any and all costs and expenses of such litigation. If [...***...] upon
 [...***...] request so joins such legal action, [...***...] may be represented by counsel of its own choosing, but [...***...] shall not be
subject to [...***...] obligation to indemnify hereunder. 

 In the event [...***...] fails within
forty-five (45) days following notice of such infringement, or earlier notifies [...***...] in writing of its intent not, to take commercially appropriate steps to remove any infringement of any Licensed Patent, then,

[...***...] shall have the [...***...], to do so at [...***...]. Upon reasonable request by [...***...], [...***...] shall give
 [...***...] all reasonable information and assistance, including allowing
[...***...] access to [...***...] files and documents and to [...***...] personnel who may have possession of relevant information at its own expense. If necessary for [...***...] to prosecute any legal action,
[...***...] may request [...***...] to join in the legal action provided that [...***...] shall hold
 [...***...] harmless from and against any and all costs and expenses of such litigation. If

  

***Confidential Treatment Requested 

  
 49 

 
[...***...] upon [...***...] request so joins such legal action, [...***...] may be represented by counsel of its own choosing, but [...***...] shall not be subject to
[...***...] obligation to indemnify hereunder. 
  

	 	16.1.1	Notwithstanding the foregoing, if either Party receives any notice of certification regarding the Licensed Patents pursuant to the U.S. “Drug Price Competition and
Patent Term Restoration Act” of 1984 (21 United States Code §355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV)) (“ANDA ACT”) claiming that any Licensed Patents are invalid or unenforceable or claiming that the Licensed Patents will
not be infringed by the Manufacture, use, marketing or sale of a product for which an application under the ANDA ACT is filed, or (b) any equivalent or similar certification or notice in any other jurisdiction, it shall provide the other Party
with a copy of such notice of certification within ten (10) days of receipt and the Parties’ rights and obligations with respect to any legal action as a result of such certification shall be as set forth in Section 16.1;
provided, however, that if [...***...] elects not to bring suit against the Third Party providing notice of such certification within thirty (30) days of receipt of such notice, [...***...] shall have the
[...***...] at [...***...], to bring suit against such Third Party. If either Party upon the other Party’s request joins such legal action, such other Party may be represented by counsel of its own choosing but any costs and
expenses of such counsel shall not be subject to the other Party’s obligation to indemnify hereunder. 

  

	16.2	 Sublicensees. In the event that either Party reasonably believes that a Sublicensee may be infringing any of the Licensed Patents by acting
beyond the scope of the licence granted to Flexion under this Agreement, such Party shall promptly notify the other Party in writing, identifying the alleged infringer and the alleged infringement complained of and furnishing the information upon
which such determination is based. Flexion shall have a period of ninety (90) days in which to resolve the matter with the Sublicensee and bring the infringing activity to an end. If Flexion has not brought the infringing activity to an end or
cannot demonstrate to AstraZeneca that it 

  

***Confidential Treatment Requested 

  
 50 

	 	
has taken appropriate steps to bring the infringing activity to an end, then AstraZeneca shall have the rights set out in Section 16.1 as if the Sublicensee were a Third Party.

  

	16.3	Costs and Expenses. Each Party shall bear [...***...] costs and expenses relating to any enforcement action pursuant to Section 16.1. Any damages or
other amounts collected shall be used to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), with any remainder being retained
by the Party that pursued such enforcement action; provided, however, that any amount received by [...***...] over and above its costs and expenses shall [...***...]. 

 

	17	Potential Third Party Rights 

  

	17.1	Third Party Licences. If the Exploitation of the Compounds or Licensed Products by Flexion, its Affiliates or any of its Sublicensees infringes or
misappropriates any Patent or any Intellectual Property Right of a Third Party in any country, such that Flexion or any of its Affiliates or Sublicensees cannot Exploit the Compounds or the Licensed Products in such country without infringing the
Patent or Intellectual Property Right of such Third Party, then, [...***...] shall secure from such Third Party such rights (“Third Party Licence”) as are necessary for the Exploitation of Compounds and Licensed Products in
such country. [...***...] shall be [...***...] responsible for [...***...] of all royalty and other payments in connection with the securing of any such rights, subject to the following: 

 

	 	17.1.1	 If Flexion for the Exploitation of the Compound(s) or Licensed Products requires a Third Party Licence for formulation technology or has to pay
royalties to the vendor of the commercially formulated compound (“Third Party Formulation Technology Licences”) and has sublicensed rights in the Compound(s) or Licensed Products, then Flexion may elect by written notice to
AstraZeneca that [...***...] of the royalties actually paid under such Third Party Formulation Technology Licence by Flexion for the sale of such Licensed Product in such country for a Calendar Quarter shall be creditable against the royalties
payable to AstraZeneca on Net Sales made by or on behalf of the Sublicensee in such country for the same Calendar Quarter subject to a 

  

***Confidential Treatment Requested 

  
 51 

	 	
maximum royalty reduction of [...***...] (as such terms are defined in Section 7.2 above), provided that Flexion shall [...***...] within thirty (30) days of the execution
of Flexion’s notice referred to above, and provided further that Flexion agrees to [...***...] each of the sales related payments under Section 7.4(ii) and Section 7.4 (iii) above, if and when such payment becomes payable
to AstraZeneca. For the sake of clarification, the aggregate compensation payable to AstraZeneca according to this Section 17.1.1 shall not [...***...]. 

 

	 	17.1.2	If Flexion for the Exploitation of the Compound(s) or Licensed Products requires at any time a Third Party Licence other than a Third Party Formulation Technology
Licence (“Other Third Party Licence(s)”) and has sub-licensed rights in the Compound(s) or Licensed Products, then Flexion may elect by written notice to AstraZeneca that
 [...***...] of the royalties actually paid under
such Other Third Party Licence by Flexion for the sale of such Licensed Product in such country for a Calendar Quarter shall be creditable against the royalties payable to AstraZeneca on Net Sales made by or on behalf of the Sublicensee in such
country for the same Calendar Quarter subject to a maximum royalty reduction of [...***...] as such terms are defined in Section 7.2 above and further provided that such Other Third Party Licence is required to [...***...].

  

	 	17.1.3	 Flexion may either elect the royalty reduction under Section 17.1.1 for Third Party Formulation Technology Licences or under Section 17.1.2
for Other Third Party Licences, but may not elect such royalty reduction under both Sections 17.1.1 and 17.1.2, even if Flexion may for the Exploitation of the 

  

***Confidential Treatment Requested 

  
 52 

	 	
Compound(s) or Licensed Products require both a Third Party Formulation Technology Licence and an Other Third Party Licence and AstraZeneca’s total royalty reduction shall [...***...].

  

	17.2	Invalidity or Unenforceability Defences or Actions. 

  

	 	17.2.1	In the event that a Third Party asserts, as a defence or as a counterclaim in any infringement action under Section 16.1, that any Licensed Patent is invalid or
unenforceable, then the Party pursuing such infringement action shall promptly give written notice to the other Party. [...***...] shall have [...***...], at [...***...] through counsel of its choosing, to respond to such defence
or defend against such counterclaim (as applicable) and, if [...***...] is pursuing the applicable infringement action under Section 16.1, [...***...] shall allow [...***...] to control such response or defence (as
applicable). If [...***...] determines not to respond to such defence or defend against such counterclaim (as applicable), [...***...] shall, at [...***...], have the right to respond to such defence or defend against such
counterclaim (as applicable); provided, however, that [...***...] shall obtain the written consent of
 [...***...], not to be unreasonably withheld or delayed, prior to ceasing to defend, settling or otherwise concluding
such defence or counterclaim. 

  

	 	17.2.2	Similarly, if a Third Party asserts, in a declaratory judgment action or similar action or claim filed by such Third Party, that any Licensed Patent is invalid or
unenforceable, then the Party first becoming aware of such action or claim shall promptly give written notice to the other Party. [...***...] shall have [...***...], at [...***...], through counsel of its choosing, to defend
against such action or claim. If [...***...] determines not to assume such defence, [...***...] shall, at [...***...], have the right to defend against such action or claim; provided, however, that

[...***...] shall obtain the written consent of [...***...], not to be unreasonably withheld or delayed, prior to ceasing to defend, settling or otherwise compromising any such action or claim. 

  

***Confidential Treatment Requested 

  
 53 

	 	17.2.3	Each Party shall provide to the other all reasonable assistance requested by the other in connection with any action, claim or suit under this Section 17.2,
including allowing access to files and documents and to personnel who may have possession of relevant information. In particular each Party shall upon reasonable request make available to the other, free of charge, all information in its possession
or control that it is aware and will assist the other Party in responding to any such action, claim or suit. 

  

	 	17.2.4	Where a Sublicensee is deemed, by virtue of Section 16.2 above to have become a Third Party for the purposes of Section 16.1, such Sublicensee shall be deemed
to be a Third Party for the purposes of this Section 17.2 also. 

  

	17.3	Third Party Litigation. In the event of any actual or threatened suit against Flexion or its Affiliates, Sublicensees or customers alleging that the Exploitation
of Compounds or Licensed Products or that the Exploitation of a Licensed Patent or the Licensed Know-How or any part thereof hereunder infringes the Patent or Intellectual Property Rights of any Person,
 [...***...] shall, at
[...***...], assume direction and control of the defence of claims arising therefrom; provided, however, that [...***...] shall obtain the written consent of [...***...], not to be unreasonably withheld or delayed,
prior to ceasing to defend, settling or otherwise compromising such claims with respect to any Licensed Patents and Licensed Know-How. 

  

	17.4	Retained Rights. Nothing in this Article 17 shall prevent Flexion, at its own expense, from obtaining any licence or other rights from Third Parties it deems
appropriate in order to permit the full and unhindered exercise of its rights under this Agreement. 

  

	18	Term and Termination 

  

	18.1	Term and Expiration. This Agreement shall become effective as of the Effective Date and shall continue in effect until such time as Flexion no longer owes any
royalty payments to AstraZeneca under this Agreement, unless earlier terminated in accordance with this Article 18 (Term and Termination) or Section 19.4 (Force Majeure). On the expiration of this Agreement, that is when Flexion no longer owes
any royalty payments to AstraZeneca under this Agreement, the provisions of Section 3.7 shall come into effect. 

  

***Confidential Treatment Requested 

  
 54 

	18.2	Termination for Breach. In the event that either Party (the “Breaching Party”) shall be in material default in the performance of any of its
obligations under this Agreement, in addition to any other right and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this Agreement in its entirety or with respect to the country or
countries to which such material default applies by sixty (60) days prior written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate, provided always that the
termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach complained about during the Notice Period (or, if such default cannot be cured within such sixty (60)-day period, if the Breaching Party
commences actions to cure such default within the Notice Period and thereafter diligently continues such actions, provided that such default is cured within one hundred and eighty (180) days after the receipt of such notice), except in the case
of a payment default, as to which the Breaching Party shall have only a thirty (30)-day cure period; provided further, that if Flexion is in default with respect to its obligations under Section 6.3 in [...***...] then AstraZeneca shall
have the right to terminate this Agreement with respect to [...***...]. A termination notice may not be given for a dispute relating to the amount of royalties owed to AstraZeneca provided that the Parties are seeking to remedy the dispute in
compliance with Section 7.9.3 of this Agreement. Notwithstanding the foregoing, any right to terminate under this Section 18.2 shall be stayed and the Notice Period stayed in the event that during the Notice Period, the Party alleged to
have been in material breach shall have initiated the dispute resolution procedure in accordance with Section 24 and provided that the Party alleged to have been in material breach diligently and in good faith co-operates in the prompt
resolution of such dispute resolution proceedings. 

  

	18.3	 Termination by AstraZeneca. In the event that Flexion or any of its Affiliates or Sublicensees, anywhere in the world, institutes, prosecutes or
otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign
counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment, injunction or any other equitable remedy, including any interference,
re-

  

***Confidential Treatment Requested 

  
 55 

	 	
examination, opposition or any similar proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable or otherwise not patentable AstraZeneca shall have the right to
immediately terminate this Agreement, including the rights of any Sublicensees, on written notice to Flexion. 

  

	18.4	Termination by Flexion. 

Flexion shall have the right at any time during the term of this Agreement to terminate this Agreement in its entirety or with respect to
one or more countries for any reason upon no less than three (3) months’ prior written notice to AstraZeneca provided that if Flexion elects to terminate this Agreement with respect to [...***...] it shall be deemed to have
terminated the Agreement with respect to [...***...]. 
  

	18.5	Territorial Effect of a Termination Notice. 

  

	 	18.5.1	In case of termination by Flexion without cause pursuant to Section 18.4 (Termination by Flexion) such termination notice may be made with respect to one country
or several specific countries as determined by Flexion (the “Affected Countries”). In the case of any termination notice for breach pursuant to Section 18.2 (Termination for Breach) if the breach of the other Party relates to
or takes effect only in certain countries (the “Affected Countries”), such termination notice may only be given with respect to such Affected Countries and must state the Affected Countries. The Affected Countries or all countries
of the Territory, as the case may be and as determined by the Party giving termination notice under Section 18.2 or Section 18.4, as the case may be, shall hereafter be referred to as the “Applicable Territory”.

  

	 	18.5.2	In case of any termination notice for breach pursuant to Section 18.2 (Termination for Breach) by either Party, such termination may be made with respect to the
entirety of this Agreement only, if the breach of the other Party relates to or takes effect in at least two or more countries of the Territory and/or affects this Agreement in a global manner, in which case the termination notice must state that
the termination shall affect this Agreement in its entirety. 

  

***Confidential Treatment Requested 

  
 56 

	 	18.5.3	In the event that a Party is entitled to provide termination notice under Section 18.2 (Termination for Breach) related to this Agreement in its entirety, but the
breach affects certain countries of the Territory only, then such Party may at its discretion select and specify in the termination notice the Affected Countries in which such termination notice shall take effect. 

 

	 	18.5.4	For the avoidance of doubt and notwithstanding the above, if a breach by Flexion relates to or takes effect in
 [...***...], then AstraZeneca shall have the
right to designate [...***...] in its notice of breach for the purposes of determining the Applicable Territory. 

  

	18.6	Consequences of Termination. 

  

	 	18.6.1	Effects of Termination by Flexion for Cause. Upon termination by Flexion in accordance with Section 18.2 (Termination for Breach), Section 18.8
(Termination for Insolvency or Bankruptcy) or Section 19.4 (Force Majeure) of this Agreement, all licences and other rights granted by AstraZeneca to Flexion in the Territory, shall terminate and revert to AstraZeneca. 

 

	 	18.6.2	Effects of Termination by Flexion. Upon termination of this Agreement by Flexion in accordance with Section 18.4 (Termination by Flexion), with respect to
the Applicable Territory, all licences and other rights granted by AstraZeneca to Flexion under this Agreement shall terminate and revert to AstraZeneca. Flexion shall further, and shall cause its Affiliates and Sublicensees to disclose to
AstraZeneca (or its designee) any and all Improvements and Know-How, including a copy of any documentation in tangible form, that is owned or otherwise Controlled by Flexion, its Affiliates or Sublicensees at the time of termination of the Agreement
that has been generated by or on behalf of Flexion, its Affiliates or Sublicensees with respect to Compounds or Licensed Products to enable AstraZeneca to continue Development of a Licensed Product and the commercialisation thereof in the Territory
or the Applicable Territory (as the case may be) (collectively, the “Flexion Product Data”). If AstraZeneca wishes to use Flexion Product Data and Grant-Back Patents in the Development or commercialisation of Compounds or Licensed
Products, then Flexion shall grant to AstraZeneca an 

  

***Confidential Treatment Requested 

  
 57 

 exclusive, (subject to the following paragraph) royalty-free, sub-licensable, assignable,
perpetual licence under the Flexion Product Data and Grant-Back Patents to Develop, make, have made, use, sell, offer for sale, have sold, import and export Compounds and Licensed Products in the Territory or the Affected Countries (as the case may
be), subject to AstraZeneca and Flexion agreeing on [...***...]. Any such Flexion Product Data shall be subject to the confidentiality obligations set forth in Article 11. 

Notwithstanding anything to the contrary in this Section 18.6.2, upon termination of this Agreement by Flexion in accordance with
Section 18.4 (Termination by Flexion) based on Flexion’s determination that the commercial viability of Compound(s) or Licensed Products has adversely changed for any reason beyond Flexion’s control, including without limitation
because of any issues related to Patents or Intellectual Property Rights of Third Parties or Third Party Licences, then a licence under the Flexion Product Data and Grant-Back Patents (if any) shall be granted on a [...***...] basis only with
[...***...] to be agreed upon by the Parties. 
  

	 	18.6.3	Effects of Termination by AstraZeneca. Upon termination by AstraZeneca in accordance with Section 3.9 (Change of Control), Section 18.2 (Termination
for Breach) or Section 18.3 (Termination by AstraZeneca) or Section 18.8 (Termination upon Insolvency or Bankruptcy) or Section 19.4 (Force Majeure): 

 

	 	a)	all licences and other rights granted by AstraZeneca to Flexion in the Territory, shall terminate and revert to AstraZeneca; 

 

	 	b)	 in the case of AstraZeneca’s termination in accordance with Section 18.2 (Termination for Breach) or Section 18.3 (Termination by
AstraZeneca), Flexion shall and shall cause its Affiliates and Sublicensees to disclose to AstraZeneca (or its designee) any and all Flexion Product Data and Flexion hereby grants AstraZeneca with respect to the Applicable Territory, an exclusive,
royalty-free, sub-

  

***Confidential Treatment Requested 

  
 58 

	 	
licensable licence, under the Flexion Product Data (if any) solely to Develop, make, have made, use, sell, have sold, offer for sale, import and export Compounds and Licensed Products in the
Applicable Territory; 

  

	 	c)	in the case of AstraZeneca’s termination in accordance with Section 3.9 (Change of Control) or Section 18.8 (Termination upon Insolvency or Bankruptcy)
or Section 19.4 (Force Majeure), Flexion shall and shall cause its Affiliates and Sublicensees to disclose to AstraZeneca (or its designee) any and all Flexion Product Data. If AstraZeneca wishes to use Flexion Product Data in the Development
or commercialisation of Compounds or Licensed Products, then Flexion shall grant to AstraZeneca an exclusive, royalty-free, sub-licensable, assignable, perpetual licence under the Flexion Product Data to Develop, make, have made, use, sell, offer
for sale, have sold, import and export Compounds and Licensed Products in the Territory or the Affected Countries (as the case may be), subject to AstraZeneca and Flexion agreeing on [...***...]. Any such Flexion Product Data shall be subject
to the confidentiality obligations set forth in Article 11. 

  

	 	d)	Flexion shall be further obliged and undertakes at no cost to AstraZeneca to assign (and does hereby assign and shall, always subject to Section 18.6.5, cause its
Affiliates and Sublicensees to assign to AstraZeneca with effect from the date of termination) all its right, title and interest in and to all Regulatory Documentation with respect to the Compounds and Licensed Products in or referring to the
Territory or the Applicable Territory as the case may be, including any Health Registration Approvals and applications therefore, to AstraZeneca. 

  

	 	e)	 Flexion and its Affiliates shall and do hereby grant to AstraZeneca (a) a non-exclusive, royalty-free, perpetual, irrevocable right and licence,

  

***Confidential Treatment Requested 

  
 59 

	 	
with the right to grant sublicences through multiple tiers of sublicensees, under any Grant-Back Patents and, (b) if Flexion has commercialised a Licensed Product, an exclusive,
royalty-free, perpetual, irrevocable right and licence, with the right to grant sublicences through multiple tiers of sublicensees of the Flexion Trademarks, in each case to Exploit the Compounds and Licensed Products in the Territory or the
Applicable Territory (as the case may be). AstraZeneca shall, at its option and at its expense, take over the filing, prosecution and maintenance of the Grant-Back Patents and Flexion Trademarks in the Territory or the Applicable Territory (as the
case may be). 

  

	 	f)	in order for AstraZeneca to smoothly continue the Exploitation of the Compounds and Licensed Products in the Territory or the Applicable Territory (as the case may be),
Flexion shall, with the limitations set out below and for a maximum period of [...***...], supply AstraZeneca in a timely manner with sufficient amount of Compound or Licensed Product in the Territory or the Applicable Territory (as the case
may be) at [...***...]. Flexion’s undertaking to supply is subject to Flexion, upon termination of this Agreement, having in its possession appropriate and regulatory approved manufacturing methods and technologies for the Compound and
Licensed Product up and running in the scales they are to be produced and available production capacity, it being understood that Flexion shall be under no obligation to develop or acquire any manufacturing methods or other technologies in addition
to what has been developed at the date of termination by it or on its behalf under this Agreement for the production of Compound and Licensed Product. The Parties shall separately negotiate in good faith the logistical and other terms and conditions
for such supplies. 

  

	 	18.6.4	Return of Material. Upon termination, but not expiration of this Agreement, by either Party pursuant to Section 3.9 or this Article 18 or Section 19.4,
and with regard to the Applicable Territory, each Party, at the request of the other 

  

***Confidential Treatment Requested 

  
 60 

 Party, shall return, or at the election of the other Party, destroy, and thereafter provide
the other Party with written certification evidencing such destruction, all data, files, records and other materials in its or its Affiliates or, with respect to Flexion, Sublicensees, possession or control containing or comprising such other
Party’s Know-How or other Confidential Information and, in each case, to which the returning Party does not retain rights hereunder (except one copy of which may be retained by the returning Party’s General Counsel solely for archival
purposes). 
  

	 	18.6.5	Effect of Termination on Sublicences. Termination of this Agreement by AstraZeneca pursuant to Section 3.9 (Change of Control), Section 18.2
(Termination for Breach), Section 18.3 (Termination by AstraZeneca) or Section 19.4 (Force Majeure) shall not automatically terminate any sublicence granted by Flexion pursuant to Section 3.5 with respect to a Sublicensee, provided
that (a) such Sublicensee is not in breach of any provision of the applicable sublicence agreement, and is not exceeding the scope of the rights granted to Flexion under this Agreement, (b) such Sublicensee agrees to perform all
obligations of Flexion under this Agreement, and (c) AstraZeneca shall have all rights with respect to any and all Sublicensees as it had hereunder with respect to Flexion prior to termination of this Agreement with respect to Flexion, and
(d) Flexion procures the assignment of its rights and obligations under the sublicense agreement to AstraZeneca. Flexion shall include in any sublicence a provision in which said Sublicensee acknowledges its obligations to AstraZeneca
hereunder, the right of AstraZeneca to step into Flexion’s position in such sublicence and acknowledges and consents to the aforementioned assignment of rights and obligations. Where AstraZeneca is the Sublicensee, the sublicence agreement
shall automatically terminate on termination of this Agreement. 

  

	 	18.6.6	Remedies. Early termination of this Agreement by a Party shall in no way affect or limit such Party’s right to claim against the other Party for any damages
arising out of the breach of this Agreement. 

  
 61 

	18.7	Accrued Rights; Surviving Obligations. 

  

	 	18.7.1	Survival. The expiry or termination of this Agreement shall not relieve the Parties from performing any obligations accrued prior to the date this Agreement
terminates. Each Party’s rights and obligations under Sections 5.2, 18.6 and this Section 18.7 and Articles 7 (with respect to obligations arising prior to expiration or termination), 9, 11, 14, 23, 24, 25 and 30 shall survive the
termination or expiration of this Agreement. 

  

	 	18.7.2	Work-in-Progress. Upon termination of this Agreement in its entirety by AstraZeneca pursuant to Section 18.2, Flexion shall be entitled, during the
following ninety (90) days, to finish any work-in-progress and to sell any inventory of the Licensed Product that remains on hand as of the date of the termination, so long as Flexion pays AstraZeneca the royalties applicable to said subsequent
sales in accordance with the terms and conditions set forth in this Agreement. 

  

	18.8	Termination Upon Insolvency or Bankruptcy. Either Party may terminate this Agreement if at any time, the other Party shall file in any court or agency pursuant
to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other
Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty
(60) days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors. 

 

	18.9	 Rights in Bankruptcy. All rights and licences granted under or pursuant to this Agreement by AstraZeneca to Licensee or by Licensee to
AstraZeneca are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, licences of right to “intellectual property” as
defined under Section 101 of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter “IP”). The Parties agree that the Parties, as licensees of such rights under

  
 62 

	 	
this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that
provide similar protection for IP. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States,
the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such IP and all embodiments of such IP, which, if not already in such other Party’s possession, shall be promptly delivered to it upon such
other Party’s written request therefor. 

  

	18.10	Consequences of AstraZeneca Breach of Section 3.1. 

  

	 	18.10.1	If, in accordance with the dispute resolution procedure set out in Section 24.3, AstraZeneca is found to have been in breach of the licence grant set out in
Section 3.1 of this Agreement, namely that it is found to have granted rights to the Licensed Patents and/or the Exclusively Licensed Know-How to a Third Party in breach of this Agreement; and Flexion has not exercised its right to terminate
this Agreement, then Flexion shall have the right either (a) to claim damages in respect of the loss suffered by it as a result of such breach; or (b) to claim a penalty from AstraZeneca in lieu of damages, such penalty to be calculated in
accordance with the following provisions: 

  

	 	(i)	If the breach is discovered by Flexion at any time after the Effective Date but prior to [...***...] then all future development, filing and approval milestone
payments due to AstraZeneca under Section 7.1 after the discovery of such breach shall be [...***...]; 

  

	 	(ii)	If the breach is discovered by Flexion after [...***...] but prior to [...***...] then all future development, filing and approval milestone payments due to
AstraZeneca under Section 7.1 after the discovery of such breach shall be [...***...]; 

  

	 	(iii)	 If the breach is discovered by Flexion after [...***...] and prior to [...***...]

  

***Confidential Treatment Requested 

  
 63 

	 	
[...***...] then all future development, filing and approval milestone payments due to AstraZeneca under Section 7.1 after the discovery of such breach shall be [...***...] and
the royalties payable to AstraZeneca under Section 7.2 after the discovery and notification of such breach shall be [...***...]; 

  

	 	(iv)	If the breach is discovered by Flexion after [...***...] but before [...***...] then all future development, filing and approval milestone payments due to
AstraZeneca under Section 7.1 after the discovery of such breach shall be [...***...] and the royalties and sales related payments payable to AstraZeneca under Sections 7.2 and 7.4 after the discovery of such breach shall be
[...***...]; 

 provided that in each case Flexion gives AstraZeneca notice of the discovery of the breach
promptly after having gained sufficiently detailed knowledge of such breach allowing Flexion to serve a notice of breach under Section 18.2 and giving AstraZeneca the opportunity to cure the breach in accordance with the provisions of
Section 18.2 above, and provided further that AstraZeneca has failed to cure the breach so notified in accordance with the timescales set out in that section. Flexion undertakes that it will promptly investigate any suspected breach by
AstraZeneca and will, notwithstanding that it may not have gained sufficient evidence formally to allege a breach of the Agreement, notify AstraZeneca promptly if any facts or matters come to its attention which lead it to believe that AstraZeneca
may have committed a breach of Section 3.1. 

  

***Confidential Treatment Requested 

  
 64 

	 	18.10.2	In the event that any payments, which would be affected by a reduction hereunder, become due for payment after the discovery and notification of such breach such
payments shall be made by Flexion when due, but in the event that AstraZeneca is found in the dispute resolution procedure set out in Section 24.3 to have breached the licence grant set out it in Section 3.1 of this Agreement, such
payments shall be promptly repaid by AstraZeneca plus accrued interest in accordance with Section 7.13 above for the period from the payment date by Flexion until repayment by AstraZeneca. 

 

	 	18.10.3	If the breach occurs or is discovered by Flexion after [...***...], then Flexion shall [...***...]. 

 

	19	Force Majeure 

  

	19.1	In this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control, including an act of God, act or
omission of the other Party, strike, lock-out or other industrial/labour dispute (whether involving the workforce of the Party so prevented or of any other Person), war, riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine,
fire, flood, storm, natural disaster or compliance with any law or governmental order, rule, regulation or direction, whether or not it is later held to be invalid. 

 

	19.2	The Force Majeure Party, shall within fifteen (15) days of the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature
and extent of the event of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to Section 19.1, the Force Majeure Party shall not be liable for delay in
performance or for non-performance of its obligations under this Agreement (other than obligations to pay monies due), in whole or in part, nor shall the other Party have the right to terminate this Agreement, except as otherwise provided in this
Agreement, where non-performance or delay in performance has resulted from an event of Force Majeure. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required.

  

***Confidential Treatment Requested 

  
 65 

	19.3	The Force Majeure Party shall take all steps as are necessary to (a) bring the Force Majeure event to a close or (b) find a solution by which the Agreement
may be performed despite the continuation of the event of Force Majeure. 

  

	19.4	If the Force Majeure Party is prevented from performing its obligations (other than obligations to pay monies due) due to a Force Majeure event for a continuous period
in excess of six (6) months after the date of the occurrence of the Force Majeure event, and such failure to perform would constitute a breach of this Agreement in the absence of such Force Majeure event, the other Party may terminate this
Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that accrued prior to the date of termination, provided that such right to
terminate shall not be available if the Force Majeure event is caused by an act or omission of the other Party. 

  

	20	Assignment 

Neither Party may assign its rights or, except as provided in Section 3.5 (Flexion’s right to sublicense) and Section 3.9
(Change of Control not resulting in termination of this Agreement), delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent
shall not be unreasonably withheld or delayed, except that each Party shall always have the right, without such consent, (a) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its
Affiliates, and (b) on written notice to the other Party, to assign any or all of its rights and delegate any or all of its obligations hereunder to any of its Affiliates. AstraZeneca shall always have the right on written notice to Flexion to
assign any of all of its obligations hereunder to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to those assets to which this Agreement relates. Any permitted successor of a Party or any permitted assignee
of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a party to this Agreement as though
named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a 

  
 66 

	 	
party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all
validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party, provided that such Party, if it survives, shall remain jointly and severally liable for the performance
of such delegated obligations under this Agreement. Any attempted assignment or delegation in violation of this Article 20 shall be void. 

  

	21	Sub-Contracting 

Flexion shall have the right to sub-contract the performance of any of its obligations under this Agreement without the prior consent of
AstraZeneca, provided that it shall remain liable for the performance or non-performance of any such obligations. 
  

	22	Severability 

 If
any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then, to the fullest extent permitted by Applicable Law: (a) such provision will be given no effect by the Parties and shall not form part of this
Agreement, (b) all other provisions of this Agreement shall remain in full force and effect, and (c) the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable
that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this
Agreement invalid, illegal or unenforceable in any respect. 
  

	23	Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of England, excluding any conflicts or choice of law rule or
principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

  
 67 

	24	Dispute Resolution and Arbitration 

  

	24.1	If a dispute arises between the Parties relating to the existence, negotiation, validity, formation, interpretation, breach, performance or application of this
Agreement, the Parties shall use the following procedure in good faith prior to either Party pursuing judicial remedies. 

  

	24.2	Each Party shall notify the other Party of the dispute in accordance with Article 25. The Parties shall use good faith efforts to resolve such dispute within thirty
(30) days after delivery of such notice, which good faith efforts shall include at least one in-person meeting between representatives of each Party having decision-making authority (subject only to Board of Directors’ or equivalent
approval, if required). All discussions under this Article 24 are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. 

 

	24.3	Any dispute arising out of or relating to the existence, negotiation, validity, formation, interpretation, breach, performance or application of this Agreement shall be
settled by binding arbitration in accordance with the ICC rules of arbitration. A sole arbitrator shall be appointed in accordance with such ICC rules of arbitration. The place of arbitration shall be London. The language used in the arbitration
proceedings shall be English. The arbitration shall be governed by the Arbitration Act 1996 to the exclusion of any inconsistent state laws and judgment on the award rendered by the arbitration may be entered by any court having jurisdiction.
Nothing in this Section 24.3 will preclude either Party from seeking equitable relief in accordance with Section 11.6 or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order,
preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. The
statute of limitations of England and Wales applicable to the commencement of a lawsuit shall apply to the commencement of arbitration under this Section 24.3. 

  
 68 

	25	Notices 

  

	25.1	Notice Requirements. 

 Any
notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by
facsimile transmission (with transmission confirmed) or by internationally recognised overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 25.2 or to such
other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Article 25. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with
transmission confirmed) or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as
practicable thereafter. This Article 25 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

 

	25.2	Address for Notice 

  

							
		  	For :  	  	AstraZeneca AB
				
		  		  	Address:        	  	S-151 85 Södertälje
		  		  		  	Sweden
				
		  		  	Facsimile:	  	+468 553 28812
			
		  		  	For the attention of: Assistant General Counsel SPBD
			
		  	With a copy to:	  	AstraZeneca UK Limited
				
		  		  	Address:	  	Alderley House
		  		  		  	Alderley Park
		  		  		  	Macclesfield
		  		  		  	Cheshire SK10 4TF
				
		  		  	Facsimile:	  	44 1625 590295
			
		  		  	For the attention of: Business Development Director for RITA

  
 69 

							
		  	For:    	  	Flexion Therapeutics AG
				
		  		  	Address:        	  	Aeschenvorstadt 36, CH-4051 Basel, Switzerland
				
		  		  	Facsimile:	  	+41 61 2069201
			
		  		  	For the attention of: CEO
			
		  	With a copy to:	  	Blum&Grob Attorneys at Law Ltd
				
		  		  	Address:	  	 Neumuehlequai 6, P.O. Box 3954, CH-8021 Zurich,
 Switzerland

				
		  		  	Facsimile:	  	+41 58 320 0001
			
		  		  	For the attention of: Ralf Rosenow

  

	26	Relationship of the Parties 

 The status of a Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency
relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements,
representations, warranties or commitments on behalf of the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for
the account and expense of such Party. 
  

	27	Entire Agreement 

This Agreement constitutes the entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement
supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set
out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules and/or Exhibits referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of
this Agreement. In the event of any inconsistency between any such Schedules or Exhibits and this Agreement, the terms of this Agreement shall govern. 

  
 70 

	28	English Language 

This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version
of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 
  

	29	Amendment 

 Any
amendment or modification of this Agreement must be in writing and signed by authorised representatives of both Parties. 
  

	30	Waiver and Non-Exclusion of Remedies 

 A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or
remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. All rights and remedies are cumulative and subject to Article 23 do not exclude
any other right or remedy provided by law or otherwise available. 
  

	31	Confirmatory Patent Licences 

 AstraZeneca shall if requested to do so by Flexion promptly enter into confirmatory licence agreements in the form or substantially the form set out in Exhibit A for purposes of recording the licences
granted under this Agreement with such Patent Offices in the Territory as Flexion reasonably considers appropriate. Until the execution of any such confirmatory licences, so far as may be legally possible, Flexion and AstraZeneca shall have the same
rights in respect of the Licensed Patents and be under the same obligations to each other in all respects as if the said confirmatory licences had been executed. 
  

	32	Further Assurance 

Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other
Party may reasonably require to implement or give effect to this Agreement. 

  
 71 

	33	Expenses  

 Except
as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution
and delivery of this Agreement. 
  

	34	Announcements 

  

	34.1	Subject to Section 34.2, no Party shall make, or permit any Person to make, any public announcement, communication or circular (“Announcement”)
concerning this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld or delayed). The Parties shall consult together on the timing, contents and manner of release of any Announcement. Each
Party acknowledges and agrees that the other party may in its absolute discretion withhold its consent to the disclosure of any or all of the financial terms of this Agreement. 

 

	34.2	Where an Announcement is required by law or any governmental or regulatory authority (including, without limitation, any relevant securities exchange), or by any court
or other authority of competent jurisdiction, the Party required to make the Announcement shall promptly notify the other Party. The Party concerned shall make all reasonable attempts to agree the contents of the Announcement before making it.

  

	35	Counterparts 

 This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by
facsimile transmission shall be as effective as an original executed signature page. 

  
 72 

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first written
above. 
  

									
	 SIGNED for and on behalf of
  

AstraZeneca AB (Pub)
	 		 	 SIGNED for and on behalf of
  

Flexion Therapeutics AG

			
	/s/ Anders Burén	 		 	/s/ Mike Clayman
	Signature	 		 	Signature
	Name:	 	Anders Burén	 		 	Name:	 	Mike Clayman
	Title:	 	Authorised Signatory	 		 	Title:	 	Chief Executive Officer

  

									
	Approved as to
legal form by /s/ illegible	 		 	 SIGNED for and on behalf of
  

Flexion Therapeutics AG

			
		 		 	/s/ Tom Woiwode
		 		 		 	Signature
		 		 	Name:	 	Tom Woiwode
		 		 	Title:	 	Chief Business Officer

  
 73 

 Schedule 1 – Primary Compound and Licensed Patents 

[...***...] 

  

***Confidential Treatment Requested for pages 74-80. Omitted pages have been filed separately with the Commission. 

  
 74-80

 [...***...] 
  

	5.	Exclusive Licensed Know-How 

 The information contained in AstraZeneca’s Data Room as of the Effective Date which relates exclusively to the Primary Compound and which was made available to Flexion prior to the Effective Date,
together with such other Know-How as AstraZeneca may make available to Flexion after the Effective Date. An index of the contents of AstraZeneca’s Data Room is set out in Exhibit 3 to this Agreement and both Parties have each signed two copies
(one copy to be retained by each Party) of a CD-Rom or DVD containing the contents of AstraZeneca’s Data Room. 

  

***Confidential Treatment Requested 

  
 81 

 Schedule 1.2 
 [...***...] 
  

  

***Confidential Treatment Requested for pages 82-85. Omitted pages have been filed separately with the Commission. 

  
 82-85

 Schedule 2—Back-Up Nomination Criteria: 

[...***...] 

  

***Confidential Treatment Requested 

  
 86 

 Schedule 3—Ethics Standards 

 

	I.	PATIENT SAFETY AND BENEFIT 

  

	 	•	 	 Compliance with all applicable procedures designed to promote product safety, efficacy and quality, such as Good Laboratory, Good Clinical and Good
Manufacturing Practice and reporting of any incidents of non-compliance. 

  

	 	•	 	 Reporting of any possible adverse effects. 

  

	 	•	 	 Reporting of any counterfeit or suspected counterfeit drugs. 

 

	II.	RESEARCH AND DEVELOPMENT ETHICS 

  

	 	•	 	 Compliance with international standards of good practice, such as the Declaration of Helsinki, Good Clinical Practice and Good Laboratory Practice.

  

	 	•	 	 Ensuring that appropriate informed consent procedures are followed when conducting clinical research or obtaining human tissue for use in scientific
studies. 

  

	 	•	 	 Compliance with data protection and associated laws when collecting or accessing any health information. 

 

	 	•	 	 Ensuring the welfare of animals used in animal experimentations. 

 

	III.	PROVIDING INFORMATION ABOUT PRODUCTS 

  

	 	•	 	 Compliance with IFPMA Code of Pharmaceutical Marketing Practices, local laws, regulations and applicable codes of marketing practice.

  

	 	•	 	 No engagement in direct consumer/patient communication unless permitted by local law. 

 

	IV.	INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND ORGANISATIONS 

  

	 	•	 	 Compliance with IFPMA Code of Pharmaceutical Marketing Practices, local laws, regulations and applicable codes of marketing practice.

  

	 	•	 	 No payments to healthcare professionals without written agreements. 

  
 87 

	 	•	 	 No offering of payments, gifts, hospitality, entertainment or anything else of value if it could constitute a bribe to a healthcare professional or
organisation. 

  

	V.	PREVENTING BRIBERY AND CORRUPTION 

  

	 	•	 	 No making or authorizing of payments or gifts in order to obtain or retain business or to secure an improper advantage. No asking or permitting of
third parties to do so. 

  

	 	•	 	 Reporting of any suspicion of potentially corrupt behaviour. 

  
 88 

 Schedule 4—Designated Persons 

For the purpose of Section 6.3.3 of the Agreement, 
  

	 	•	 	 Flexion’s designated person shall initially be 

 [...***...]; and 
  

	 	•	 	 AstraZeneca’s designated person shall be AstraZeneca’s [...***...] which at the date of this Agreement is [...***...].

 The Parties shall duly notify each other of any changes to its respective designated person. 

  

***Confidential Treatment Requested 

  
 89 

 Exhibit 1 

[...***...] 

  

***Confidential Treatment Requested for pages 90-91. Omitted pages have been filed separately with the Commission. 

  
 90-91

 Exhibit 2 

[...***...] 

  

***Confidential Treatment Requested 

  
 92 

 Exhibit 3 

[...***...] 

  

***Confidential Treatment Requested for pages 93-158. Omitted pages have been filed separately with the Commission. 

  
 93-158EX-10.11

 Exhibit 10.11 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406. 

OUT-LICENCE AGREEMENT 
 by and between 
 ASTRAZENECA AB 

and 

FLEXION THERAPEUTICS INC 
 DATE: 3RD SEPTEMBER, 2010 

 TABLE OF CONTENTS 
  

							
	 1
	 	Definitions	  	 	1	  
			
	 2
	 	Construction	  	 	15	  
			
	 3
	 	Grant of Rights	  	 	15	  
			
	 4
	 	Improvements	  	 	24	  
			
	 5
	 	Development	  	 	24	  
			
	 6
	 	Consideration	  	 	27	  
			
	 7
	 	Purchase of Study Drug	  	 	37	  
			
	 8
	 	Ownership of Intellectual Property	  	 	38	  
			
	 9
	 	Adverse Event Reporting	  	 	39	  
			
	 10
	 	Confidentiality & Non-Disclosure	  	 	39	  
			
	 11
	 	Trademarks	  	 	43	  
			
	 12
	 	Representations and Warranties	  	 	43	  
			
	 13
	 	Indemnity	  	 	46	  
			
	 14
	 	Maintenance and Prosecution of Patents	  	 	48	  
			
	 15
	 	Enforcement of Patents	  	 	49	  
			
	 16
	 	Potential Third Party Rights	  	 	51	  
			
	 17
	 	Term and Termination	  	 	54	  
			
	 18
	 	Force Majeure	  	 	66	  
			
	 19
	 	Assignment	  	 	68	  
			
	 20
	 	Sub-Contracting	  	 	68	  
			
	 21
	 	Severability	  	 	68	  
			
	 22
	 	Governing Law	  	 	69	  

  
 (i)

							
			
	 23
	 	Dispute Resolution and Arbitration	  	 	69	  
			
	 24
	 	Notices	  	 	70	  
			
	 25
	 	Relationship of the Parties	  	 	71	  
			
	 26
	 	Entire Agreement	  	 	71	  
			
	 27
	 	English Language	  	 	72	  
			
	 28
	 	Amendment	  	 	72	  
			
	 29
	 	Waiver and Non-Exclusion of Remedies	  	 	72	  
			
	 30
	 	Confirmatory Patent Licences	  	 	72	  
			
	 31
	 	Further Assurance	  	 	72	  
			
	 32
	 	Expenses	  	 	73	  
			
	 33
	 	Announcements	  	 	73	  
			
	 34
	 	Contract (Rights of Third Parties) Act 1999	  	 	73	  
			
	 35
	 	Counterparts	  	 	73	  

 Schedule 1—Compound and Licensed Patents 
 Schedule 2—Ethics Standards 
 Schedule 3—Designated Persons 

Schedule 4—Description of Trk 
 Schedule
5—Disclosure Letter 
 Exhibit l—Short Form Patent Licence Agreement 
 Exhibit 2—List Two Countries 
 Exhibit 3—Index of the Contents of the AstraZeneca Data
Room 

  
 (ii)

 LICENCE AGREEMENT 
 This Licence Agreement (the “Agreement”) is made as of the     of September, 2010 (the “Effective Date”) by and between: 

 

	(1)	ASTRAZENECA AB, a Swedish corporation with offices at S-151 85 Södertälje, Sweden (“AstraZeneca”); and 

 

	(2)	Flexion Therapeutics Inc, a Delaware corporation with offices at 300 Trade Center, Suite 2460, Woburn, MA 01801, The United States (“Flexion”).

 Recitals 
  

	(A)	WHEREAS, AstraZeneca is or has been engaged in the research of inhibitors of Tropomyosin-related kinase (the “Trk Programme”) and in relation to which AZ has
identified the compound known as [...***...]. 

  

	(B)	WHEREAS, Flexion has specialised experience in, among other things, the development and commercialisation of pharmaceutical compounds; and 

 

	(C)	WHEREAS, AstraZeneca desires to grant a licence to Flexion, and Flexion desires to take a licence, to develop and commercialise the above-mentioned pharmaceutical
compound in accordance with the terms and conditions set forth below. 

 NOW, THEREFORE, in consideration of the mutual covenants
contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

 

	1	Definitions 

Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, shall have the
following meanings: 
  

	1.1	“Affected Countries” shall have the meaning set out in Section 17.5.1. 

 

	1.2	 “Affiliate” means, with respect to a Person, any Person that controls, is controlled by or is under common control with such first
Person. For purposes of this definition only, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract relating to
voting rights or corporate governance or otherwise, or (b) to 

  

***Confidential Treatment Requested 

  
 1 

	 	
own, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or other ownership interest of such Person. 

 

	1.3	“Applicable Fee” shall have the meaning set out in Section 3.9.3. 

 

	1.4	“Applicable Law” means the applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Health
Authorities, that may be in effect from time to time in the Territory. 

  

	1.5	“Arbitrator” shall have the meaning set out in Section 6.9.3. 

 

	1.6	“Breaching Party” has the meaning set forth in Section 17.2. 

 

	1.7	“Business Day” means a day other than a Saturday, Sunday, bank or other public holiday in the United Kingdom. 

 

	1.8	“Calendar Quarter” means each successive period of three (3) calendar months commencing on 1st January, 1st April, 1st July and
1st October and “Quarterly” shall be construed accordingly. 

  

	1.9	“Calendar Year” means each successive period of twelve (12) calendar months commencing on 1st January. 

 

	1.10	“Change of Control,” with respect to Flexion, means an event in which: 

 

	 	1.10.1	any other Person or group of Persons (i) acquires beneficial ownership of securities of Flexion representing more than fifty percent (50%) of the voting power
of the then outstanding securities of Flexion with respect to the election of directors of Flexion (“Controlling Ownership”) or (ii) controls such number of the votes at meetings or votes of the board of directors of Flexion
which may pass resolutions in accordance with Flexion’s corporate charter documents, without or against the other directors not appointed by such other Person or group of Persons; or 

 

	 	1.10.2	Flexion enters into a merger, consolidation or similar transaction with another Person in which (i) Flexion is not the surviving entity in such transaction and
(ii) Persons having Controlling Ownership in Flexion immediately prior to such transaction do not have Controlling Ownership in the surviving entity immediately after the transaction; or 

  
 2 

	 	1.10.3	a sale of a material portion of the assets of Flexion representing not less than fifty percent (50%) of the fair market value of Flexion; 

provided always that any of the above-listed events shall not be considered a Change of Control, if the sole or predominant purpose of the
event or the related transaction is the financing of Flexion’s business activities from private (e.g. venture capital or private equity companies or private investors) or public (e.g. capital markets) sources. For the purposes of this
Agreement, a Change of Control shall be deemed to occur upon the closing of the respective event or transaction and upon satisfaction of all regulatory or other requirements or conditions in relation to such event or transaction. 

 

	1.11	“Collaborator” shall mean (i) in respect of Flexion, a Third Party that Flexion is collaborating with for the purpose of research and development
of the Compound and (ii) in respect of AstraZeneca, a Third Party that AstraZeneca or any of its Affiliates is collaborating with in respect of its or their business. 

 

	1.12	“Combination Products” means products in forms suitable for human applications that contain Compound as an active ingredient, together with one or more
other active ingredients. 

  

	1.13	“Commence” or “Commencement” when used to describe a Phase I Clinical Trial, Phase II Clinical Trial, or Phase III Clinical Trial,
means the first administration of Compound or Licensed Product or the comparator or the placebo to the first human in such trial related to Compound or Licensed Product. 

 

	1.14	 “Commercially Reasonable Endeavours” mean, with respect to the performance of each of the obligations of each Party under this
Agreement, efforts and resources commonly used in the research-based pharmaceutical industry for compounds or products with similar commercial and scientific potential at a similar stage in their lifecycle. Commercially Reasonable Endeavours after
First Regulatory Approval Filing shall be determined on a market-by-market basis for Compound and each Licensed Product, as applicable, provided that it is understood that Commercially Reasonable Endeavours with respect to commercialisation require
the Party responsible for commercialisation of Compound or Licensed Product under this Agreement to apply for Health Registration Approval and Exploit Compound or Licensed Product at least in the Major Markets, unless commercialisation in a specific

  
 3 

	 	
Major Market is (in itself) commercially not viable and/or reduces the overall economic value of a Compound or Licensed Product. Commercially Reasonable Endeavours require that a Party, at a
minimum, assign responsibility for such obligations to qualified employees, set annual goals and objectives for carrying out such obligations, and allocate resources designed to meet such goals and objectives. 

 

	1.15	“Complaining Party” has the meaning set forth in Section 17.2. 

 

	1.16	“Completion” when used to describe a Phase I Clinical Trial, a Phase II Clinical Trial or a Phase III Clinical Trial, means the date of database lock
related to such clinical trial, or in the absence of a database lock, the read-out of the trial results and “Complete” shall be construed accordingly. 

 

	1.17	“Compound” means the Trk Inhibitor, known as, [...***...] which is more particularly described in Schedule 1. 

 

	1.18	“Confidential Information” has the meaning set forth in Section 10.1. 

 

	1.19	“Control” means, with respect to any item of Information, Patent or Intellectual Property Right, possession of the right, whether directly or
indirectly, and whether by ownership, licence or otherwise, to assign, or grant a licence, sublicence or other right to or under, such Information, Patent or Intellectual Property Right as provided for herein, without violating the terms of any
agreement or other arrangement with any Third Party. 

  

	1.20	“Data Exclusivity” means any data or market exclusivity periods established by Applicable Law, including any such periods listed in the FDA’s
Orange Book or periods under national implementations of Article 10.l(a)(iii) of Directive 2001/83/EC (as amended), and all international equivalents. 

  

	1.21	“Data Room” a due diligence data room containing the data and information to the extent required and necessary for a party to take an informed decision
related to the Compound and Licensed Product(s), that Flexion has generated since the Effective Date, including the final report of clinical trial results, minutes of interactions with regulatory bodies and summary Chemistry,
Manufacturing & Controls (“CMC”) as part of a New Drug Application to the FDA and manufacturing data and batch reports. 

  

***Confidential Treatment Requested 

  
 4 

	1.22	“Develop” or “Development” means, with respect to the Compound and/or Licensed Product(s), the performance of all research,
pre-clinical, clinical and regulatory activities required to obtain Health Registration Approval of a Product in the Territory. 

  

	1.23	“Direct Licence Agreement” has the meaning set forth in 17.6.6(c) 

 

	1.24	“Disclosing Party” has the meaning set forth in Section 10.1. 

 

	1.25	“Disclosure Letter” has the meaning set forth in Section 12.2. 

 

	1.26	“Effective Date” has the meaning set forth in the preamble to this Agreement. 

 

	1.27	“Ethics Standards” means the standards set out in Schedule 2. 

 

	1.28	“Europe” means the European Economic Area as it may be constituted from time to time and Switzerland. 

 

	1.29	“Exclusive Licensed Know-How” shall mean the Know-How described as such in Schedule 1.1. 

 

	1.30	“Expiration Date” has the meaning set forth in Section 17.1. 

 

	1.31	“Exploit” and “Exploiting” means to make, have made, import, use, sell, or offer for sale, including to research, Develop, register,
modify, enhance, improve, Manufacture, have Manufactured, hold/keep (whether for disposal or otherwise), formulate, have used, export, transport, distribute, promote, market or have sold or otherwise dispose or offer to dispose of, a product or
process. 

  

	1.32	“Exploitation” means the act of Exploiting a product or process. 

 

	1.33	“Field” means the prevention, diagnosis and treatment of medical conditions in humans. 

 

	1.34	 “First Commercial Sale” means the first sale for monetary value for use or consumption by the general public of a Licensed Product in
a country in the Territory after all Regulatory Approvals for such Licensed Product have been obtained in such country. For the avoidance of doubt, sales prior to receipt of all Regulatory Approvals necessary to commence regular commercial sales,
such as so-called 

  
 5 

	 	
“treatment IND sales”, “named patient sales” and “compassionate use sales”, shall not be construed as a First Commercial Sale. 

 

	1.35	“First Regulatory Approval Filing” means the date on which the first Regulatory Filing for the Compound or Licensed Products in any country in the
Territory has been submitted to a Health Authority. 

  

	1.36	“Flexion Product Data” has the meaning set forth in Section 17.6.2. 

 

	1.37	“Flexion Trademarks” means all Trademarks used by or on behalf of Flexion, its Affiliates or Sublicensees prior to the termination of this Agreement in
connection with the Compound or Licensed Products and any registrations thereof, or any pending applications relating thereto. 

  

	1.38	“Force Majeure” has the meaning set forth in Section 18.1. 

 

	1.39	“Force Majeure Party” means a Party prevented or delayed in its performance under this Agreement by an event of Force Majeure.

  

	1.40	“GMP Study Drug” has the meaning set forth in Section 7.1. 

 

	1.41	“Good Clinical Practices” or “GCP” means current Good Clinical Practices as specified in the United States Code of Federal
Regulations, at the time of testing, and all FDA and ICH guidelines, including the ICH Consolidated Guidelines on Good Clinical Practices (and each as amended from time to time). 

 

	1.42	“Good Laboratory Practices” or “GLP” means current Good Laboratory Practices as specified in the United States Code of Federal
Regulations at Title 21 (21 CFR § 58) at the time of testing and all applicable ICH guidelines (and each as amended from time to time). 

  

	1.43	 “Good Manufacturing Practices” or “GMP” means current Good Manufacturing Practices and standards as provided for (and each
as amended from time to time) in European Community Directive 91/356/EEC (Principles and Guidelines of Good Manufacturing Practice for Medicinal Products) and in the Current Good Manufacturing Practice Regulations of the United States Code of
Federal Regulations Title 21 (21 CFR §§ 210-211) in relation to the production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by ICH Harmonized Tripartite Guideline, Good Manufacturing Practice Guide
for Active 

  
 6 

	 	
Pharmaceutical Ingredients, and subject to any arrangements, additions or clarifications agreed from time to time between the Parties. 

 

	1.44	“Grant-Back Patents” means any Patents that, at the termination of this Agreement, Flexion or its Affiliates own or otherwise Control and are necessary
or reasonably useful for the Exploitation of the Licensed Products or Compound or that claim or cover Flexion’s Improvements to the Licensed Products or Compound and any freedom to operate and immunity from suit rights granted to Flexion and/or
its Affiliates in respect of the Licensed Products or Compound. 

  

	1.45	“Health Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments,
bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Compound or Licensed Products in the Territory. 

 

	1.46	“Health Registration Approval” means, with respect to a country in the Territory, any and all approvals, licences, registrations or authorisations of
any Health Authority necessary to commercially distribute, sell or market a Licensed Product in such country, including, where applicable, (a) Regulatory Approval, (b) pricing or reimbursement approval in such country, (c) pre- and
post-approval marketing authorisations (including any prerequisite Manufacturing approval or authorisation related thereto), (d) labelling approval and (e) technical, medical and scientific licences. 

 

	1.47	“Improvements” means any invention, discovery, development or modification with respect to Compound or a Licensed Product or relating to the
Exploitation thereof, whether or not patented or patentable, that is conceived, reduced to practice, discovered, Developed or otherwise made at any time during the term of this Agreement, including any enhancement in the efficiency, operation,
Manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of Compound or such Licensed Product, any discovery or Development of any new or expanded indications for Compound or such Licensed Product or any
discovery or Development that improves the stability, safety or efficacy of Compound or such Licensed Product. 

  
 7 

	1.48	“IND Filing” means an Investigational New Drug Application (as more fully defined in Title 21 CFR 312.22 and 312.23) and all amendments and supplements
thereto filed with the FDA. 

  

	1.49	“Indemnified Party” means a Party seeking to recover a Loss under Section 13.1 or 13.2. 

 

	1.50	“Indemnifying Party” means a Party from whom recovery of a Loss is sought under Section 13.1 or 13.2. 

 

	1.51	“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes. 

 

	1.52	“Intellectual Property Rights” means trademarks, service marks, trade names, registered designs, design rights, copyrights (including rights in
computer software), database rights and any rights or property similar to any of the foregoing (other than Patents) in any part of the world whether registered or not registered together with the right to apply for the registration of any such
rights. 

  

	1.53	“IP” has the meaning set forth in Section 17.9. 

  

	1.54	“Knowledge” has the meaning set out in Section 12.2. 

 

	1.55	“Know-How” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes,
techniques, practices, formulae, instructions, skills, techniques, procedures, formulations, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, databases, inventions, specifications,
data, results and other material, including: high-throughput screening, gene expression, genomics, proteomics and other drug discovery and development technology; biological, chemical, biochemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, pre-clinical, clinical, safety, manufacturing, stability and quality control data and information, including study designs and protocols; assays and biological methodology; Manufacturing and quality control procedures and
data, including test procedures; and synthesis, purification and isolation techniques; in each case, whether or not confidential, proprietary, patented or patentable in written, electronic or any other form now known or hereafter developed.

  
 8 

	1.56	“Licensed Know-How” means (a) the Exclusive Licensed Know-How and (b) the Non-Exclusive Licensed Know-How. 

 

	1.57	“Licensed Patents” means (a) all patents identified as such and set forth in Schedule 1 hereto, and (b) any patents deriving from the Patents
under (a) that AstraZeneca or its Affiliates Control at any time during the term of this Agreement that cover or claim Compound or any Licensed Product in the Territory. 

 

	1.58	“Licensed Products” means the Products and the Combination Products. 

 

	1.59	“List Two Countries” has the meaning set out in Section 14.1. 

 

	1.60	“Losses” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties, reasonable
lawyers’ fees and disbursements and “Loss” shall be construed accordingly. 

  

	1.61	“Major Market” means [...***...]. 

  

	1.62	“Manufacture” and “Manufacturing” and “Manufactured” means, with respect to a Licensed Product or Compound, the
synthesis, manufacturing, processing, formulating, packaging, labelling, holding and quality control testing of such Licensed Product or Compound. 

  

	1.63	“Net Sales” means the gross amount invoiced for Licensed Products by Flexion and its Affiliates and Sublicensees to Third Parties after deduction of:

  

	 	1.63.1	normal and customary trade or quantity discounts (including chargebacks and allowances) actually allowed; 

 

	 	1.63.2	amounts repaid or credited by reason of rejection, returns (including allowance for specific return reserves based on notified returns) or recalls of goods, rebates or
bona fide price reductions determined by Flexion or its Affiliates or Sublicensees in good faith; 

  

	 	1.63.3	 rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in
limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare 

  

***Confidential Treatment Requested 

  
 9 

	 	
or similar state programme in the United States or equivalent governmental programme in any other country; 

 

	 	1.63.4	transportation costs, distribution expenses, special packaging and related insurance charges to the extent that such items are included in the gross amount invoiced;

  

	 	1.63.5	excise taxes, Indirect Taxes and customs duty imposed on the sale, importation, use or distribution of the Licensed Products (but not including taxes assessed against
the income derived from such sale). 

 Any of the deductions listed above that involves a payment by Flexion or its
Affiliates or Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is incurred by such entity. For purposes of calculating the Net Sales of bundled products, deductions shall be apportioned across all products in
the bundle on a fair and reasonable basis, provided that the percentage rebate or discount apportioned to the Licensed Product shall not exceed the percentage rebate or discount applied in total to the bundled products. Similarly the total price
payable for a bundled product shall be apportioned between Licensed Product and other product within the bundle on a fair and reasonable basis. For the avoidance of doubt, if in addition to the invoiced amount for a specific shipment of Product,
Flexion, an Affiliate or a Sub-Licensee receives another cash payment as consideration for such Product from a Third Party, then that payment will be deemed to be a Net Sale in that Calendar Quarter for the purpose of calculating payments to
AstraZeneca from Flexion, its Affiliate or Sub-Licensee. 
  

	1.64	“Non-Exclusive Licensed Know-How” means the Know-How specified in Schedule 1.2. 

 

	1.65	“Non GMP Study Drug” has the meaning set forth in Section 7.1. 

 

	1.66	“Non-OA Indications” means indications in the Field other than Osteoarthritis. 

 

	1.67	“Notice Period” has the meaning set forth in Section 17.2. 

 

	1.68	 “Osteoarthritis” means arthritis typically with onset during middle or old age that is characterized by degenerative and sometimes
hypertrophic changes in the bone and cartilage of one or more joints and a progressive wearing down of apposing joint 

  
 10 

	 	
surfaces with consequent distortion of joint position and is marked symptomatically especially by pain, swelling, and stiffness. 

 

	1.69	“Other Third Party Licence(s)” has the meaning set out in Section 16.1.2. 

 

	1.70	“Party” means either AstraZeneca or Flexion and “Parties” means both AstraZeneca and Flexion. 

 

	1.71	“Patents” means (a) all national, regional and international patents and patent applications, including provisional patent applications,
(b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part,
provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and
design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary
protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction
patent or registration patent or patent of additions to any such foregoing patent applications and patents. 

  

	1.72	“Payments” has the meaning set forth in Section 6.12.1. 

 

	1.73	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organisation, including a government or political subdivision, department or agency of a government. 

 

	1.74	“Phase I Clinical Trial” means a clinical trial during which the Compound or a Licensed Product is given for the first time to a human volunteer or
patient. 

  

	1.75	 “Phase II Clinical Trial” means a clinical trial of a Product in humans, including possibly pharmacokinetic studies, the principal
purpose of which is to make a preliminary determination that such Product is safe for its intended use and to obtain 

  
 11 

	 	
sufficient information about such Product’s efficacy to permit the design of further clinical trials, and generally consistent with Title 21 (21 CFR § 312.2l(b)) or the equivalent
legislation in a country other than the United States (as amended from time to time). A Phase II Clinical Trial may be either a Phase II(a) Clinical Trial or a Phase II(b) Clinical Trial. 

 

	1.76	“Phase II(a) Clinical Trial” means a Phase II Clinical Trial intended for dose exploration, dose response, duration of effect, kinetic/dynamic
relationship and preliminary efficacy and safety study of a candidate drug in the target patient population. 

  

	1.77	“Phase II(b) Clinical Trial” means a controlled dose ranging Phase II Clinical Trial to evaluate further the efficacy and safety of a candidate drug in
the target patient population and to define the optimal dosing regimen. 

  

	1.78	“Phase III Clinical Trial” means a large scale, pivotal, multi-centre, human clinical trial to be conducted in a number of patients estimated to be
sufficient to primarily establish efficacy of a Licensed Product in the claim(s) of Osteoarthritis and/or Non-OA Indications and at a standard suitable to obtain a Health Registration Approval to market and sell such Licensed Product in a Major
Market. A Phase III Clinical Trial shall also include any well-controlled study intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable Health Registration Approval (such as a combined Phase II/Phase
III study, or any Phase III study in lieu of a Phase II study), whether or not such study is a traditional Phase III study. 

  

	1.79	“Products” means products in forms suitable for human application that contain the Compound as the sole active ingredient. 

 

	1.80	“Proof of Concept” means, with regard to Compound or a Licensed Product, clinical trial results which provide meaningful evidence of efficacy and
safety in not less than [...***...]. 

  

	1.81	“Regulatory Approval” means, with respect to a country in the Territory any approval, licence, registration or authorisation approving a Regulatory
Filing issued by any Health Authority with respect to a Licensed Product. 

  

***Confidential Treatment Requested 

  
 12 

	1.82	“Regulatory Documentation” means all applications, registrations, licences, authorisations and approvals (including all Regulatory Filings, Regulatory
Approvals and Health Registration Approvals), all correspondence submitted to or received from Health Authorities (including minutes and official contact reports relating to any communications with any Health Authority) and all supporting
non-clinical and clinical documents and data. Non-clinical documents and data include but are not limited to toxicology, pharmacology, bioanalytical methods and validation and batch records. The aforementioned supporting documents and data shall be
given in their entirety or, at a minimum, in sufficient detail and form to support future Regulatory Filings, Regulatory Approvals and Health Registration Approvals, relating to Compound or any Licensed Products. 

 

	1.83	“Regulatory Filing” means a New Drug Application (as more fully defined in Title 21 CFR § 314.5 et. seq) and all amendments and supplements
thereto, filed with the FDA or the equivalent application or filing filed with any equivalent Heath Authority outside the United States (including any supra-national agency such as in the European Union) (for example a marketing authorisation
application in the European Union or Japanese New Drug Application in Japan) necessary to receive Regulatory Approval with respect to a Licensed Product in such jurisdiction, and including all FDA regulations and equivalent foreign regulations,
including all documents, data and other information concerning a pharmaceutical product which are necessary for gaining Regulatory Approval to market and sell such pharmaceutical product. 

 

	1.84	“Retained Patents” means (a) all patent applications and patents identified as such and set forth in Schedule 1 hereto, and (b) any patent
applications or patents not identified as such in Schedule 1 hereto that AstraZeneca or its Affiliates Control at any time during the term of this Agreement which are discovered by AstraZeneca or its Affiliates (and notified in writing by
AstraZeneca to Flexion) or Flexion after the Effective Date which would restrict Flexion’s ability to exercise the licences granted to it pursuant to Section 3.1 (where Flexion notifies AstraZeneca in writing of Flexion’s discovery of
such patent application or patent and AstraZeneca agrees in writing that such a patent application or patent should be covered by this definition), and (c) any Patents deriving from such patent applications or patents that AstraZeneca or its
Affiliates Control at any time during the term of this Agreement that cover or claim the Compound in the Territory. 

  
 13 

	1.85	“Semi-Pure Study Drug” has the meaning set out in Section 7.2. 

 

	1.86	“Sublicensee” has the meaning set out in Section 3.5. 

 

	1.87	“Territory” means all countries in the world except for those Affected Countries in respect of which this Agreement is terminated.

  

	1.88	“Third Party” means any Person not including the Parties, the Parties’ respective Affiliates or Sublicensees. 

 

	1.89	“Third Party Claim” has the meaning set forth in Section 13.1. 

 

	1.90	“Third Party Formulation Technology Licences” has the meaning set out in Section 16.1.1. 

 

	1.91	“Third Party Licence” has the meaning set forth in Section 16.1. 

 

	1.92	“Tier 1”, “Tier 2”, “Tier 3”, “Tier 4” and “Tier 5” each have the meaning set out
in Sections 6.2.1-6.2.5 respectively. 

  

	1.93	“Trademark” means any word, name, symbol, colour, designation or device or any combination thereof, including any trademark, trade dress, brand mark,
trade name, brand name, logo or business symbol used by Flexion or its Affiliates or Sublicensees in connection with the Compound or Licensed Products. 

  

	1.94	“Trk” means a neurotrophin receptor kinase known as tropomyosin receptor kinase, a high affinity catalytic receptor for neurotrophins, whose receptors
comprise three isoforms (TrkA, TrkB and TrkC as more fully described in Schedule 4). 

  

	1.95	“Trk Inhibitor” means a compound whose primary known mechanism of action is the direct inhibition of Trk. 

 

	1.96	“United States” or “U.S.” means the United States of America, including its territories and possessions, the District of Columbia and
Puerto Rico. 

  

	1.97	“Valid Claim” means, with respect to a particular country, either: 

 

	 	1.97.1	 any claim of a granted and unexpired Patent in such country that (i) has not been held permanently revoked, unenforceable or invalid by a decision
of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, and (ii) has 

  
 14 

	 	
not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; or 

 

	 	1.97.2	a claim of a pending Patent application, which claim was filed and is being prosecuted in good faith and has not been cancelled, withdrawn, abandoned or finally
disallowed without the possibility of appeal or re-filing of the application. 

  

	2	Construction 

Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of
any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to
calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or limit the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term
“including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the
Parties and no rule of strict construction shall be applied against any Party. 
  

	3	Grant of Rights 

  

	3.1	Licence Grants to Flexion. Subject to the terms and conditions of this Agreement, AstraZeneca hereby grants to Flexion in each case to Develop and Exploit the
Compound and the Licensed Products for all purposes in the Field: 

  

	 	(i)	an exclusive (including with regard to AstraZeneca and its Affiliates) royalty-bearing licence in the Territory, with the right to grant sublicences through multiple
tiers pursuant to Section 3.5, under AstraZeneca’s rights, titles, and interests in and to the Licensed Patents and the Exclusive Licensed Know-How, and 

 

	 	(ii)	 a non-exclusive royalty-bearing licence in the Territory, with the right to grant sublicences through multiple tiers pursuant to Section 3.5 under
AstraZeneca’s rights, titles and interests in and to the Non-Exclusive Licensed Know-How, in 

  
 15 

	 	
each case to Develop and Exploit the Compound and the Licensed Products for all purposes in the Field. For the avoidance of doubt, the grant of rights in this Section 3.1 does not include
the right for Flexion to Develop and Exploit any compounds covered or claimed in the Licensed Patents other than the Compound. 

  

	3.2	AstraZeneca Retained Rights. The exclusive rights granted to Flexion under Section 3.1 above are subject to the following retained rights:

  

	 	3.2.1	The right of AstraZeneca, its Affiliates and any Collaborators of AstraZeneca to use the Licensed Patents to the extent only that the relevant use is solely for
(a) the purposes of research in Non-OA Indications by and on behalf of AstraZeneca, its Affiliates and Collaborators and not for the purposes of the development or commercialisation of any pharmaceutical product falling within the scope of the
Licensed Patents; (b) the research does not include [...***...] trials; and (c) disclosure of the results of the research is in connection with [...***...]. 

 

	 	3.2.2	Notwithstanding the limitations of the rights retained pursuant to sub-section (a) above, the right of AstraZeneca, its Affiliates and any Collaborators of
AstraZeneca to use the Licensed Patents (a) to make or have made intermediates other than for the purpose of selling them as active ingredients for the Licensed Products; and (b) to use processes disclosed under the Licensed Patents for
any purpose other than any use in relation to Compound or Licensed Products. 

 AstraZeneca shall be entitled to
assign its rights under this Section 3.2 without the prior written consent of Flexion. 
  

	3.3	 Licensed Know-How. Flexion acknowledges that (a) the Licensed Know-How is secret and substantial and that without the Licensed Know-How,
Flexion would not be able to apply to obtain and maintain Health Registration Approvals, (b) such Health Registration Approvals together with the Health Registration Approvals assigned or licensed to Flexion hereunder may give, or may allow
Flexion to obtain and maintain, Data Exclusivity with respect to the Compound and Licensed Products, 

  

***Confidential Treatment Requested 

  
 16 

	 	
(c) access to the Licensed Know-How and such Health Registration Approvals may provide Flexion with a competitive advantage in the marketplace beyond the exclusivity afforded by the Licensed
Patents and the Data Exclusivity, and (d) the milestone payments and royalties set forth in Sections 6.1 and 6.2 are, in part, intended to compensate AstraZeneca for such exclusivity and such competitive advantage, and shall be payable
regardless of whether or not Flexion does in fact achieve a competitive advantage therefrom. 

  

	3.4	Freedom to Operate. AstraZeneca shall not, and shall procure that its Affiliates, Collaborators, sub-licensees and assigns shall not, enforce any Retained
Patents against Flexion, its Affiliates and Sublicensees in respect of any use by Flexion, its Affiliates, and Sublicensees to the extent only that the relevant use is solely for the purposes of exercising the rights granted at Section 3.1
above. If Flexion abandons (without the consent of AstraZeneca) the prosecution and/or maintenance of a Licensed Patent then AstraZeneca’s undertaking in this Section shall automatically terminate with respect to the country in which the
Licensed Patent has been abandoned. 

  

	3.5	 Sublicences. Subject to Section 17.6.5, Flexion shall have the right to grant sublicences through multiple tiers under the licences granted
in Section 3.1, to its Affiliates and to any other Persons in the Territory or in any country of the Territory without the prior written consent of AstraZeneca; provided, however, that: (a) Flexion shall ensure the
performance by each Sublicensee of the terms of each such sublicence; (b) notwithstanding any such sublicence, Flexion shall remain solely liable for the performance of its obligations hereunder, and (c) Flexion shall promptly after the
execution of each such sublicence notify AstraZeneca in writing of such sublicence stating the name of the Sublicensee and the countries covered by such sub-licence; and (d) Flexion shall not seek to grant or grant any sublicences, in any part
of the Territory other than Japan, prior to [...***...]; and (e) Flexion’s selection of a Sublicensee shall be made in good faith consideration of the Ethics Standards and Flexion shall ensure that any subsequent sublicensee selected
by Flexion’s Sublicensee will also make such consideration. Where Flexion grants a sublicence to a Person that is not an Affiliate of Flexion, including to market, promote, sell, distribute or otherwise Exploit Compound or Licensed Products in
any country in the Territory such Person shall be a 

  

***Confidential Treatment Requested 

  
 17 

	 	
“Sublicensee” for the purposes of this Agreement. Flexion shall ensure that all Persons to which it grants sublicences will not exceed the scope of the rights granted to Flexion
under this Agreement with respect to the Licensed Patents, the Licensed Know-How and the Retained Patents. The sublicence shall contain obligations on the Sublicensee which are no less onerous than those set out in Section 5.3 (Diligence
Obligations, except for Sub-Section 5.3.4), Section 5.5 (Records and Reporting); Section 6.9 (Records Retention and Audit); Section 8 (Ownership of Intellectual Property); Section 9 (Adverse Event Reporting) Section 10
(Confidentiality and Non-Disclosure); Section 17.2 (Termination for Breach); Section 17.6.5 (Effect of Termination on Sublicences); Section 17.8 (Termination upon Insolvency or Bankruptcy); Section 19 (Assignment). Each
sublicence granted by Flexion shall further contain such covenants or representations and warranties as reasonably required to ensure that the Sublicensee meets the Ethics Standards during the term of such sublicence and Flexion shall make it a term
of any Sublicence granted by it, that Flexion’s Sublicensee will impose such covenants or representations and warranties on any Sublicensee with which it enters into a sublicence. For the avoidance of doubt, any sublicence to be granted by
Flexion to a sublicensee will contain a section requiring a Sublicensee not to challenge the validity of the intellectual property licensed to it, on substantially similar terms to Section 17.3. 

 

	3.6	AstraZeneca Right of Final Offer. 

  

	 	3.6.1	If Flexion, at any time prior to [...***...] is interested in offering rights relating to Compound or a Licensed
 Product(s) to a Third Party, Flexion shall
have the obligation to inform AstraZeneca promptly in writing accordingly. Within [...***...] days after receipt of Flexion’s written notice, AstraZeneca shall confirm to Flexion whether AstraZeneca is interested to review further
information related to Compound or such Licensed Product(s). If during the above-mentioned [...***...] day period, AstraZeneca confirms that it is not interested, or if AstraZeneca does not contact Flexion at all, then Flexion shall be free to
enter into an agreement with a Third Party related to Compound or such Licensed Product without further notice to AstraZeneca. 

  

***Confidential Treatment Requested 

  
 18 

	 	3.6.2	If AstraZeneca does confirm its interest to Flexion then as soon as reasonably possible after Flexion receives such confirmation, Flexion shall make available to
AstraZeneca a Data Room. Flexion shall allow a reasonable number of AstraZeneca personnel to access the Data Room. 

  

	 	3.6.3	Within [...***...] days following the opening of the Data Room to AstraZeneca, AstraZeneca shall advise Flexion if it is interested in acquiring the rights to the
Compound and/or Licensed Product(s) offered by Flexion pursuant to a sublicence agreement. If AstraZeneca is interested in acquiring the rights, then it shall make an initial good faith offer as to the commercial terms and conditions on which it
would be prepared to acquire the rights offered by Flexion. Following receipt of such initial offer, Flexion shall either enter into non-exclusive good faith negotiations to agree to a definitive sublicence agreement with AstraZeneca with regard to
the rights, for a maximum period of [...***...] days (or such other time period as the Parties may mutually agree), or reject such offer outright. If the Parties have not agreed a definitive sublicence agreement within the [...***...]
day period (or such longer period as they may mutually agree) or if Flexion at any time in its discretion terminates such negotiations, then Flexion shall be free to enter into a transaction regarding the Compound or such Licensed Product with any
Third Party, provided that, AstraZeneca shall have the right to make a final offer to Flexion within [...***...] days after [...***...], and provided further that Flexion shall not enter into any agreement with a Third Party on financial
terms and conditions which are more favourable for the Third Party when taken in their totality than the terms and conditions last offered by AstraZeneca [...***...]. 

 

	3.7	 Exclusivity Term. Flexion’s exclusive position granted by Section 3.1 shall expire with respect to each separate Licensed Product, on
a country-by-country basis, on the date when Flexion’s obligation to pay royalties with respect to such Licensed Product pursuant to Section 6.6 expires. Upon expiry of Flexion’s exclusive position with respect to a Licensed Product
in a country, Flexion’s licence with respect to such Licensed Product in such country shall become non-exclusive, fully paid-up, 

  

***Confidential Treatment Requested 

  
 19 

	 	
perpetual and irrevocable and the Net Sales of such Licensed Product in such country shall be excluded from the royalty calculations in Sections 6.2 and 6.3 (but not the thresholds and ceilings
contained in Sections 6.2 and 6.4). Flexion and its Affiliates and Sublicensees shall be allowed to continue Exploiting such Licensed Product and using all Non-Exclusive Licensed Know-How in connection therewith on a non-exclusive basis and all
Exclusive Licensed Know-How on an exclusive basis in such country with no further consideration to AstraZeneca. 

  

	3.8	Assignment of Regulatory Documentation. AstraZeneca hereby assigns to Flexion free of charge all of its rights, title and interest in and to all Regulatory
Documentation (if any), Controlled by AstraZeneca as of the Effective Date and will do all further acts and things as needed to perfect such assignment. Flexion shall be responsible for the payment of any fee becoming due after the Effective Date
payable by Flexion to Third Parties on the transfer of such Regulatory Documentation. For the avoidance of doubt, such rights assigned pursuant to this Section will be assigned back to AstraZeneca by Flexion in the event of a reversion of rights
pursuant to Section 3.6 above. 

  

	3.9	Change of Control. 

  

	 	3.9.1	If a Change of Control occurs at any time within [...***...] of the Effective Date of this Agreement, then AstraZeneca shall have the right to terminate this
Agreement by giving [...***...] notice in writing to Flexion. Flexion shall give AstraZeneca notice of any Change of Control of Flexion as soon as practicable (taking into account any restrictions imposed by Applicable Law) and in any event
within thirty (30) days after the occurrence of the Change of Control. AstraZeneca’s right to terminate this Agreement under this Section 3.9.1 shall expire at the later of [...***...] days after the occurrence or after the
notification of such Change of Control. 

  

	 	3.9.2	If a Change of Control occurs after [...***...] from the Effective Date but prior to the Commencement of [...***...] with respect to Compound, then
AstraZeneca shall have the right to terminate this Agreement in its entirety, in accordance with and subject to the following provisions: 

  

***Confidential Treatment Requested 

  
 20 

	 	a)	Flexion shall give AstraZeneca written notice of any Change of Control of Flexion as soon as practicable (taking into account any restrictions imposed by Applicable
Law) and in any event within thirty (30) days after the occurrence of the Change of Control. Flexion shall, at the same time as it notifies AstraZeneca of the Change of Control, also [...***...]. 

 

	 	b)	Upon receipt of the notification as per sub-section (a) above, AstraZeneca may in its sole discretion, elect to terminate this Agreement by serving immediate
written notice to Flexion. 

  

	 	c)	In case AstraZeneca elects to initiate [...***...], AstraZeneca shall, at the latest sixty (60) days after
 [...***...], notify Flexion in writing
whether AstraZeneca has decided to terminate the Agreement or not. 

  

	 	d)	If AstraZeneca elects to terminate this Agreement in accordance with sub-sections (b) or (c) above, the Applicable Fee (as defined below) shall become due for
payment by AstraZeneca within thirty (30) days after AstraZeneca has sent the termination notice to Flexion. 

Flexion may, it its sole discretion, at any time after receipt of a termination notice from AstraZeneca (if any) in accordance with
sub-sections (b) or (c) above, but by no later than fifteen (15) days after the commencement of the payment period in sub-section (d) above, notify AstraZeneca in writing that Flexion is willing to pay AstraZeneca the Applicable
Fee. In such case, and provided that AstraZeneca receives the Applicable Fee within the time period stated below (and subject to a cure period for payment delay under Section 17.2 below), AstraZeneca’s right to terminate for the Change of
Control shall be forfeit and this Agreement shall continue in full force and effect as if AstraZeneca had not served the notice to terminate for a Change of Control. The Applicable Fee shall become payable by Flexion within thirty (30) days

  

***Confidential Treatment Requested 

  
 21 

	 	following Flexion’s written notification of its intention to pay to AstraZeneca the Applicable Fee. 

 

	 	3.9.3	For the purposes of this Section 3.9, the “Applicable Fee” shall be defined as follows: If the Change of Control occurs in the period which is
later than [...***...] after the Effective Date and prior to [...***...], then the Applicable Fee shall be [...***...]. If the Change of Control occurs in the period which is after [...***...], then the Applicable Fee shall
be [...***...]. 

  

	 	3.9.4	If Flexion pays AstraZeneca the Applicable Fee in accordance with Section 3.9.2 above, then it shall be entitled to offset the Applicable Fee against milestones
payable to AstraZeneca under Section 6 below. 

  

	3.10	Japan. 

  

	 	3.10.1	The Parties recognise that Japan is an important market. In consideration for the fact that Japan [...***...] for the purposes of this Agreement and in
consideration for the enhanced sub-licensing rights which AstraZeneca has granted to Flexion with respect to Japan, the Parties have agreed the following provisions with regard to Japan. 

 

	 	3.10.2	If upon [...***...], neither Flexion nor its Sublicensee has [...***...] in Japan, then Flexion shall at its option either (a) pay to AstraZeneca
[...***...] or (b) terminate this Agreement on no less than thirty (30) days prior written notice to AstraZeneca with respect to Japan only whereupon the provisions of Section 17.6.2 shall apply. 

 

	 	3.10.3	 If Flexion has sublicensed the rights to Japan prior to [...***...] and [...***...] then Flexion shall pay to AstraZeneca

  

***Confidential Treatment Requested 

  
 22 

	 	
the sublicensing fee in consideration for the rights to sublicense in Japan, of [...***...] payable in the manner set out below if and when the following events occur (and in the case of
(b), (c) and (d) below within thirty (30) days of the date of AstraZeneca’s written notice to Flexion that such event has occurred): 

  

	 	a)	Upon [...***...] an amount of [...***...]; and 

  

	 	b)	Upon [...***...], an amount of [...***...]; and 

  

	 	c)	Upon [...***...], an amount of [...***...]; and 

  

	 	d)	Upon [...***...], an amount of [...***...]. 

  

	3.11	Reversion of Rights in Compound. Subject to the obligation to perform Commercially Reasonable Endeavours to Develop and/or commercialize the Compound or to
sublicence, if Flexion decides that it no longer wishes to do so, then it shall promptly notify AstraZeneca in writing of such decision whereupon the rights granted to Flexion pursuant to Section 3.1 with respect to the Compound shall terminate
and revert to AstraZeneca and, the provisions of Section 17.6.2 shall apply. For the avoidance of doubt, in the event that Flexion notifies AstraZeneca of such a decision prior to the payment of the second non-refundable payment of
[...***...] due pursuant to Section 6.1.1, then this amount will become immediately due and payable to AstraZeneca. 

  

	3.12	 Notification of Flexion by AstraZeneca re: [...***...] or other Trk Inhibitors. Flexion agrees that as of the Effective Date, rights to
the AstraZeneca compound [...***...] or other Trk Inhibitors do not form a part of the Intellectual Property Rights being 

  

***Confidential Treatment Requested 

  
 23 

	 	
licensed to Flexion pursuant to the terms and conditions of this Agreement. In the event that AstraZeneca is in a position to offer to license such rights to Flexion after the Effective Date,
AstraZeneca will perform Commercially Reasonable Endeavours to notify Flexion first of the availability of such rights to [...***...] or other Trk Inhibitors. For the avoidance of doubt, the notification obligations of this Section do not
constitute a binding obligation upon AstraZeneca to enter into any further agreement with Flexion. 

  

	4	Improvements 

  

	4.1	Any and all Improvements which Flexion and or its Affiliates or Sublicensees make during the term of this Agreement shall be the sole and exclusive property of Flexion,
its Affiliates, and Sublicensees (as the case may be), and save as set out in this Agreement, AstraZeneca shall not acquire any right to or under any such Improvements. 

 

	4.2	Flexion shall have the right, at its sole discretion, to apply for and file in its own name any and all Intellectual Property Rights and Patents arising in any
Improvement created by Flexion, its Affiliates or any Sublicensee of Flexion. 

  

	5	Development  

  

	5.1	Know-How Disclosure. 

AstraZeneca shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to Flexion, Regulatory
Documentation, and Licensed Know-How in each case that is in existence as of the Effective Date, as listed in Schedule 1. In the event that after the Effective Date and the initial disclosure of Regulatory Documentation and Licensed Know-How by
AstraZeneca, Flexion has any requests related to transferred Regulatory Documentation and Licensed Know-How in the [...***...] after the Effective Date, then AstraZeneca will use reasonable endeavours to answer such requests and provide
additional data and reports available at AstraZeneca not yet disclosed to Flexion (if any), provided that AstraZeneca shall not have any obligation to generate any new data not in existence at the Effective Date. After such [...***...] period,
Flexion may make only limited 

  

***Confidential Treatment Requested 

  
 24 

 
requests as needed by Flexion in the context of any submission to or communication with a Health Authority. 
  

	5.2	Research and Development costs. All research and Development costs will be the responsibility of Flexion. 

 

	5.3	Diligence Obligations. 

  

	 	5.3.1	Flexion undertakes to use Commercially Reasonable Endeavours at its own cost to, directly or through
 Sublicence(s), (a) Develop and commercialise at least one
(1) Licensed Product in each Major Market in the Territory in accordance with the terms and conditions of this Agreement, and (b) obtain Health Registration Approval(s) to market and sell at least one (1) Licensed Product in each
Major Market in the Territory and (c) market and sell at least one (1) Licensed Product in each Major Market in the Territory. 

  

	 	5.3.2	Flexion shall perform, or cause to be performed, any and all of its Development and commercialisation obligations as set forth in this Agreement, including those
obligations identified in Section 5.3.1, in good scientific manner, and in compliance in all material respects with all Applicable Law. 

  

	 	5.3.3	Flexion’s designated person shall report verbally to AstraZeneca’s designated person (the Parties’ designated persons are further specified in Schedule 3
to this Agreement) on a Quarterly basis (at a time and via a media to be mutually agreed between the Parties) on its progress in the Development of the Licensed Products in the Territory in reasonable detail in order to keep AstraZeneca informed of
its progress. Such Quarterly updates in respect of Development shall cease upon the First Commercial Sale of the first Licensed Product, unless the Parties agree otherwise. 

 

	 	5.3.4	 Flexion’s designated person shall report verbally to AstraZeneca’s designated person (the Parties’ designated persons are further
specified in Schedule to this Agreement) on a Quarterly basis (at a time and via a media to be mutually agreed between the Parties) on its progress in the commercialisation of the Licensed Products in the Territory in reasonable detail in order to
keep 

  
 25 

	 	
AstraZeneca informed of its progress, commencing from [...***...] prior to the estimated date of First Commercial Sale. 

 

	5.4	Breach of Diligence Obligations. 

  

	 	5.4.1	Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Flexion is in breach of its obligations under Section 5.3 with
respect to a Major Market, then AstraZeneca shall so notify Flexion, specifying the basis for its belief, and the Parties shall meet [...***...] after such notice to discuss in good faith AstraZeneca’s concerns and Flexion’s
Development and commercialisation plans with respect to the Licensed Product(s) to attempt to eliminate AstraZeneca’s concerns. 

  

	 	5.4.2	Right of Termination. If after good faith discussions pursuant to Section 5.4.1, AstraZeneca’s concerns have not been eliminated and (a) the
Parties have not agreed [...***...] under Section 5.4.1 above, upon the reasonable steps to be taken to eliminate such concerns [...***...]; or (b) Flexion does not take the agreed upon reasonable steps
 [...***...]
designed to rectify its breach of its obligations under Section 5.3 in such Major Market [...***...] and thereafter diligently pursue such actions, AstraZeneca may exercise its right of termination provided under Section 17.2.

  

	5.5	 Records and Reporting. Flexion shall prepare and maintain complete and accurate records regarding the Development and commercialisation of the
Licensed Products. Commencing on 31st January 2011
and on each anniversary of this during the term, Flexion shall provide AstraZeneca a report for the previous Calendar Year describing the progress in the Development and commercialisation of Licensed Products in the Territory in reasonable detail in
order to keep AstraZeneca informed of its progress. Such report shall cover, in relation to the Compound and Licensed Products, general information on Flexion’s Development and commercialisation activities in the previous Calendar Year and a
summary of the activities planned in the next Calendar Year. If and when a Health Registration Approval is obtained in any country of the 

  

***Confidential Treatment Requested 

  
 26 

	 	
Territory, Flexion shall inform AstraZeneca of such Health Registration Approval within thirty (30) days. 

 

	6	Consideration 

  

	6.1	Milestone Payments. In partial consideration of the licences and other rights granted by AstraZeneca to Flexion herein and subject to the terms and conditions of
this Agreement, Flexion shall pay AstraZeneca the following sums: 

  

	 	6.1.1	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) of which USD [...***...] is to be paid within thirty (30) days of
the Effective Date and the remaining USD [...***...] to be paid within one hundred and eighty days (180) of the Effective Date. For the avoidance of doubt, this amount includes a payment from Flexion to AstraZeneca of USD
[...***...] per kilogramme in consideration for the [...***...]); 

  

	 	6.1.2	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days of
 [...***...]; and

 Osteoarthritis 
 For the first Licensed Product Developed by Flexion (or its Affiliates or a Sublicensee) for the treatment of Osteoarthritis: 

 

	 	6.1.3	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	6.1.4	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	6.1.5	 a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]

  

***Confidential Treatment Requested 

  
 27 

	 	
[...***...]; 

  

	 	6.1.6	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	6.1.7	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]; and

  

	 	6.1.8	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...].

 The milestones payable for Japan shall also be payable in the circumstances set out in Section 3.10 (Japan). 

Non-OA Indications 
 For the first Licensed Product Developed by Flexion (or its Affiliates or a Sublicensee) for the treatment of any Non-OA Indication: 

 

	 	6.1.9	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	6.1.10	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

	 	6.1.11	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...];

  

***Confidential Treatment Requested 

  
 28 

	 	6.1.12	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...]; and

  

	 	6.1.13	a non-refundable payment of USD [...***...] ([...***...] United States Dollars) within thirty (30) days following [...***...].

 Milestone payments in Section 6.1 will be payable [...***...] and will be payable for such
[...***...]. Other than as outlined above [...***...]. Flexion shall notify AstraZeneca within thirty (30) days of any determination, filing or approval that would trigger a payment by Flexion to AstraZeneca under this
Section 6.1, with details of the amount of the payment required and funds to meet the payment required. 
  

	6.2	Royalties. In addition to the foregoing payments, Flexion shall pay AstraZeneca with respect to the Licensed Products the following royalties on the Net Sales of
the Licensed Products in the Territory during each Calendar Year (provided that calculations for the Combination Products are to be made in accordance with the formula set out in Section 6.3 below) in respect of sales of Licensed Products:

  

	 	6.2.1	[...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products in the Territory during such Calendar
Year that are less than USD [...***...] ([...***...] United States Dollars) (“Tier 1”) ; 

  

	 	6.2.2	[...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products in the Territory during such Calendar
Year that equal or exceed USD [...***...] ([...***...] United States Dollars) but are less than USD [...***...] ([...***...] United States Dollars) (“Tier 2”); and 

  

***Confidential Treatment Requested 

  
 29 

	 	6.2.3	[...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products in the Territory during such Calendar
Year that equal or exceed USD [...***...] ([...***...] United States Dollars) but are less than USD [...***...] ([...***...] United States Dollars) (“Tier 3”); and 

 

	 	6.2.4	[...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products in the Territory during such Calendar
Year that equal or exceed USD [...***...] ([...***...] United States Dollars) but are less than USD [...***...] ([...***...] United States Dollars) (“Tier 4”); and 

 

	 	6.2.5	[...***...] percent ([...***...]%) of Net Sales for that portion of aggregate Net Sales of those Licensed Products in the Territory during such Calendar
Year that equal or exceed USD [...***...] ([...***...] United States Dollars) (“Tier 5”). 

 The calculation of royalties under this Section 6.2 shall be conducted separately for each Licensed Product. All sales of a Licensed Product, whether sold for the treatment of Osteoarthritis or
Non-OA Indications or as a Combination Product, shall [...***...]. Thus if Flexion [...***...]. 
  

	6.3	Combination Products. With respect to Combination Products, the Net Sales used for the calculation of the royalties under Section 6.2 shall be determined as
follows: 

    A                 
    X                     Net Sales of the Combination Product, where: 

  A+B 
  

	 	A =	standard sales price of the Licensed Product, containing a comparable amount of Compound as the sole active ingredient as the Combination Product in question, in the
given country. 

  

***Confidential Treatment Requested 

  
 30 

	 	B  =	standard sales price of the ready-for-sale form of a product, containing a comparable amount of the other therapeutically active ingredient(s) that is contained in the
Combination Product in question, in the given country. 

  

	 	6.3.1	In the event, however, that if, in a specific country, (a) the other therapeutically active ingredient(s) in such Combination Product is not sold separately in
such country, Net Sales shall be adjusted by multiplying actual Net Sales of such Combination Product by the fraction A/C, where C is the standard sales price in such country of such Combination Product, and (b) if a Product containing such
compound(s) is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-B)/C, where B is the standard sales price in such country of the other therapeutically active
ingredient(s) in the Combination Product and C is the standard sales price in such country of the Combination Product. The standard sales price for the Product containing such compound(s) and for each other active ingredient shall be for a quantity
comparable to that used in such Combination Product and of the same class, purity and potency. 

  

	 	6.3.2	If, in a specific country, the foregoing calculations do not fairly represent the value of the various active ingredients included in a Combination Product, the
allocation of Net Sales for such Combination Product shall be negotiated by the Parties in good faith comparable to such Product or such other active ingredients, as applicable. 

 

	 	6.3.3	If, after good faith negotiations the Parties cannot agree on the appropriate allocation of Net Sales for such a Combination Product in any given country, then either
Party shall have the right to refer such dispute to an independent third party who has had experience in a Major Market pricing and reimbursement authority and who is acceptable to both Parties, (agreement not to be unreasonably withheld or delayed
by either Party). 

  

	6.4	Sales Related Payments. 

Flexion shall pay to AstraZeneca the following sales related payments: 

 

	 	(i)	USD [...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed USD
[...***...] ([...***...] United States Dollars) for the first time. 

  

***Confidential Treatment Requested 

  
 31 

	 	(ii)	USD [...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed USD
[...***...] ([...***...] United States Dollars) for the first time. 

  

	 	(iii)	USD [...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed USD
[...***...] ([...***...] United States Dollars) for the first time. 

  

	 	(iv)	USD [...***...] ([...***...] United States Dollars) when cumulative Net Sales across all Licensed Products throughout the Territory exceed USD
[...***...] ([...***...] United States Dollars) for the first time. 

  

	 	6.4.2	The sales related payments shall be paid at the end of the Calendar Quarter in which the relevant Net Sales threshold was achieved at the same time as Flexion pays the
royalties due for that Calendar Quarter. 

  

	 	6.4.3	The sales-related payments set out above are subject to increase in accordance with the terms of Section 16 below (Potential Third Party Rights).

  

	6.5	Reduction of Royalty. 

 In
the event that, or from and after the date on which, (a) [...***...] exists in a country, and (b) [...***...] exists in such country, the royalty rate payable to AstraZeneca by Flexion under Section 6.2 with respect to Net
Sales of such Licensed Product in such country, shall be [...***...]. Any royalties owed to AstraZeneca after such a reduction in the royalty rate shall be compensation for Flexion’s use of the Licensed Know-How in accordance with
Section 3.3. 
  

	6.6	 Royalty Term. Flexion’s obligation to pay royalties shall commence, on a country-by-country basis, with respect to each separate Licensed
Product, on the date of First 

  

***Confidential Treatment Requested 

  
 32 

	 	
Commercial Sale of such Licensed Product in such country. The obligation shall expire, on a country-by-country basis, with respect to each separate Licensed Product on the later to occur of
(a) the twelfth (12th) anniversary of the First Commercial Sale of such Licensed Product in such country, and (b) such time as there is no longer (i) any Valid Claim of a Licensed Patent that claims or covers the Exploitation of
such Licensed Product in such country, and (ii) any Data Exclusivity with respect to such Licensed Product in such country. 

  

	6.7	Sales Subject to Royalties. Sales between Flexion, its Affiliates and Sublicensees shall not be subject to royalties hereunder. Royalties shall be calculated on
Flexion’s, its Affiliates’ and its Sublicensees’ sale of the Licensed Products to a Third Party. Royalties shall be payable only once for any given batch of the Licensed Products. For purposes of determining Net Sales, the Licensed
Product shall be deemed to be sold to third party wholesalers, pharmacies or other customers when it leaves Flexion’s premises or those of its subcontractor and a “sale” shall not include, and no royalties shall be payable on,
transfers of Licensed Products that are used as samples or in clinical trials or other transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory or governmental purposes. 

 

	6.8	Royalty Payments. The royalties shall be calculated Quarterly as of the last day of March, June, September and December respectively, for the Calendar Quarter
ending on that date. Flexion shall pay the royalties in conjunction with the delivery of a written report to AstraZeneca within sixty (60) days after the end of each Calendar Quarter that shows, with respect to each country and each Licensed
Product, the sales volume, gross sales amount and Net Sales of the Licensed Products during such Calendar Quarter. 

  

	6.9	Records Retention; Audit. 

  

	 	6.9.1	 Flexion shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate records or books of account in accordance with generally
accepted accounting principles showing the information that is necessary for the accurate determination of the royalties due hereunder with respect to the sale of such Licensed Product. Such books and records shall be retained by Flexion and its
Affiliates and Sublicensees until the later of (a) five (5) years after the end of the period to which such books and records pertain, and (b) the 

  
 33 

	 	
expiration of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be required by Applicable Law. 

 

	 	6.9.2	Upon the written request of AstraZeneca, Flexion shall, and shall cause its Affiliates to permit a certified public accountant or a person possessing similar
professional status and associated with an independent accounting firm acceptable to the Parties to inspect during regular business hours and no more than [...***...] per year and not more than [...***...] for the same reporting period
(unless Flexion or AstraZeneca provide reasonable reasons for a [...***...] audit of such a reporting period to be performed), all or any part of the records and hooks of Flexion and its Affiliates necessary to check the accuracy of the
royalties paid. Such a review may look back on the preceding [...***...] years of records and books of Flexion and its Affiliates. The accounting firm shall enter into appropriate obligations with Flexion to treat all information it receives
during its inspection in confidence, subject to its reporting obligations to AstraZeneca in respect of the accuracy of the royalty payments made. In the event of any finding of understatement or underpayment of royalties, Flexion will pay the unpaid
amount to AstraZeneca with interest calculated from the date of underpayment pursuant to the terms of Section 6.13 below. The charges of the accounting firm conducting the review shall be paid by [...***...], except that if the royalties
paid to AstraZeneca have been [...***...] by more than [...***...], the costs of such accounting firm shall be paid by [...***...]. In the event of a [...***...] audit for a particular reporting period becoming necessary as a
result of an act or omission of Flexion in the [...***...] audit of such reporting period, [...***...] will pay for its own costs incurred in the conduct of such a [...***...] audit, and for the avoidance of doubt,
[...***...] will not pay for any costs incurred by [...***...] related to such an audit. Further, Flexion will include in any sublicence similar rights for itself to audit the Sublicensee (and for the Sublicensee itself to audit its
sublicensee in turn) to those contained earlier in this Section 6.9.2. Flexion will provide AstraZeneca’s auditor with such documents as AstraZeneca reasonably requests that have been generated by an auditor in respect of that
auditor’s review of any Sublicensee such that AstraZeneca is in a position to meet all 	 

  

***Confidential Treatment Requested 

  
 34 

	 	requirements of a requesting tax authority. In the event that a tax authority requires further information to be disclosed by Flexion, Flexion agrees to assist such a
tax authority as required. 

  

	 	6.9.3	In the event of a dispute regarding the amount of royalties owed to AstraZeneca under Section 6.2 or 6.3, AstraZeneca and Flexion shall work in good faith to
resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, the dispute shall be submitted for arbitration to a certified public accounting firm selected jointly by
each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Arbitrator”). The decision of the Arbitrator shall be final and the costs of such arbitration as well as the initial
review shall be borne by the losing Party. Not later than ten (10) days after such decision, Flexion shall pay to AstraZeneca any additional royalties owed to AstraZeneca in accordance with such decision. 

 

	 	6.9.4	The receiving Party shall treat all information subject to review under this Section 6.9 in accordance with the confidentiality provisions of Article 10 and the
Parties shall cause the Arbitrator to enter into a reasonably acceptable confidentiality agreement with Flexion obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement.

  

	6.10	Mode of Payment. All payments set forth in this Article 6 shall be remitted by wire transfer to the following bank account of AstraZeneca or such other account
as AstraZeneca may designate in writing to Flexion: 

 BANK ACCOUNT 

Pay to: [...***...] 
 For the account of: [...***...]. 
 For further credit to: [...***...]

 IBAN: [...***...] 
  

	6.11	 Currency. All payments required under this Article 6 shall be made in U.S. Dollars. If any currency conversion shall be required in connection
with any payment 

  

***Confidential Treatment Requested 

  
 35 

	 	
hereunder, such conversion shall be made by using the arithmetic mean of the exchange rates for the purchase of U.S. dollars as published in The Wall Street Journal, Eastern Edition, on
the first Business Day of each Calendar Quarter and the last Business Day of each month in the Calendar Quarter to which such payments relate. 

  

	6.12	Taxes. 

  

	 	6.12.1	General. The royalties, milestones and other amounts payable by Flexion to AstraZeneca pursuant to this Agreement (“Payments”) shall not be
reduced on account of any taxes unless required by Applicable Law. AstraZeneca alone shall be responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be paid by Flexion) levied on account of, or measured
in whole or in part by reference to, any Payments it receives. Flexion shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if AstraZeneca is entitled under
any applicable tax treaty to a reduction of the rate of, or the elimination of applicable withholding tax, it may deliver to Flexion or the appropriate governmental authority (with the assistance of Flexion to the extent that this is reasonably
required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Flexion of its obligation to withhold tax, and Flexion shall apply the reduced rate of withholding, or dispense
with withholding, as the case may be, provided that Flexion has received evidence, in a form reasonably satisfactory to Flexion, of AstraZeneca’s delivery of all applicable forms (and, if necessary, its receipt of appropriate
governmental authorization) at least fifteen (15) days prior to the time that the Payments are due. If, in accordance with the foregoing, Flexion withholds any amount, it shall pay to AstraZeneca the balance when due, make timely payment
to the proper taxing authority of the withheld amount, and send to AstraZeneca proof of such payment within sixty (60) days following that payment. 

  

	 	6.12.2	 Indirect Taxes. Notwithstanding anything contained in Section 6.12.1, this Section 6.12.2 shall apply with respect to Indirect Taxes.
All Payments are 

  
 36 

	 	
exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, Flexion shall pay Indirect Taxes at the applicable rate in respect of any such Payments following the
receipt of an Indirect Taxes invoice in the appropriate form issued by AstraZeneca in respect of those Payments, such Indirect Taxes to be payable on the later of the due date of the payment of the Payments to which such Indirect Taxes relates and
sixty (60) days after the receipt by Flexion of the applicable invoice relating to that Indirect Taxes payment. 

  

	6.13	Interest on Late Payment. If any payment due to AstraZeneca under this Agreement is overdue then Flexion shall pay interest thereon (before and after any
judgment) at an annual rate (but with interest accruing on a daily basis) of [...***...] published in respect of the period starting on the due date of payment and ending on the actual date of payment, such interest to run from the date upon
which payment of such sum became due until payment thereof in full together with such interest. 

  

	7	Purchase of Study Drug 

  

	 	7.1	After payment by Flexion to AstraZeneca at a rate of USD [...***...] per kilogramme (which payment for the avoidance of doubt is included in the milestone payment
under Section 6.1.1 and shall not exceed USD [...***...]), AstraZeneca shall provide up to [...***...] of GMP Study Drug [...***...] and up to [...***...] of non-GMP Study Drug [...***...] that AstraZeneca has
stored (the “GMP Study Drug” and “Non GMP Study Drug” respectively) available to Flexion at locations in the United States to be designated by AstraZeneca. 

 

	 	7.2	 In addition, AstraZeneca at its sole discretion shall provide up to [...***...] of Semi Pure Study Drug (the “Semi Pure Study
Drug”) available to Flexion at a location to be designated by AstraZeneca. Flexion shall at its own cost and risk, take possession of such GMP Study Drug, Non-GMP Study Drug and Semi Pure Study Drug by collecting it at said location and
AstraZeneca shall co-operate fully with Flexion to enable 

  

***Confidential Treatment Requested 

  
 37 

	 	
shipping of GMP Study Drug, Non-GMP Study Drug and Semi Pure Study Drug to a destination of Flexion’s choosing. For the avoidance of doubt, any GMP Study Drug, Non-GMP Study Drug and Semi
Pure Study Drug provided will be provided as-is, without a current certificate of analysis (CoA). For the GMP Study Drug, AstraZeneca will provide the last CoA dated 22nd February 2008, Statement of GMP compliance dated 12th April 2007 and a TSE Statement dated 12th February 2008. For the Semi Pure Study Drug, AstraZeneca shall provide the Statement of GMP Compliance dated
22nd October 2008 and the TSE Statement dated
22nd October 2008. 

 

	 	7.3	If the GMP Study Drug or the Semi Pure Study Drug are to be used in clinical study, Flexion shall undertake the responsibility of ensuring the GMP Study Drug or the
Semi Pure Study Drug meets all regulatory and other legal requirements for such use meeting the standards as described in the IND Filing for the Compound to the extent applicable to comply with the prevailing regulatory and other legal requirements.
Flexion hereby undertakes to use any Non-GMP Study Drug only for non-clinical studies. Flexion undertakes to indemnify AstraZeneca for all Losses incurred by AstraZeneca as a result of such use of the GMP Study Drug, Non-GMP Study Drug and Semi-Pure
Study Drug in accordance with Section 13.1 below. 

  

	8	Ownership of Intellectual Property 

  

	8.1	Ownership of Technology. Subject to Section 8.2 and the licence grants to Flexion under Section 3.1, as between the Parties, each Party shall own and
retain all right, title and interest in and to any and all: (a) Know-How and other inventions that are conceived, discovered, developed or otherwise made, as necessary to establish authorship, inventorship or ownership under Applicable Law, by
or on behalf of such Party under or in connection with this Agreement (or its Affiliates or its licensors or sublicensees), whether or not patented or patentable, and any and all Patent and Intellectual Property Rights with respect thereto, and
(b) other Know-How or other inventions, and Patent and Intellectual Property Rights that are owned or otherwise Controlled (other than pursuant to the licence grants set forth in Section 3.1) by such Party, its Affiliates or its Licensors
or sublicensees. 

  
 38 

	8.2	Ownership of Licensed Patents and Licensed Know-How. Subject to the licence grants to Flexion under Section 3.1 as between the Parties, AstraZeneca shall own
and retain all right, title and interest in and to all Licensed Patents and Licensed Know-How. 

  

	8.3	Ownership of Retained Patents. As between the Parties, AstraZeneca shall own and retain all right, title and interest in and to all Retained Patents and without
prejudice to Section 3.4 grants no right, title and interest in or to the Retained Patents to Flexion. 

  

	9	Adverse Event Reporting 

 Flexion shall undertake all responsibility for all pharmacovigilance activities relating to the safety of each Licensed Product and will ensure that all Sublicensees comply with such obligations to the
same standards. 
  

	10	Confidentiality and Non-Disclosure 

  

	10.1	Defined; General Obligations. 

  

	 	10.1.1	In this Agreement, “Confidential Information” shall, subject to Section 10.3, mean any and all data, results, know-how (including the Licensed
Know-How), plans, business information and other Know-How, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party, including the terms of this Agreement. At all times
during the term of this Agreement and for a period of five (5) years following termination or expiration hereof, each Party (the “Receiving Party”) shall, and shall cause its officers, directors, employees, agents, Affiliates
and Sublicensees to keep confidential and not publish or otherwise disclose and not use, directly or indirectly, for any purpose, any Confidential Information provided to it by the other Party (the “Disclosing Party”), except to the
extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary for the performance of this Agreement. 

  

	10.2	Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: 

  
 39 

	 	10.2.1	made in response to a valid order of a court of competent jurisdiction or other competent authority; provided, however, that the Receiving Party shall,
where practical and permitted, first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash any such order or obtain a protective order requiring that the Confidential Information and documents
that are the subject of such order be held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order was issued and, where permitted, have the commercial terms redacted; and provided further that if
such order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in response to such
court or governmental order; 

  

	 	10.2.2	made by the Receiving Party to a Health Authority as may be necessary in connection with any filing, application or request for or to achieve a Health Registration
Approval; provided, however, that reasonable measures shall be taken to ensure confidential treatment of such information, to the extent such protection is available; 

 

	 	10.2.3	made by the Receiving Party to a patent authority as may be necessary or reasonably useful for purposes of obtaining or enforcing a Patent (consistent with the terms
and conditions of Article 15); provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

 

	 	10.2.4	otherwise required by law; provided, however, that the Receiving Party shall (a) provide the Disclosing Party, where practicable and permitted, with
reasonable advance notice of and an opportunity to comment on any such required disclosure, (b) if requested by the Disclosing Party, seek confidential treatment with respect to any such disclosure to the extent available, and (c) use good
faith efforts to incorporate the comments of the Disclosing Party in any such disclosure or request for confidential treatment; or 

  

	 	10.2.5	 made by Flexion or its Affiliates or Sublicensees to Third Parties as may be necessary in connection with the Development, Exploitation or Manufacture
of the Compound or the Licensed Products as contemplated by this 

  
 40 

	 	
Agreement, including permitted subcontracting or sublicensing transactions in connection therewith provided all such disclosures are subject to obligations of confidentiality substantially
similar to the terms set out in this Article 10; or 

  

	 	10.2.6	made by Flexion to Third Parties in connection with fund raising or financings or a due diligence or similar investigations by such Third Parties, and disclosure to
potential Third Party investors or financial institutions or advisors in financing documents, provided in each case that any such Third Party agrees to be bound by obligations of confidentiality and non-use on substantially similar terms as those
set out in this Article 10. for a minimum period of three years. 

 Notwithstanding the foregoing, in the event
that either Party is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body to disclose this Agreement, in whole or in part, the Parties shall reasonably agree on a redacted version of
this Agreement as necessary to protect the Confidential Information of the other Party prior to making such disclosure. 
  

	10.3	Exclusions. Notwithstanding the foregoing, Confidential Information shall not include any information that 

 

	 	10.3.1	is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of
the Receiving Party; 

  

	 	10.3.2	can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s or its Affiliates’ possession prior to disclosure by the
Disclosing Party; 

  

	 	10.3.3	is subsequently received by the Receiving Party or its Affiliates from a Third Party who is not bound by any obligation of confidentiality with respect to said
information; 

  

	 	10.3.4	is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or 

 

	 	10.3.5	is independently developed by or for the Receiving Party or its Affiliates without reference to the Disclosing Party’s Confidential Information.

  
 41 

 Specific aspects or details of Confidential Information shall not be deemed to be within the
public domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential
Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the
combination and its principles are in the public domain or in the possession of the Receiving Party. 
  

	10.4	Publications. 

 During the
term of this Agreement, Flexion shall have the sole right to publish any papers regarding results and other information related to Compound and Licensed Products or the development thereof, including oral presentations and abstracts. Upon submission
for peer review, Flexion shall provide AstraZeneca with a copy of each such proposed publication. 
  

	10.5	Use of Name. Neither Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in
any publication, press release, promotional material or other form of publicity without the prior written consent of the other Party (which shall not be unreasonably withheld or delayed), except for those disclosures for which consent has previously
been obtained. The restrictions imposed by this Section 10.5 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law or the requirements of a national securities exchange or
another similar regulatory body, provided that any such disclosure shall be governed by this Article 10. Further, the restrictions imposed on each Party under this Section 10.5 are not intended, and shall not be construed, to prohibit a Party
from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this Article 10, 

 

	10.6	 Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in this Article 10 are reasonable and necessary to protect
the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any

  
 42 

	 	
provision of this Article 10 will result in irreparable injury to the other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision
of this Article 10 by one Party, the other Party shall be authorised and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such other Party may be entitled in law or equity. Nothing in this Section 10.6 is
intended, or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. 

 

	11	Trademarks 

Flexion shall have the sole right to select the Trademarks for the marketing and sale of the Licensed Products in the Territory. Flexion
shall own such Trademarks and all rights and goodwill with respect thereto. 
  

	12	Representations and Warranties 

  

	12.1	Representations, Warranties and Covenants. Each Party hereby represents, warrants and covenants to the other Party as of the Effective Date as follows:

  

	 	12.1.1	Corporate Authority. Such Party (a) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder,
and (b) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party
and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of
creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. 

 

	 	12.1.2	 Litigation. Such Party is not aware of any pending or threatened litigation (and has not received any communication) that alleges that such
Party’s 

  
 43 

	 	
activities related to this Agreement have violated, or that by conducting the activities as contemplated herein such Party would violate, any of the Intellectual Property Rights of any other
party. 

  

	 	12.1.3	Consents, Approvals, etc. All necessary consents, approvals and authorizations of all Health Authorities and other Persons required to be obtained by such Party
in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

  

	 	12.1.4	Conflicts. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate
any provision of the articles of incorporation, bylaws or any similar instrument of such Party in any material way, and (b) do not conflict with, violate, or breach or constitute a default or require any consent under, any contractual
obligation or court or administrative order by which such Party is bound. 

  

	 	12.1.5	Debarment. Neither Party nor any of its Affiliates has been debarred or is subject to debarment and neither such Party nor any of its Affiliates will use in any
capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act, as amended, or who is the subject of a
conviction described in such section. Each Party will inform the other Party in writing immediately if it or any Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 of the United
States Federal Food, Drug, and Cosmetic Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to such Party’s knowledge, is threatened, relating to the debarment or conviction of such Party or
any Person performing services hereunder. 

  

	 	12.1.6	Compliance with Applicable Laws. 

 Each Party shall use all reasonable efforts to comply with all Applicable Laws in exercising its rights and complying with its obligations pursuant to this Agreement. 

  
 44 

	12.2	Additional Representations and Warranties of AstraZeneca. As of the Effective Date and subject to the disclosures against such warranties made in Schedule 5 (the
“Disclosure Letter”), AstraZeneca represents and warrants to Flexion that within AstraZeneca’s Knowledge, (where “Knowledge” means the good faith understanding of the [...***...] and the [...***...]
of the facts and information in their possession as at the Effective Date, and without any duty to conduct any investigation with respect to such facts and information): 

 

	 	12.2.1	AstraZeneca Controls the Patents listed in Schedule 1 and the Licensed Know-How, and is entitled to grant the licences specified herein and except as set forth in
Section 3.1, neither AstraZeneca nor any of its Affiliates has granted any licence or other right to any Third Party with respect to the Compound, Licensed Products, Licensed Patents or Exclusive Licensed Know-How; 

 

	 	12.2.2	To AstraZeneca’s Knowledge, the Licensed Patents are being procured from the respective Patent Offices in accordance with Applicable Law; 

 

	 	12.2.3	AstraZeneca has not received notice from any Third Party claiming that the manufacture, use or sale of the Compound or Licensed Products infringes the Patents of any
Third Party; 

  

	 	12.2.4	AstraZeneca is not a party to any legal action, suit or proceeding relating to the Compound, Licensed Products, Licensed Patents or Licensed Know-How;

  

	 	12.2.5	To AstraZeneca’s Knowledge, it has not withheld any material information relating to (a) pre-clinical and clinical data, regulatory filings and regulatory
communications, relating exclusively to the Compound and the Licensed Products and (b) the filing and prosecution of the Licensed Patents, and (c) ownership of the Licensed Patents and the Licensed Know-How. 

For the avoidance of doubt Flexion acknowledges and agrees that AstraZeneca shall not be in breach of this warranty for failure to
disclose, and shall be under no obligation to disclose, to Flexion any opinions created or obtained by or on behalf of AstraZeneca with regard to the potential infringement or non-infringement of any intellectual property rights of Third Parties.

  

***Confidential Treatment Requested 

  
 45 

	12.3	DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 12.1 AND 12.2, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR USE OR PURPOSE OR IN THE CASE OF ASTRAZENECA ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

 

	13	Indemnity 

  

	13.1	Indemnification of AstraZeneca. In addition to any other remedy available to AstraZeneca, Flexion shall indemnify, defend and hold harmless AstraZeneca, its
Affiliates and its and their directors, officers and employees (“AstraZeneca Indemnitees”) in full and on demand, from and against any and all Losses incurred by them to the extent resulting from, or arising out of, or in
connection with, any claims made or suits brought by a Sublicensee or Third Party (collectively, “Third Party Claims”) against any AstraZeneca Indemnitee, that arise or result from (a) any intentional misconduct or negligence
on the part of Flexion or its Affiliates in performing any activity contemplated by this Agreement, or the breach of any provision of this Agreement by Flexion or (b) the Exploitation by Flexion or its Affiliates or Sublicensees of the Licensed
Products (including any claims for death, personal injury or infringement of a Third Party’s rights) or (c) the use of Study Drug provided by AstraZeneca to Flexion under Article 7 above, except where and to the extent that any such Third
Party Claims or Losses have been caused or increased by the negligence or wilful misconduct of any AstraZeneca Indemnitee after the Effective Date of this Agreement. 

 

	13.2	 Indemnification of Flexion. In addition to any other remedy available to Flexion, AstraZeneca shall indemnify, defend and hold harmless Flexion,
its Affiliates and its and their directors, officers and employees (“Flexion Indemnitees”) in full and on demand, from and against any and all Losses incurred by them to the extent resulting

  
 46 

	 	
from, or arising out of, or in connection with, any Third Party Claims against any Flexion Indemnitee, that arise or result from any intentional misconduct or negligence on the part of
AstraZeneca or its Affiliates in performing any activity contemplated by this Agreement, or the breach of any provision of this Agreement by AstraZeneca, except where and to the extent that any such Third Party Claims or Losses have been caused or
increased by the negligence or wilful misconduct of any Flexion Indemnitee after the Effective Date of this Agreement. 

  

	13.3	Indemnification Procedure. Should the Indemnified Party intend to claim indemnification hereunder from the Indemnifying Party, the Indemnified Party shall
promptly notify the Indemnifying Party in writing of any Losses in respect of which the Indemnified Party intends to claim such indemnification and the Indemnifying Party shall be entitled, but not obligated, to assume the defence of any Third Party
Claim thereof with counsel selected by it. The Indemnified Party, including its Affiliates, directors, officers and employees, shall co-operate fully, at the Indemnifying Party’s expense, with the Indemnifying Party and its legal
representatives in the investigation and defence of any Third Party Claim covered by this indemnification. The indemnification shall not apply to amounts paid in settlement of any Third Party Claim if such settlement is effected without the consent
of the Indemnifying Party, not to be unreasonably withheld or delayed. 

  

	13.4	LIMITATION ON DAMAGES. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS
UNDER SECTION 13.1 OR 13.2, NO PARTY OR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (a) THE
DEVELOPMENT, MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT OR COMPOUND DEVELOPED, MANUFACTURED OR MARKETED HEREUNDER, (b) THE USE OR REFERENCE OF THE LICENSED PATENTS, LICENSED KNOW-HOW, REGULATORY DOCUMENTATION, OR (c) ANY BREACH OF OR
FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT. 

  
 47 

	13.5	Insurance. Flexion shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply, use and sale of the Compound and the
Licensed Products as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, and shall upon request provide AstraZeneca with confirmation of such insurance in that regard, and any amendments and revisions
thereto. 

  

	14	Maintenance and Prosecution of Patents 

  

	14.1	Licensed Patents. Flexion shall at its sole cost and expense, using reputable patent and legal counsel of its own choosing, file, prosecute (including any
interferences, reissue proceedings and re-examinations) and maintain the Licensed Patents in at least the List Two Countries (the “List Two Countries” are defined as those counties set out in Exhibit 2 to this Agreement). In the
prosecution, maintenance, and defence of the Licensed Patents, Flexion shall always act in good faith and in the best interests of obtaining and maintaining a scope of claims providing sufficient exclusionary protection to commercialise Licensed
Products or Compound. 

  

	14.2	 Co-operation. AstraZeneca shall, and shall cause its Affiliates, as applicable, to cooperate fully with Flexion in the preparation, filing,
prosecution, and maintenance of the Licensed Patents. Such cooperation includes (a) executing all papers and instruments and requiring employees to execute such papers and instruments as reasonable and appropriate so as to enable Flexion to
file, prosecute and maintain the Licensed Patents in any country, and (b) informing Flexion of matters that may affect the preparation, filing, prosecution or maintenance of any such Licensed Patents. Flexion shall provide AstraZeneca with an
opportunity to review and comment on the nature and text of new or pending applications for Licensed Patents and shall advise AstraZeneca, if practicable and possible, at least one (1) month before each patent prosecution deadline as to the response
that Flexion proposes to make. If AstraZeneca provides to Flexion comments with respect to any such application or submission, to the extent such comments relate to any Licensed Patents, Flexion shall reasonably consider such comments, it being
understood that Flexion retains the right to determine whether to comply with or incorporate such comments, if at all. Flexion shall advise AstraZeneca on an annual basis of progress in the prosecution of all patent applications and in the
maintenance or extension of patents falling within the 

  
 48 

	 	
Licensed Patents and shall, on request, furnish AstraZeneca with a copy of the patent application, patent or other document pertinent to the prosecution, maintenance or extension of such
applications and patents. 

  

	14.3	Additional Patent Protection. Flexion may seek additional patent protection for the Compound or Licensed Products in any part of the Territory, for example, by
way of patent registration, patent of importation or revalidation or the like in the name of Flexion, at [...***...]. Any such additional patents shall be [...***...] for the purposes of this Agreement. 

 

	15	Enforcement of Patents 

  

	15.1	Rights and Procedures. 

  

	15.1.1	In the event that either Party reasonably believes that a Third Party may be infringing any of the Licensed Patents such Party shall promptly notify the other Party in
writing, identifying the alleged infringer and the alleged infringement complained of and furnishing the information upon which such determination is based. [...***...] shall have the [...***...], through counsel of its choosing and at
[...***...], to take any measures it deems appropriate to stop such infringing activities by such Third Party in any part of the Territory. Upon reasonable request by [...***...], [...***...] shall give [...***...] all
reasonable information and assistance, including allowing [...***...] access to [...***...] files and documents and to [...***...] personnel who may have possession of relevant information at [...***...]. If necessary for
[...***...] to prosecute any legal action, [...***...] may request [...***...] to join in the legal action provided that [...***...] shall hold [...***...] harmless from and against any and all costs and expenses of
such litigation. If [...***...] upon [...***...] request so joins such legal action, [...***...] may be represented by counsel of its own choosing, but [...***...] shall not be subject to [...***...] obligation to
indemnify hereunder. 

  

	15.1.2	 In the event [...***...] fails within forty-five (45) days following notice of such infringement, or earlier notifies [...***...] in
writing of its intent not to take commercially appropriate steps to remove any infringement of any Licensed Patent, then,
 [...***...] shall have the [...***...], to do so at

  

***Confidential Treatment Requested 

  
 49 

	 	
[...***...]. Upon reasonable request by [...***...], [...***...] shall give [...***...] all reasonable information and assistance, including allowing [...***...]
access to [...***...] files and documents as is reasonable and during normal business hours wherever such items are kept, and to [...***...] personnel who may have possession of relevant information at its own expense. If necessary for
[...***...] to prosecute any legal action, [...***...] may request [...***...] to join in the legal action provided that [...***...] shall hold [...***...] harmless from and against any and all costs and expenses of
such litigation. If [...***...] upon [...***...] request so joins such legal action, [...***...] may be represented by counsel of its own choosing, but [...***...] shall not be subject to [...***...] obligation to
indemnify hereunder. 

  

	15.1.3	Notwithstanding the foregoing, if either Party receives any notice of certification regarding the Licensed Patents pursuant to the U.S. “Drug Price Competition and
Patent Term Restoration Act” of 1984 (21 United States Code §355(b)(2)(A)(iv) or
 (j)(2)(A)(vii)(IV)) (“ANDA ACT”) claiming that any Licensed Patents are invalid or unenforceable or claiming that the Licensed Patents
will not be infringed by the Manufacture, use, marketing or sale of a product for which an application under the ANDA ACT is filed, or (b) any equivalent or similar certification or notice in any other jurisdiction, it shall provide the other Party
with a copy of such notice of certification within ten (10) days of receipt and the Parties’ rights and obligations with respect to any legal action as a result of such certification shall be as set forth in this Section 15.1; provided,
however, that if [...***...] elects not to bring suit against the Third Party providing notice of such certification within thirty (30) days of receipt of such notice, [...***...] shall have the [...***...] at
[...***...], to bring suit against such Third Party. If either Party upon the other Party’s request joins such legal action, such other Party may be represented by counsel of its own choosing but any costs and expenses of such counsel
shall not be subject to the other Party’s obligation to indemnify hereunder. 

  

	15.2	 Sublicensees. In the event that either Party reasonably believes that a Sublicensee may be infringing any of the Licensed Patents by acting
beyond the scope of the licence granted to Flexion under this Agreement, such Party shall promptly notify the other Party in writing, identifying the alleged infringer and the alleged infringement

  

***Confidential Treatment Requested 

  
 50 

	 	
complained of and furnishing the information upon which such determination is based. Flexion shall have a period of ninety (90) days in which to resolve the matter with the Sublicensee and
bring the infringing activity to an end. If Flexion has not brought the infringing activity to an end or cannot demonstrate to AstraZeneca that it has taken appropriate steps to bring the infringing activity to an end, then AstraZeneca shall have
the rights set out in Section 15.1 as if the Sublicensee were a Third Party. 

  

	15.3	Costs and Expenses. Each Party shall bear [...***...] costs and expenses relating to any enforcement action pursuant to Section 15.1. Any damages or
other amounts collected shall be used to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), with any remainder being retained
by the Party that pursued such enforcement action; provided, however, that any amount received by [...***...] over and above its costs and expenses shall [...***...]. 

 

	16	Potential Third Party Rights 

  

	16.1	Third Party Licences. If the Exploitation of the Compound or Licensed Products by Flexion, its Affiliates or any of its Sublicensees infringes or misappropriates
any Patent or any Intellectual Property Right of a Third Party in any country, such that Flexion or any of its Affiliates or Sublicensees cannot Exploit the Compound or the Licensed Products in such country without infringing the Patent or
Intellectual Property Right of such Third Party, then [...***...] shall secure from such Third Party such rights (“Third Party Licence”) as are necessary for the Exploitation of Compound and Licensed Products in such country.
[...***...] shall be [...***...] responsible for [...***...] of all royalty and other payments in connection with the securing of any such rights, subject to the following: 

 

	 	16.1.1	 If Flexion for the Exploitation of the Compound or Licensed Products requires a Third Party Licence for formulation technology or has to pay royalties
to the vendor of the commercially formulated compound (“Third Party Formulation Technology Licences”) and has sublicensed rights in the Compound or Licensed Products, then Flexion may elect by written notice to AstraZeneca that
[...***...] of the royalties actually paid under such Third Party 

  

***Confidential Treatment Requested 

  
 51 

	 	
Formulation Technology Licence by Flexion for the sale of such Licensed Product in such country for a Calendar Quarter shall be creditable against the royalties payable to AstraZeneca on Net
Sales made by or on behalf of the Sublicensee in such country for the same Calendar Quarter subject to a maximum royalty reduction of [...***...] (as such terms are defined in Section 6.2.1 to 6.2.5 above), provided that Flexion shall
[...***...] within thirty (30) days of the execution of Flexion’s notice referred to above, and provided further that Flexion agrees to [...***...] each of the sales related payments under Section 6.4(ii) and Section 6.4 (iii)
above, if and when such payment becomes payable to AstraZeneca. For the sake of clarification, the aggregate compensation payable to AstraZeneca according to this Section 16.1.1 shall not [...***...]. 

 

	 	16.1.2	If Flexion for the Exploitation of the Compound or Licensed Products requires at any time a Third Party Licence other than a Third Party Formulation Technology Licence
(“Other Third Party Licence(s)”) and has sublicensed rights in the Compound or Licensed Products, then Flexion may elect by written notice to AstraZeneca that
 [...***...] of the royalties actually paid under such Other
Third Party Licence by Flexion for the sale of such Licensed Product in such country for a Calendar Quarter shall be creditable against the royalties payable to AstraZeneca on Net Sales made by or on behalf of the Sublicensee in such country for the
same Calendar Quarter subject to a maximum royalty reduction of [...***...] as such terms are defined in Section 6.2.1 to 6.2.5 above and further provided that such Other Third Party Licence is required to [...***...].

  

***Confidential Treatment Requested 

  
 52 

	 	16.1.3	Flexion may either elect to utilise the royalty reduction under Section 16.1.1 for Third Party Formulation Technology Licences or under Section 16.1.2 for Other Third
Party Licences, but may not elect to utilise such royalty reduction under both Sections 16.1.1 and 16.1.2, even if Flexion may for the Exploitation of the Compound or Licensed Products require both a Third Party Formulation Technology Licence and an
Other Third Party Licence and AstraZeneca’s total royalty reduction shall [...***...]. 

  

	16.2	Invalidity or Unenforceability Defences or Actions. 

  

	 	16.2.1	In the event that a Third Party asserts, as a defence or as a counterclaim in any infringement action under Section 15.1, that any Licensed Patent is invalid or
unenforceable, then the Party pursuing such infringement action shall promptly give written notice to the other Party. [...***...] shall have [...***...], at [...***...] through counsel of its choosing, to respond to such defence
or defend against such counterclaim (as applicable) and, if [...***...] is pursuing the applicable infringement action under Section 15.1, [...***...] shall allow [...***...] to control such response or defence (as applicable). If
[...***...] determines not to respond to such defence or defend against such counterclaim (as applicable), [...***...] shall, at [...***...], have the right to respond to such defence or defend against such counterclaim (as
applicable); provided, however, that [...***...] shall obtain the written consent of
 [...***...], not to be unreasonably withheld or delayed, prior to ceasing to defend, settling or otherwise concluding such defence or
counterclaim. 

  

	 	16.2.2	 Similarly, if a Third Party asserts, in a declaratory judgment action or similar action or claim filed by such Third Party, that any Licensed Patent is
invalid or unenforceable, then the Party first becoming aware of such action or claim shall promptly give written notice to the other Party. [...***...] shall have [...***...], at [...***...], through counsel of its choosing, to
defend against such action or claim. If [...***...] determines not to assume such defence, [...***...] shall, at [...***...], have the right to defend against such action or claim; provided, however, that

[...***...] shall obtain the written consent of [...***...], not to be 

  

***Confidential Treatment Requested 

  
 53 

	 	
unreasonably withheld or delayed, prior to ceasing to defend, settling or otherwise compromising any such action or claim. 

 

	 	16.2.3	Each Party shall provide to the other all reasonable assistance requested by the other in connection with any action, claim or suit under this Section 16.2,
including allowing access to files and documents and to personnel who may have possession of relevant information. In particular, each Party shall upon reasonable request make available to the other, free of charge, all information in its possession
or control of which it is aware that will assist the other Party in responding to any such action, claim or suit, 

  

	 	16.2.4	Where a Sublicensee is deemed, by virtue of Section 15.2 above to have become a Third Party for the purposes of Section 15.1, such Sublicensee shall be deemed
to be a Third Party for the purposes of this Section 16.2 also. 

  

	16.3	Third Party Litigation. In the event of any actual or threatened suit against Flexion or its Affiliates, Sublicensees or customers alleging that the Exploitation
of Compound or Licensed Products or that the Exploitation of a Licensed Patent or the Licensed Know-How or any part thereof hereunder infringes the Patent or Intellectual Property Rights of any Person, [...***...] shall, at [...***...],
assume direction and control of the defence of claims arising therefrom; provided, however, that [...***...] shall obtain the written consent of [...***...], not to be unreasonably withheld or delayed, prior to ceasing to
defend, settling or otherwise compromising such claims with respect to any Licensed Patents and Licensed Know-How. 

  

	16.4	Retained Rights. Nothing in this Article 16 shall prevent Flexion, at its own expense, from obtaining any licence or other rights from Third Parties that it
deems appropriate in order to permit the full and unhindered exercise of its rights under this Agreement. 

  

	17	Term and Termination 

  

	17.1	 Term and Expiration. This Agreement shall become effective as of the Effective Date and shall continue in effect until such time as Flexion no
longer owes any royalty payments to AstraZeneca under this Agreement (the “Expiration Date”), unless earlier terminated in accordance with this Article 17 (Term and Termination) or

  

***Confidential Treatment Requested 

  
 54 

	 	
Section 18.4 (Force Majeure). On the Expiration Date, the provisions of Section 3.7 shall come into effect. 

 

	17.2	Termination for Breach. In the event that either Party (the “Breaching Party”) shall be in material default in the performance of any of its
obligations under this Agreement, in addition to any other right and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this Agreement in its entirety or with respect to the country or
countries to which such material default applies by ninety (90) days prior written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate, provided always that the
termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach complained about during the Notice Period; provided further, that if Flexion is in default with respect to its obligations under
Section 5.3 (Diligence Obligations) in [...***...] then AstraZeneca shall have the right to terminate this Agreement with respect to [...***...]. A termination notice may not be given for a dispute relating to the amount of
royalties owed to AstraZeneca provided that the Parties are seeking to remedy the dispute in compliance with Section 6.9.3 of this Agreement. Notwithstanding the foregoing, any right to terminate under this Section 17.2 shall be stayed and
the Notice Period stayed in the event that during the Notice Period, the Party alleged to have been in material breach shall have initiated the dispute resolution procedure in accordance with Section 23 and provided that the Party alleged to
have been in material breach diligently and in good faith co-operates in the prompt resolution of such dispute resolution proceedings. 

  

	17.3	 Termination by AstraZeneca. In the event that Flexion or any of its Affiliates or Sublicensees, anywhere in the world, institutes, prosecutes or
otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign
counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, opposition or any similar
proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable or otherwise not patentable, then AstraZeneca shall have the right to immediately terminate this Agreement, on

  

***Confidential Treatment Requested 

  
 55 

	 	
provision of written notice to Flexion, or in respect of any such action by a Sublicensee, AstraZeneca may require that Flexion terminates the sublicense. For the avoidance of doubt, the
termination of this Agreement under this Section 17.3 will, subject to Section 17.6.5 below, terminate any sublicence granted by Flexion to a sublicensee of any Intellectual Property Rights licensed to it by AstraZeneca under this Agreement.

  

	17.4	Termination by Flexion. 

Flexion shall have the right at any time during the term of this Agreement to terminate this Agreement in its entirety or with respect to
one or more countries for any reason upon no less than three (3) months’ prior written notice to AstraZeneca provided that if Flexion elects to terminate this Agreement with respect to [...***...] it shall be deemed to have terminated the
Agreement with respect to [...***...]. 
  

	17.5	Territorial Effect of a Termination Notice. 

  

	 	17.5.1	In case of termination by Flexion without cause pursuant to Section 17.4 (Termination by Flexion) such termination notice may be made with respect to one country
or several specific countries as determined by Flexion (the “Affected Countries”). In the case of any termination notice for breach pursuant to Section 17.2 (Termination for Breach) if the breach of the other Party relates to
or takes effect only in certain countries (also, the “Affected Countries”), such termination notice may only be given with respect to such Affected Countries and must state the Affected Countries. 

 

	 	17.5.2	In case of any termination notice for breach pursuant to Section 17.2 (Termination for Breach) by either Party, such termination may be made with respect to the
entirety of this Agreement only, if the breach of the other Party relates to or takes effect in at least two or more countries of the Territory and/or affects this Agreement in a global manner, in which case the termination notice must state that
the termination shall affect this Agreement in its entirety. 

  

	 	17.5.3	 In the event that a Party is entitled to provide a termination notice under Section 17.2 (Termination for Breach) related to this Agreement in its
entirety, 

  

***Confidential Treatment Requested 

  
 56 

	 	
but the breach affects certain countries of the Territory only, then such Party may at its discretion select and specify in the termination notice the Affected Countries in which such termination
notice shall take effect. 

  

	 	17.5.4	For the avoidance of doubt and notwithstanding the above, if a breach by Flexion relates to or takes effect in
 [...***...], then AstraZeneca shall have the
right to designate [...***...] in its notice of breach as the Affected Countries. 

  

	17.6	Consequences of Termination. 

  

	 	17.6.1	Effects of Termination by Flexion for Cause. Upon termination by Flexion in accordance with Section 17.2 (Termination for Breach), Section 17.8 (Termination
for Insolvency or Bankruptcy) or Section 18.4 (Force Majeure) of this Agreement, all licences and other rights granted by AstraZeneca to Flexion in the Territory, shall terminate and revert to AstraZeneca. 

 

	 	17.6.2	Effects of Termination by Flexion. 

  

	 	a)	 Upon termination of this Agreement by Flexion in accordance with Section 17.4 (Termination by Flexion), with respect to the Affected Countries,
all licences and other rights granted by AstraZeneca to Flexion under this Agreement shall terminate and revert to AstraZeneca. Flexion shall further, and shall cause its Affiliates and Sublicensees (subject to Section 17.6.5 below, where the
sublicence survives) to disclose to AstraZeneca (or its designee) any and all Improvements and Know-How, including a copy of any documentation in tangible form, that is owned or otherwise Controlled by Flexion, its Affiliates or Sublicensees at the
time of termination of the Agreement that has been generated by or on behalf of Flexion, its Affiliates or Sublicensees with respect to the Compound or Licensed Products to enable AstraZeneca to continue Development of a Licensed Product and the
commercialisation thereof in the Territory or the Affected Countries (as the case may be) (collectively, the “Flexion Product Data”). If AstraZeneca wishes to use Flexion Product Data and Grant-Back Patents in the Development or
commercialisation of the Compound or Licensed Products, then Flexion shall grant to AstraZeneca an exclusive, (subject to the following paragraph) royalty-free, sub-licensable, assignable, perpetual licence

  

***Confidential Treatment Requested 

  
 57 

	 	
under the Flexion Product Data and Grant-Back Patents to Develop, make, have made, use, sell, offer for sale, have sold, import and export the Compound and Licensed Products in the Territory or
the Affected Countries (as the case may be), subject to AstraZeneca and Flexion agreeing on [...***...]. Any such Flexion Product Data shall be subject to the confidentiality obligations set forth in Article 10. 

 

	 	b)	Notwithstanding anything to the contrary in this Section 17.6.2, upon termination of this Agreement by Flexion in accordance with Section 17.4 (Termination by
Flexion) based on Flexion’s determination that the commercial viability of Compound or Licensed Products has adversely changed for any reason beyond Flexion’s control, including without limitation because of any issues related to Patents
or Intellectual Property Rights of Third Parties or Third Party Licences, then a licence under the Flexion Product Data and Grant-Back Patents (if any) shall be granted on a [...***...] basis only with [...***...] to be agreed upon by
the Parties. 

  

	 	17.6.3	Effects of Termination by AstraZeneca. Upon termination by AstraZeneca in accordance with Section 3.9 (Change of Control), Section 17.2 (Termination for Breach)
or Section 17.3 (Termination by AstraZeneca) or Section 17.8 (Termination upon Insolvency or Bankruptcy) or Section 18.4 (Force Majeure): 

  

	 	a)	all licences and other rights granted by AstraZeneca to Flexion in the Territory, shall terminate and revert to AstraZeneca; 

 

	 	b)	 in the case of AstraZeneca’s termination in accordance with Section 17.2 (Termination for Breach) or Section 17.3 (Termination by
AstraZeneca), Flexion shall and shall cause its Affiliates and Sublicensees (subject to Section 17.6.5 below, where the sublicence survives) to disclose to AstraZeneca (or its designee) any and all

  

***Confidential Treatment Requested 

  
 58 

 
Flexion Product Data and Flexion hereby grants AstraZeneca with respect to the Affected Countries, an exclusive, royalty-free, sub-licensable licence, under the Flexion Product Data (if any)
solely to Develop, make, have made, use, sell, have sold, offer for sale, import and export Compound and Licensed Products in the Affected Countries; 
  

	 	c)	in the case of AstraZeneca’s termination in accordance with Section 3.9 (Change of Control) or Section 17.8 (Termination upon Insolvency or Bankruptcy)
or Section 18.4 (Force Majeure), Flexion shall and shall cause its Affiliates and Sublicensees (subject to Section 17.6.5 below, where the sublicence survives) to disclose to AstraZeneca (or its designee) any and all Flexion Product Data.
If AstraZeneca wishes to use Flexion Product Data in the Development or commercialisation of Compound or Licensed Products, then Flexion shall grant to AstraZeneca an exclusive, royalty-free, sub-licensable, assignable, perpetual licence under the
Flexion Product Data to Develop, make, have made, use, sell, offer for sale, have sold., import and export Compound and Licensed Products in the Territory or the Affected Countries (as the case may be), subject to AstraZeneca and Flexion agreeing on
[...***...]. Any such Flexion Product Data shall be subject to the confidentiality obligations set forth in Article 10. 

  

	 	d)	 Flexion shall be further obliged and undertakes at no cost to AstraZeneca to assign and do all further acts and things as necessary (and does hereby
assign and shall, always subject to Section 17.6.5, cause its Affiliates and Sublicensees (subject to Section 17.6.5 below, where the sublicence survives) to assign to AstraZeneca with effect from the date of termination) all its right, title
and interest in and to all 

  

***Confidential Treatment Requested 

  
 59 

 
Regulatory Documentation with respect to the Compound and Licensed Products in or referring to the Territory or the Affected Countries as the case may be, including any Health Registration
Approvals and applications therefore, to AstraZeneca. 
  

	 	e)	Flexion and its Affiliates shall and do hereby grant to AstraZeneca (a) a non-exclusive, royalty-free, perpetual, irrevocable right and licence, with the
right to grant sublicences through multiple tiers of sublicensees, under any Grant-Back Patents and, (b) if Flexion has commercialised a Licensed Product, an exclusive, royalty-free, perpetual, irrevocable right and licence, with the right to
grant sublicences through multiple tiers of sublicensees of the Flexion Trademarks, in each case to Exploit the Compound and Licensed Products in the Territory or the Affected Countries (as the case may be). AstraZeneca shall, at its option and at
its expense, take over the filing, prosecution and maintenance of the Grant-Back Patents and Flexion Trademarks in the Territory or the Affected Countries (as the case may be). 

 

	 	f)	 in order for AstraZeneca to smoothly continue the Exploitation of the Compound and Licensed Products in the Territory or the Affected Countries (as the
case may be), Flexion shall, with the limitations set out below and for a maximum period of [...***...], supply AstraZeneca in a timely manner with sufficient amount of Compound or Licensed Product in the Territory or the Affected Countries
(as the case may be) at [...***...]. Flexion’s undertaking to supply is subject to Flexion, upon termination of this Agreement, having in its possession appropriate and regulator—approved manufacturing methods and technologies for
the Compound and Licensed Product Further, it is also conditional upon such manufacturing methods and technologies being functional and capable of manufacturing to the scale and available production capacity required. The Parties agree that
Flexion shall be under no obligation to develop or acquire any manufacturing methods, technologies or capacity in addition to what has been 

  

***Confidential Treatment Requested 

  
 60 

	 	
developed or acquired by it al the date of termination by it or on its behalf under this Agreement for the production of Compound and Licensed Product. The Parties shall separately negotiate in
good faith the logistical and other terms and conditions for such supplies. 

  

	 	17.6.4	Return of Material. Upon termination, but not expiration of this Agreement, by either Party pursuant to Section 3.9 (Change of Control) or this Article 17
or Section 18.4 (Force Majeure), and with regard to the Affected Countries, each Party, at the request of the other Party, shall return, or at the election of the other Party, destroy, and thereafter provide the other Party with written
certification evidencing such destruction, all data, files, records and other materials in its or its Affiliates or, with respect to Flexion, Sublicensees (subject to Section 17.6.5 below, where the sublicence survives), possession or control
containing or comprising such other Party’s Know-How or other Confidential Information and, in each case, to which the returning Party does not retain rights hereunder (except one copy of which may be retained by the returning Party solely for
archival purposes). 

  

	 	17.6.5	Effect of Termination on Sublicences. Termination of this Agreement by AstraZeneca pursuant to Section 3.9 (Change of Control), Section 17.2
(Termination for Breach), Section 17.3 (Termination by AstraZeneca) or Section 18.4 (Force Majeure) or by Flexion pursuant to Section 17.2 (Termination for Breach), Section 17.4 (Termination by Flexion) or Section 18.4 (Force Majeure)
shall terminate the sublicence granted by Flexion pursuant to Section 3.5 with respect to a Sublicensee, subject to Section 17.6.6 below. 

  

	 	17.6.6	Provided that such Sublicensee: 

  

	 	a)	is not in breach of any provision of the applicable sublicence agreement required under Section 15 above to be included in such sublicence, and

  

	 	b)	is not exceeding the scope of the rights granted to Flexion under this Agreement, and 

 

	 	c)	 has agreed to enter into a new licence agreement directly with AstraZeneca on terms which are substantially identical to those set out in this
Agreement, 

  
 61 

 
except that the territory for which the sublicence was granted by Flexion to such Sublicensee will be the territory for such new licence agreement (hereinafter the “Direct Licence
Agreement”), 
 then AstraZeneca agrees to enter into such Direct Licence Agreement with such Sublicensee subject to
the following: 
  

	 	17.6.6.1	Upon a termination of this Agreement becoming effective, such termination shall only become effective for such countries of the Territory in which Flexion has not
entered into a sublicence agreement pursuant to Section 3.5 above, but this Agreement shall remain in force and effect in such countries with a sublicence agreement until terminated in accordance with the provisions set forth herein below.

  

	 	17.6.6.2	Flexion shall within two (2) Business Days after a termination becoming effective notify each Sublicensee of such termination and provide each Sublicensee with a
non-redacted copy of this Agreement. Each Sublicensee shall have thirty (30) days of its receipt of the notice of the termination of this Agreement to notify AstraZeneca (with copy to Flexion) to confirm that such Sublicensee meets the
requirements for a Direct Licence Agreement with AstraZeneca pursuant to this Section 17.6.6 (a) and (b) and is willing to enter into a Direct Licence Agreement with AstraZeneca pursuant to Section 17.6.6 (c). If no such notice
is received by AstraZeneca within this thirty-day period, the respective sublicence agreement and this Agreement for the territory covered by such sublicence agreement shall terminate. 

 

	 	17.6.6.3	Within not more than sixty (60) days following receipt of such notice by AstraZeneca from a Sublicensee, AstraZeneca shall have the right to verify whether the
conditions under Section 17.6.6 (a) and (b) are met by such Sublicensee and, if such conditions are not met, notify the Sublicensee (with copy to Flexion) the reasons for such findings and upon such notice the sublicence agreement and
this Agreement for the territory covered by such sublicence agreement shall terminate. 

  

	 	17.6.6.4	 If AstraZeneca has not sent, or elects not to send, a notice to the Sublicensee pursuant to the preceding paragraph, then AstraZeneca and the

  
 62 

	 	
Sublicensee will enter into a Direct Licence Agreement, upon execution of which the sublicence agreement between Flexion and the respective Sublicensee and this Agreement with respect to the
territory covered by such sublicence agreement shall terminate. 

  

	 	17.6.7	Post-Termination Licence Agreement. In the event that such a Direct Licence Agreement between AstraZeneca and one or more Sublicensees is executed, Flexion
agrees that it will enter into a post-termination licence agreement with each Sublicensee for any Intellectual Property Rights owned by Flexion which may be necessary or useful for the Sublicensees to continue Development. 

 

	 	17.6.8	Remedies. Early termination of this Agreement by a Party shall in no way affect or limit such Party’s right to claim against the other Party for any damages
arising out of the breach of this Agreement. 

  

	17.7	Accrued Rights: Surviving Obligations. 

  

	 	17.7.1	Survival. The expiry or termination of this Agreement shall not relieve the Parties from performing any obligations accrued prior to the date this Agreement
terminates. Each Party’s rights and obligations under Article 4, 17.6 and this Section 17.7 and Articles 6 (with respect to obligations arising prior to expiration, or termination or for any post-termination sales in the event that
these may arise), 8 (Ownership of Intellectual Property),
 10 (Confidentiality and Non-Disclosure), 13 (Indemnity), 22 (Governing Law), 23 (Dispute Resolution and Arbitration), 24 (Notices) and 29 (Waiver and Non-Exclusion of Remedies) shall
survive the termination or expiration of this Agreement. 

  

	 	17.7.2	Work-in-Progress. Upon termination of this Agreement in its entirety by AstraZeneca pursuant to Section 17.2, Flexion shall be entitled, during the
following ninety (90) days, to finish any work-in-progress and to sell any inventory of the Licensed Product that remains on hand as of the date of the termination, so long as Flexion pays AstraZeneca the royalties and any other payments
applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement. 

  
 63 

	17.8	Termination Upon Insolvency or Bankruptcy. Either Party may terminate this Agreement if, at any time, the other Party shall file in any court or agency pursuant
to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other
Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty
(60) days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors. 

 

	17.9	Rights in Bankruptcy. All rights and licences granted under or pursuant to this Agreement by AstraZeneca to Flexion or by Flexion to AstraZeneca are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, licences of right to “intellectual property” as defined under Section 101
of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter “IP”). The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully
exercise all of their rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that provide similar protection for IP. The Parties further agree that, in the event of the commencement of
a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate)
any such IP and all embodiments of such IP, which, if not already in such other Party’s possession, shall be promptly delivered to it upon such other Party’s written request therefor. 

 

	17.10	Consequences of AstraZeneca Breach of Section 3.1. 

  

	 	17.10.1	 If, in accordance with the dispute resolution procedure set out in Section 23.3, AstraZeneca is found to have been in breach of the licence grant set
out in Section 3.1 of this Agreement, namely, that it is found to have granted rights to the Licensed Patents and/or the Exclusively Licensed Know-How to a 

  
 64 

	 	
Third Party in breach of this Agreement; and Flexion has not exercised its right to terminate this Agreement, then Flexion shall have the right either (a) to claim damages in respect of the
loss suffered by it as a result of such breach; or (b) to claim an amount from AstraZeneca in lieu of damages, such amount to be calculated in accordance with the following provisions: 

 

	 	(i)	If the breach is discovered by Flexion at any time after the Effective Date but prior to [...***...] then all future development, filing and approval milestone
payments due to AstraZeneca under Section 6.1 after the discovery of such breach shall be [...***...]; 

  

	 	(ii)	If the breach is discovered by Flexion after [...***...] but prior to [...***...] then all future development, filing and approval milestone payments due to
AstraZeneca under Section 6.1 after the discovery of such breach shall be [...***...]; 

  

	 	(iii)	If the breach is discovered by Flexion after [...***...] and prior to [...***...] then all future development, filing and approval milestone payments due to
AstraZeneca under Section 6.1 after the discovery of such breach shall be [...***...] and the royalties payable to AstraZeneca under Section 6.2 after the discovery and notification of such breach shall be [...***...];

  

	 	(iv)	 If the breach is discovered by Flexion after [...***...] but before [...***...] then all future development, filing and approval milestone
payments due to AstraZeneca under Section 6.1 after the discovery of such breach shall be [...***...] and the royalties and sales related payments payable to AstraZeneca under Sections 6.2 and 6.4 after the discovery of such breach shall
be [...***...] 

  

***Confidential Treatment Requested 

  
 65 

	 	
[...***...]; 

 provided that in each case Flexion
gives AstraZeneca notice of the discovery of the breach promptly after having gained sufficiently detailed knowledge of such breach allowing Flexion to serve a notice of breach under Section 17.2 and giving AstraZeneca the opportunity to cure
the breach in accordance with the provisions of Section 17.2 above, and provided further that AstraZeneca has failed to cure the breach so notified in accordance with the timescales set out in that section. Flexion undertakes that it will
promptly investigate any suspected breach by AstraZeneca and will, notwithstanding that it may not have gained sufficient evidence formally to allege a breach of the Agreement, notify AstraZeneca promptly if any facts or matters come to its
attention which lead it to believe that AstraZeneca may have committed a breach of Section 3.1. 
  

	 	17.10.2	In the event that any payments, which would be affected by a reduction hereunder, become due for payment after the discovery and notification of such breach, such
payments shall be made by Flexion when due, but in the event that AstraZeneca is found in the dispute resolution procedure set out in Section 23.3 to have breached the licence grant set out it in Section 3.1 of this Agreement, such
payments shall be promptly repaid by AstraZeneca plus accrued interest in accordance with Section 6.13 above for the period from the payment date by Flexion until repayment by AstraZeneca. 

 

	 	17.10.3	If the breach occurs or is discovered by Flexion after [...***...], then Flexion shall [...***...]. 

 

	18	Force Majeure 

  

	18.1	 In this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control, including an act
of God, act or omission of the 

  

***Confidential Treatment Requested 

  
 66 

	 	
other Party, strike, lock-out or other industrial/labour dispute (whether involving the workforce of the Party so prevented or of any other Person), war, riot, civil commotion, terrorist act,
malicious damage, epidemic, quarantine, fire, flood, storm, natural disaster or compliance with any law or governmental order, rule, regulation or direction, whether or not it is later held to be invalid. 

 

	18.2	The Force Majeure Party, shall within fifteen (15) days of the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature
and extent of the event of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to Section 18.1, the Force Majeure Party shall not be liable for delay in
performance or for non-performance of its obligations under this Agreement (other than obligations to pay monies due), in whole or in part, nor shall the other Party have the right to terminate this Agreement, except as otherwise provided in this
Agreement, where non-performance or delay in performance has resulted from an event of Force Majeure. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required.

  

	18.3	The Force Majeure Party shall take all steps as are necessary to (a) bring the Force Majeure event to a close or (b) find a solution by which the Agreement
may be performed despite the continuation of the event of Force Majeure. 

  

	18.4	If the Force Majeure Party is prevented from performing its obligations (other than obligations to pay monies due) due to a Force Majeure event for a continuous period
in excess of three (3) months after the date of the occurrence of the Force Majeure event, and such failure to perform would constitute a breach of this Agreement in the absence of such Force Majeure event, the other Party may terminate this
Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that accrued prior to the date of termination, provided that such right to
terminate shall not be available if the Force Majeure event is caused by an act or omission of the other Party. 

  
 67 

	19	Assignment 

Neither Party may assign its rights or, except as provided in Section 3.5 (Flexion’s right to sublicense) and Section 3.9
(Change of Control not resulting in termination of this Agreement), delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent
shall not be unreasonably withheld or delayed, except that each Party shall always have the right, without such consent, (a) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its
Affiliates, and (b) on written notice to the other Party, to assign any or all of its rights and delegate any or all of its obligations hereunder to any of its Affiliates. AstraZeneca shall always have the right, on providing written notice to
Flexion, to assign any of all of its obligations hereunder to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to those assets to which this Agreement relates. 

 

	20	Sub-Contracting 

Flexion shall have the right to sub-contract the performance of any of its obligations under this Agreement without the prior consent of
AstraZeneca, provided that it shall remain liable for the performance or non-performance of any such obligations. 
  

	21	Severability 

 If
any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then, to the fullest extent permitted by Applicable Law: (a) such provision will be given no effect by the Parties and shall not form part of this
Agreement, (b) all other provisions of this Agreement shall remain in full force and effect, and (c) the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable
that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this
Agreement invalid, illegal or unenforceable in any respect. 

  
 68 

	22	Governing Law  

This Agreement shall be governed by and construed in accordance with the laws of England. 

 

	23	Dispute Resolution and Arbitration  

  

	23.1	If a dispute arises between the Parties relating to the existence, negotiation, validity, formation, interpretation, breach, performance or application of this
Agreement, the Parties shall use the following procedure in good faith prior to either Party pursuing judicial remedies. 

  

	23.2	Each Party shall notify the other Party of the dispute in accordance with Article 24, The Parties shall use good faith efforts to resolve such dispute within thirty
(30) days after delivery of such notice, which good faith efforts shall include at least one in-person meeting between representatives of each Party having decision-making authority (subject only to Flexion’s Board of Directors’ or
equivalent approval, if required). All discussions under this Article 23 are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. 

 

	23.3	Any dispute arising out of or relating to the existence, negotiation, validity, formation, interpretation, breach, performance or application of this Agreement shall be
settled by binding arbitration in accordance with the ICC rules of arbitration. A sole arbitrator shall be appointed in accordance with such ICC rules of arbitration. The place of arbitration shall be London. The language used in the arbitration
proceedings shall be English. The arbitration shall be governed by the Arbitration Act 1996 to the exclusion of any inconsistent state laws and judgment on the award rendered by the arbitration may be entered by any court having jurisdiction.
Nothing in this Section 23.3 will preclude either Party from seeking equitable relief in accordance with Section 10.6 or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order,
preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. The
statute of limitations of England and Wales applicable to the commencement of a lawsuit shall apply to the commencement of arbitration under this Section 23.3. 

  
 69 

	24	Notices 

  

	24.1	Notice Requirements 

 Any
notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by
facsimile transmission (with transmission confirmed) or by internationally recognised overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 24.2 or to such
other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Article 24. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with
transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognised overnight delivery service, Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as
practicable thereafter. This Article 24 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

 

	24.2	Address for Notice 

  

	 	For:	AstraZeneca AB 

  

	 	Address:	S-151 85 Södertälje 

	 	    	Sweden 

  

	 	Facsimile:	+468 553 28812 

 For the
attention of: Assistant General Counsel SPBD 
 With a copy to: AstraZeneca UK Limited 

 

	 	Address:	Alderley House 

	 	    	Alderley Park 

	 	    	Macclesfield 

	 	    	Cheshire SK10 4TF 

  

	 	Facsimile:	44 1625 590295 

 For the
attention of: Business Development Director for RITA 
  

	 	For:	Flexion Therapeutics Inc. 

  

	 	Address:	300 Trade Center, Suite 2460, Woburn, MA 01801, USA 

  
 70 

	 	Facsimile:	+1 781-897-9970 

 For the
attention of: CEO 
  

	 	With a copy to:	Blum&Grob Attorneys at Law Ltd 

  

	 	Address:	Neumuehlequai 6, P.O. Box 3954, CH-8021 Zurich, 

	 	    	Switzerland 

  

	 	Facsimile:	+41 58 320 0001 

 For the
attention of: Ralf Rosenow 
  

	25	Relationship of the Parties 

 The status of a Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency
relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements,
representations, warranties or commitments on behalf of the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for
the account and expense of such Party. 
  

	26	Entire Agreement 

This Agreement constitutes the entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement
supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set
out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules and/or Exhibits referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of
this Agreement. In the event of any inconsistency between any such Schedules or Exhibits and the operative terms of this Agreement, the operative terms of this Agreement shall govern. 

  
 71 

	27	English Language 

This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version
of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 
  

	28	Amendment 

 Any
amendment or modification of this Agreement must be in writing and signed by authorised representatives of both Parties. 
  

	29	Waiver and Non-Exclusion of Remedies 

 A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or
remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. All rights and remedies are cumulative and subject to Article 22 do not exclude
any other right or remedy provided by law or otherwise available. 
  

	30	Confirmatory Patent Licences 

 AstraZeneca shall if requested to do so by Flexion promptly enter into confirmatory licence agreements in the form or substantially the form set out in Exhibit 1 for purposes of recording the licences
granted under this Agreement with such Patent Offices in the Territory as Flexion reasonably considers appropriate. Until the execution of any such confirmatory licences, so far as may be legally possible, Flexion and AstraZeneca shall have the same
rights in respect of the Licensed Patents and be under the same obligations to each other in all respects as if the said confirmatory licences had been executed. 
  

	31	Further Assurance 

Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other
Party may reasonably require to implement or give effect to this Agreement. 

  
 72 

	32	Expenses 

 Except
as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution
and delivery of this Agreement. 
  

	33	Announcements 

  

	33.1	Subject to Section 33.2, no Party shall make, or permit any Person to make, any public announcement, communication or circular (“Announcement”)
concerning this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld or delayed). The Parties shall consult together on the timing, contents and manner of release of any Announcement. Each
Party acknowledges and agrees that the other party may in its absolute discretion withhold its consent to the disclosure of any or all of the financial terms of this Agreement. 

 

	33.2	Where an Announcement is required by law or any governmental or regulatory authority (including, without limitation, any relevant securities exchange), or by any court
or other authority of competent jurisdiction, the Party required to make the Announcement shall promptly notify the other Party. The Party concerned shall make all reasonable attempts to agree the contents of the Announcement before making it.

  

	34	Contract (Rights of Third Parties) Act 1999 

  

	34.1	A person who is not a party to this Agreement shall not have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement.

  

	34.2	The rights of the parties to terminate, rescind or agree any variation, waiver or settlement under this Agreement are not subject to the consent of any person that is
not a party to this Agreement. 

  

	35	Counterparts 

 This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by
facsimile transmission shall be as effective as an original executed signature page. 

  
 73 

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first written
above. 
  

									
	 SIGNED for and on behalf of
  

AstraZeneca AB (Pub)
	 		 	 SIGNED for and on behalf of
  

Flexion Therapeutics Inc.

			
	/s/ Anders Burén	 		 	/s/ Mike Clayman
	Signature	 		 	Signature
	Name:	 	Anders Burén	 		 	Name:	 	Mike Clayman
	Title:	 	Authorised Signatory	 		 	Title:	 	Chief Executive Officer

  
 74 

 Schedule 1—Compound and Licensed Patents 

[...***...]. 

  

***Confidential Treatment Requested for pages 75-78. Omitted pages have been filed separately with the Commission. 

  
 75-78

 [...***...]. 
  

	5.	Exclusive Licensed Know-How 

 The information contained in AstraZeneca’s data room as of the Effective Date which relates exclusively to the Compound and which was made available to Flexion prior to the Effective Date, together
with such other Know-How as AstraZeneca may make available to Flexion after the Effective Date. An index of the contents of AstraZeneca’s data room is set out in Exhibit 3 to this Agreement and both Parties have each signed two copies (one copy
to be retained by each Party) of a CD-Rom or DVD containing the contents of AstraZeneca’s data room. 

  

***Confidential Treatment Requested 

  
 79 

 Schedule 1.2 
 [...***...] 
  

  

***Confidential Treatment Requested for pages 80-82. Omitted pages have been filed separately with the Commission. 

  
 80-82

 Schedule 2—Ethics Standards 

 

	I.	PATIENT SAFETY AND BENEFIT 

  

	 	•	 	 Compliance with all applicable procedures designed to promote product safety, efficacy and quality, such as Good Laboratory, Good Clinical and Good
Manufacturing Practice and reporting of any incidents of non-compliance. 

  

	 	•	 	 Reporting of any possible adverse effects. 

  

	 	•	 	 Reporting of any counterfeit or suspected counterfeit drugs. 

 

	II.	RESEARCH AND DEVELOPMENT ETHICS 

  

	 	•	 	 Compliance with international standards of good practice, such as the Declaration of Helsinki, Good Clinical Practice and Good Laboratory Practice.

  

	 	•	 	 Ensuring that appropriate informed consent procedures are followed when conducting clinical research or obtaining human tissue for use in scientific
studies. 

  

	 	•	 	 Compliance with data protection and associated laws when collecting or accessing any health information. 

 

	 	•	 	 Ensuring the welfare of animals used in animal experimentations. 

 

	III.	PROVIDING INFORMATION ABOUT PRODUCTS 

  

	 	•	 	 Compliance with IFPMA Code of Pharmaceutical Marketing Practices, local laws, regulations and applicable codes of marketing practice.

  

	 	•	 	 No engagement in direct consumer/patient communication unless permitted by local law. 

 

	IV.	INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND ORGANISATIONS 

  

	 	•	 	 Compliance with IFPMA Code of Pharmaceutical Marketing Practices, local laws, regulations and applicable codes of marketing practice.

  

	 	•	 	 No payments to healthcare professionals without written agreements. 

  
 83 

	 	•	 	 No offering of payments, gifts, hospitality, entertainment or anything else of value if it could constitute a bribe to a healthcare professional or
organisation. 

  

	V.	PREVENTING BRIBERY AND CORRUPTION 

  

	 	•	 	 No making or authorizing of payments or gifts in order to obtain or retain business or to secure an improper advantage. No asking or permitting of
third parties to do so. 

  

	 	•	 	 Reporting of any suspicion of potentially corrupt behaviour. 

 

	 	•	 	 Compliance with all applicable laws on bribery and corruption including without limitation, the US Foreign Corrupt Practices Act and the UK Bribery Ad
2010 

  
 84 

 Schedule 3—Designated Persons 

For the purpose of Section 5.3.3 and 5.3.4 of the Agreement, 
  

	 	•	 	 Flexion’s designated person shall initially be 

 [...***...]; and 
  

	 	•	 	 AstraZeneca’s designated person shall be AstraZeneca’s [...***...] which at the date of this Agreement is [...***...].

 The Parties shall duly notify each other of any changes to its respective designated person. 

  

***Confidential Treatment Requested 

  
 85 

 Schedule 4—Description of TrK 

TrkA is the specific receptor for nerve growth factor (NGF); 
 TrkB is the specific receptor for brain derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5); and 
 TrkC is the specific receptor for neurotrophin-3 (NT-3). 

  
 86 

 Schedule 5—Disclosure Letter 

Licence Agreement to be made between AstraZeneca AB and Flexion Therapeutics Inc. in respect of the compound [...***...] 

We refer to the licence agreement (“Agreement”) to be entered into today between AstraZeneca AB (“AstraZeneca”) and Flexion
Therapeutics Inc (“Flexion”) for the licensing of certain intellectual property rights by AstraZeneca to Flexion. 
 This letter is
the Disclosure Letter referred to in the Agreement and constitutes formal disclosure to Flexion for the purposes of the Agreement of the facts and circumstances which are or may be inconsistent with the representations and warranties in
Section 12.2 of the Agreement (Additional Representations and Warranties of AstraZeneca) (hereinafter referred to as “Warranties”) or which otherwise give or may give rise to a claim under the Agreement by Flexion in
respect of the Warranties. Such facts and circumstances will be deemed to qualify the Warranties accordingly. 
 The disclosures are made
against the Warranties as a whole. A disclosure or qualification made by reference to any particular paragraph shall be deemed to be made also in respect of any other paragraph to which the disclosure or qualification may be applicable. 

The disclosure of any matter or document shall not imply any representation, warranty or undertaking not expressly given in the Agreement nor shall such
disclosure be taken as extending the scope of any of the Warranties. 
 By way of general disclosure, the following matters are disclosed or
deemed disclosed to Flexion by AstraZeneca: 
 1. The contents of the Agreement and all statements in respect of intellectual property referred
to therein. 
 2. All matters contained or referred to in the documents in the CD-ROM annexed to this Disclosure Letter, which is the CD-ROM
delivered by AstraZeneca to Flexion/its patent 

  

***Confidential Treatment Requested 

  
 87 

 
attorney on or prior to the Effective Date, the index of which is attached to this Agreement at Exhibit 3 (as the index of the full contents of the data room which were made available to Flexion
for the conduct of its due diligence prior to and during the negotiation of this Agreement). 
 3. Any matters referred to in correspondence
between AstraZeneca or its advisers and Flexion or its advisers together with all enclosures attached thereto in a CD-ROM annexed to this Disclosure Letter which is a CD-ROM delivered by AstraZeneca to Flexion/its patent attorney on or prior to the
Effective Date. 
 4. All matters which would be revealed by a search of the files of the UK Intellectual Property Office
and other patent offices, in respect of the Licenced Patents and Retained Patents publicly available and accessible in online databases as 1st September 2010. 
 Please acknowledge receipt and acceptance of this Disclosure Letter by signing, dating and returning the enclosed copy of this Disclosure Letter. 
 Yours faithfully, 
  

	
	/s/ Anders Burén
	 AstraZeneca AB (publ)

Anders Burén
 Authorised
Signatory

 We hereby acknowledge receipt and accept the contents of this Disclosure Letter 

Signed /s/ Mike
Clayman                                 

Date Sept. 15, 2010 

  
 88 

 Exhibit 1 

[...***...] 
  

  

***Confidential Treatment Requested for pages 89-90. Omitted pages have been filed separately with the Commission. 

  
 89-90

 Exhibit 2 

[...***...] 
  

  

***Confidential Treatment Requested 

  
 91 

 Exhibit 3 

[...***...] 
  

  

***Confidential Treatment Requested for pages 92-130. Omitted pages have been filed separately with the Commission. 

  
 92-130

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]